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Abstract 
 
Chondrogenesis, the differentiation of mesenchymal progenitor cells from the 
mesoderm germ layer during embryonic development, is partly regulated by epigenetic 
mechanisms such as histone modifications and DNA methylation. Histone proteins 
possess protruding N-terminal tails which may be post-translationally modified to alter 
the structure of chromatin resulting in a change in the accessibility of genes to the 
transcription machinery. In the genome, histone modifications mark cis-regulatory 
elements such as gene promoters and enhancers while DNA methylation occurs on 
cytosine residues at CpG sites and typically leading to transcriptional repression.  
 
The aim of this project was to characterise the epigenome during in vitro differentiation 
of human mesenchymal stem cells (hMSCs) into chondrocytes. Chromatin 
immunoprecipitation followed by next-generation sequencing (ChIP-seq) was used to 
assess genome-wide a range of N-terminal post-transcriptional modifications (marks) 
to histone H3 lysines (H3K4me3, H3K4me1, H3K27ac, H3K27me3 and H3K36me3) in 
both hMSCs and differentiated chondrocytes. Chromatin states were characterised 
using the software ChromHMM and cis-regulatory elements were identified. Integration 
of DNA methylation data with chondrogenesis chromatin states revealed that 
enhancers marked by H3K4me1 and H3K27ac were hypomethylated during in vitro 
chondrogenesis. Similarity analysis between chondrogenesis chromatin states with 
epigenomes of cell types defined by the Roadmap Epigenomics project revealed that 
enhancers are more distinct between cell types compared to other chromatin states.  
SOX9 is regarded as the master transcription factor for chondrogenesis. An external 
mouse Sox9 ChIP-seq dataset was used to identify super enhancers in chondrocytes. 
Luciferase reporter assays showed that selected regions of super enhancers exhibit 
independent enhancer activity.   
 
In conclusion, we observed that CpG sites within enhancers are de-methylated during 
hMSC differentiation into chondrocytes and propose that gene transcription during 
chondrogenesis is regulated by epigenetic changes at enhancers. Epigenetic changes 
have been implicated in cartilage diseases and greater understanding of the 
chondrocyte epigenome may have potential therapeutic value.  
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Chapter 1. Introduction 
 
1.1 Articular cartilage 
 
Chondrogenesis is the differentiation of mesenchymal progenitor cells into 
chondrocytes from the mesoderm germ layer during embryonic development. 
Chondrocytes are the only cell type found in articular cartilage within synovial joints 
such as the knee or hip and are responsible for the secretion of extracellular matrix 
(ECM) and homeostasis of cartilage. Articular cartilage is the hyaline cartilage found 
at bone ends in the synovial joint (Fig. 1.1) and aids in movement of the joint and 
protects bone ends from degradation.  
 
 
 
Figure 1.1 – Structure of a healthy synovial joint. Articular cartilage covers the end of bones within the synovial 
joint, protecting the bone ends and aiding in lubricating and movement of the joint. Chondrocytes are present 
only within the articular cartilage. Synovial fluid is present in the cavity between bone ends, covered by the 
synovial membrane. The articular capsule surrounds the synovial joint. Image from ARUK.  
 
Chondrocytes synthesise, secrete and maintain the ECM proteins in their surrounding 
environment. Type II collagen is the main collagen present in articular cartilage and is 
highly expressed by chondrocytes. A network of collagen fibrils run through articular 
cartilage, along with proteoglycans such as perlecan which is required for 
fibrillogenesis (Kvist et al, 2006). The main proteoglycan in cartilage is aggrecan, which 
exists in large aggregates and is responsible for the hydrated gel structure seen in 
articular cartilage (Watanabe et al, 1998). As well as secreting ECM proteins, 
chondrocytes also produce and secrete enzymes responsible for the degradation of 
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the ECM such as matrix metalloproteinases (MMPs). There are four main zones in 
articular cartilage (Fig. 1.2). The composition and properties of cartilage varies 
between each zone. Water is a major component of articular cartilage; up to 80% of 
articular cartilage is water, with the highest concentration of water in the tangential 
zone. The morphology of chondrocytes also changes depending on which zone they 
are found in, with cells becoming larger and more spherical in the deeper zones.  
 
 
Figure 1.2 - Schematic cross section through articular cartilage. There are four main zones in articular cartilage, 
each with different ECM proteins and water compositions. The morphology of chondrocytes differs depending 
on where they are found within the cartilage, with spherical cells found near the subchondral site in the deep 
zone and becoming flatter towards the articular surface. The tangential (aka superficial) zone is near the 
articular surface and is in contact with synovial fluid in the joint. This zone acts as a defence for lower zones and 
is the site of most mechanical stress. The tangential zone consists of densely packed collagen type II and type IX 
fibres which contributes to the tensile properties of cartilage and allows it to resist the forces and stresses 
caused by joint movement. The transitional or middle zone contains thicker collagen fibrils and chondrocytes 
are sparse throughout this zone. The radial zone has the greatest resistance to mechanical loading and consists 
of the thickest collagen fibrils and more proteoglycan content than other zones. Chondrocytes are arranged in 
columns in this zone. 
 
Articular cartilage is an avascular tissue and ECM proteins have a long half-life, factors 
which contribute to the low turnover and repair capacity of cartilage. Chondrocytes in 
adult cartilage are therefore comparatively inert and repair is a slow process. Healing 
in cartilage is incomplete and results in a fibrocartilage scar which is inferior to normal 
cartilage (Gomoll and Minas, 2014). Studies into the regeneration of articular cartilage 
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have focused on the chondrocyte as they are responsible for the maintenance of 
cartilage integrity. Although articular cartilage in the adult body has a limited potential 
for regeneration, during development it is formed and remodelled on a large scale 
(Goldring, 2012). The limited capacity of mature chondrocytes for healing makes 
cartilage injury and disease extremely difficult to treat. However, during development, 
cartilage is extremely amenable to repair and remodelling. At this time, cartilage is able 
to successfully heal injuries without leaving a fibrocartilage scar (Namba et al, 1998). 
 
1.2 Cartilage development 
 
During development, chondrocytes are derived from the skeletal blastoma, a dense 
cluster of mesenchymal progenitors found in the mesoderm germ layer. 
Chondrogenesis is a multi-step tightly regulated process mediated by different 
transcription and growth factors at each stage (Fig. 1.3). Each stage is characterised 
by gene expression and cell morphology changes. The first step in chondrocyte 
differentiation is the migration of progenitor cells to the site of chondrogenesis, followed 
by interactions of progenitors to epithelial cells and the third stage is the condensation 
of chondrocyte progenitors. The critical stage in the development of mesenchymal 
tissues is condensation. This step involves the aggregation of progenitor cells that 
accumulate together to form a specific tissue type. Signalling molecules and cellular 
interactions are crucial for development of cartilage and other tissues. The lineage of 
mesenchymal progenitors is determined by this stage and cells express markers and 
genes specific for their intended cell type. Chondrogenic progenitors express 
transcription factors such as SOX9 pre-condensation which determine them for the 
chondrocyte cell lineage (Lorda-Diez et al, 2011). Mesenchymal stem cells (MSCs; 
discussed in section 1.4) found in the adult body can differentiate into chondrocytes 
and many in vitro studies elucidating the mechanisms of chondrogenesis have been 
performed using MSC chondrogenesis.  
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Figure 1.3 – Stages of chondrogenesis. Following MSC condensation, cells determined for the chondrogenic 
lineage undergo further differentiation steps. SOX9 is required for the initiation of MSC differentiation into 
chondrocytes and is involved throughout chondrogenesis. Each step is characterised by the engagement of 
various growth factors and changes in gene expression and cell morphology. The final step of chondrogenesis is 
the hypertrophy of chondrocytes. After this, the majority of chondrocytes apoptose and endochondral 
ossification occurs. However, some chondrocytes may transdifferentiate into osteoblasts. Image adapted from 
Vinatier et al, 2009.  
 
The master transcriptional regulators for chondrogenesis are the SOX (SRY-related 
high-mobility-group (HMG) box) trio of transcription factors, SOX9, SOX5 and SOX6 
(Akiyama, 2008). These transcription factors activate expression of genes that drive 
MSCs down the chondrocyte cell fate. SOX9 in particular is important for 
chondrogenesis and acts upstream of SOX5 and SOX6. Without SOX9, 
chondrogenesis cannot occur (Mori-Akiyama et al, 2003). The exact molecular 
mechanisms of SOX9 are not fully understood but it acts in concordance with multiple 
signalling pathways. For example, the TGFβ signalling pathway in particular is 
important in early chondrogenesis (Kawakami et al, 2006). The SOX9 protein binds to 
DNA to regulate transcription of genes either as a homodimer or a heterodimer with 
different binding partners. At different stages of chondrogenesis, SOX9 binds as a 
heterodimer to other transcription factors to regulate different genes and may positively 
or negatively regulate transcription depending on the binding partner. SOX9 partners 
with GLI proteins to repress COL10A1, a gene up-regulated in hypertrophic 
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chondrocytes (Leung et al, 2011). However, SOX9 also co-binds with the AP-1 
transcription factor to promote chondrocyte hypertrophy (He et al, 2016).  
Chondrogenesis requires a balance of pro- and anti-chondrogenic factors for normal 
development. For example, BMP signalling is necessary for differentiation of MSCs 
into chondrocytes. However, the BMP antagonist Noggin is also required; lack of 
Noggin leads to abnormal joint development (Brunet et al, 1998). Homozygous 
knockout of Sox9 is embryonic lethal in mice (Chaboissier et al, 2004) whereas 
heterozygous knockout in mice leads to severe abnormal cartilage development and 
perinatal lethality (Bi et al, 2001). Overexpression of SOX9 also induces abnormal 
cartilage and skeletal development. SOX9 interacts with β-catenin and the canonical 
Wnt pathway to decrease levels of cyclin D, inhibiting chondrocyte proliferation 
(Akiyama et al, 2004). SOX9 therefore affects chondrogenesis in a concentration 
dependent manner. SOX9 is also involved in other developmental processes such as 
sex determination in mammals, neurogenesis, lung, pancreas and liver development 
(Koopman 2001; Jo et al, 2014).  
The initial steps of chondrogenesis and osteoblastogenesis are identical and MSCs 
differentiate into either chondrocytes or osteoblasts depending on the signals received 
from the interaction with epithelial cells (Hall and Miyake, 2000). Furthermore, during 
the early stages of skeletal development, most of the skeleton is formed from the 
cartilage anlagen, a template for bone formation. As development progresses, the 
transitory cartilaginous skeleton is gradually replaced by bone, a process called 
endochondral ossification. Most of the cartilage is slowly replaced except articular 
cartilage in locations such as synovial joints which are left intact and remain present in 
the adult body. During endochondral ossification, chondrocytes enter a hypertrophic 
stage, the terminal stage of chondrocyte differentiation. The ECM calcifies and hardens 
and chondrocytes undergo apoptosis, leaving cavities that osteoblasts and osteoclasts 
migrate into (Mackie et al, 2008).  There is also evidence that chondrocytes can 
transdifferentiate into osteoblasts. Although the majority of chondrocytes die during 
endochondral ossification, a subset of chondrocytes are able to transdifferentiate into 
osteoblasts (Thesingh et al, 1991; Yang et al, 2014; Park et al, 2015). This 
transdifferentiation process is also seen during the healing of bone fractures in adults 
(Zhou et al, 2014).  
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During development, large scale changes in gene expression occur in a temporal 
manner. Gene expression during chondrogenesis is in part regulated by epigenetic 
mechanisms such as DNA methylation and histone modifications (Furumatsu and 
Ozaki, 2010; Hata, 2015). MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) 
also play a role in chondrogenesis (Yang et al, 2011; Barter et al, 2017; Tian et al, 
2016). For example, the miRNA miR-140 was found to be important for regulating 
chondrogenesis related genes during differentiation (Barter et al, 2015). Furthermore, 
genome wide histone modification changes have been observed during in vitro 
differentiation of MSCs into chondrocytes (Herlofsen et al, 2013).  
 
The epigenetic changes that occur during chondrogenesis are not yet fully understood. 
Understanding how genes are regulated is important for understanding how they 
become dysregulated during disease processes.  
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1.3 Cartilage diseases  
 
Mutations in chondrogenesis-related genes and aberrant gene expression can lead to 
congenital cartilage disorders. Chondrodysplasias describe a group of skeletal 
conditions characterised by abnormal bone and cartilage development. 
Chondrodysplasias can be caused by mutations in regulatory regions of cartilage 
genes as well as the gene itself. Deletions in a distal regulatory region of the SOX9 
gene and within the SOX9 HMG domain both lead to campomelic dysplasia in humans 
(Meyer et al, 1997; Wunderle et al, 1998). Mutations in collagen genes COL2A1 and 
COL9A1-3 can also lead to some forms of chondrodysplasia (Tiller et al, 1995; 
Paassilita et al, 1999).  
 
Cartilage diseases can also be acquired post-development. Osteoarthritis (OA) is an 
age-related cartilage disease characterised by progressive degradation of the articular 
cartilage in synovial joints such as the hip and knee joints (Fig. 1.4). Symptoms of OA 
can include pain, stiffness, lack of flexibility and loss of mobility. The most common 
joints affected are the knee, hands and hips (Wood et al, 2013). Gene expression 
changes are seen in OA chondrocytes. One of the major changes seen in the 
progression of OA is the upregulation of MMP13, which encodes for a matrix 
matalloproteinase that degrades type II collagen (Wang et al, 2013). The composition 
of articular cartilage also changes in OA; the amount of water present increases to 
over 90%, affecting the load bearing properties of the cartilage (Bhosale and 
Richardson, 2008). 
 
Although age is a major risk factor, OA is distinct from normal synovial joint ageing and 
is not an inevitable result of age (Loeser et al, 2016). Genetic susceptibility loci that 
predisposes individuals to developing OA have been identified (Zeggini et al, 2012). 
However, OA is a complex multifactorial disease and more research is necessary to 
elucidate why and how individuals develop OA. There are currently no disease 
modifying drugs available for OA and patients are advised to manage symptoms using 
pain, anti-inflammatory medicine and lifestyle changes. End stage OA may be treated 
using joint replacement surgery which replaces the affected joint with an artificial 
prosthesis. Although joint replacements are generally successful, the artificial joint has 
a limited lifespan of 15-20 years (Arthritis Research UK). This means a patient may 
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need to undergo multiple joint replacements depending on their lifespan. Furthermore, 
as OA is typically related to age, patients are often elderly which is associated with 
increased risk of complications when undergoing surgical procedures (Turrentine et al, 
2006). OA presents a significant economic burden to the UK; joint replacements cost 
the NHS £852 million in 2010. Indirect costs of OA, such as loss of productivity, 
unemployment and disability payments, exceed £2.4 billion (Chen et al, 2012). 
Increases in global life expectancy have led to an increase in age-related diseases 
such as OA. As lifespan is set to increase further, there is a crucial need to develop 
better healthcare solutions to improve the quality of life for the elderly population (Jin 
et al, 2015).  
 
 
 
 
Figure 1.4 – Synovial joint with OA. Articular cartilage covering the bone ends is progressively degraded until the bone is 
exposed. In severe OA, the unprotected exposed bone is also degraded. Although OA was traditionally thought to be non-
inflammatory, it is now known that affected joints may be characterised by a low level of chronic inflammation, particularly 
in the synovium (Sokolove and Lepus, 2013). Image from ARUK.  
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Cartilage diseases such as OA are difficult to treat due to the limited responses of 
chondrocytes and the low capacity for regeneration in cartilage tissue. Studies show 
that the pathways involved in OA development are also involved in chondrogenesis 
(Goldring, 2012; Pitsillides and Beier, 2013). Epigenetic changes have also been 
implicated in OA. Changes in DNA methylation have been characterised in patients 
with hip and knee OA compared to non-OA controls (Rushton et al, 2012). Loss of 
DNA methylation in the enhancer of the inducible nitric oxide synthase gene is 
associated with gene expression changes in human OA chondrocytes (de Andrés et 
al, 2013). Loss of miR-140 in mice leads to impaired cartilage development and an 
OA-like phenotype (Miyaki et al, 2010). Long non-coding RNAs (lncRNAs) also play 
roles in chondrogenesis, cartilage homeostasis and disease (Huynh et al, 2017). 
These studies show that non-coding regions of the genome and regulatory elements 
can be just as important as coding genes during the development of cartilage diseases.   
 
Congenital cartilage diseases such as chondrodysplasias are caused by abnormal 
development whereas acquired cartilage diseases such as OA have shown a link to 
developmental pathways. Therefore, investigations into the epigenome during 
chondrogenesis may lead to a better understanding of OA and other cartilage 
diseases. Due to the inherently low regeneration potential of cartilage in the adult body, 
tissue engineering and stem cell transplantation methods have been explored as a 
way to replace damaged or diseased cartilage.   
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1.4 Mesenchymal stem cells: use in research and regenerative medicine 
 
Stem cells, also known as progenitor cells, are defined as undifferentiated or 
unspecialised cells that are able to self-regenerate as well as differentiate into multiple 
more specialized cell types. In mammals, there are many different stem cells 
characterised by where they originate and the cell types they can differentiate into. For 
example, embryonic stem cells (ESCs) are pluripotent stem cells capable of 
differentiating into any cell type in the body and are therefore the starting point of 
development of all tissue types in the body. All cells from the three primary germ layers 
- the ectoderm, endoderm and mesoderm, ultimately derive from ESCs. ESCs only 
exist during the early stages of development and can be extracted from the blastocyst 
stage of embryogenesis, although this results in the destruction of the embryo which 
raises difficult moral and ethical questions (Lo and Parham, 2009).  
 
Post development, maintenance of tissues and creation of new cells is orchestrated 
by adult or somatic stem cells. In recent years, adult stem cells have been a large focus 
of research into regenerative medicine. Stem cells can be used to replace or repair 
injured and diseased tissues, especially important in tissues with constrained 
regeneration capacities such as tendon, nerve tissue and cartilage. Human adult stem 
cells in particular have received a lot of attention due to fewer ethical concerns 
compared to hESCs and the potential for personalised, autologous cell implants. 
However, unlike ESCs, adult stem cells do not have unlimited differentiation potential 
and are typically tissue specific. There are many adult stem cells, each able to 
differentiate into a limited subset of cell types depending on their stem cell niche. One 
example is haematopoietic stem cells (HSCs), these give rise to cells of the 
haematopoietic system, including cells involved in the immune response such as 
lymphocytes and monocytes (Eaves, 2015). In adults, HSCs are found in bone marrow. 
Other adult stem cells include epithelial stem cells responsible for the maintenance of 
epithelium in organs such as skin and intestines (Blanpain et at, 2007), and neural 
stem cells which generate cells in the nervous system including neurons and glial cells 
(Kornblum, 2007). 
 
Mesenchymal stem cells (MSCs) are multipotent adult stem cells able to differentiate 
into a variety of cell types, mainly those comprising the musculoskeletal system. MSCs 
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are also known as mesenchymal stromal cells. MSCs are often described as having a 
fibroblast-like cell morphology with thin, elongated cell bodies (Haniffa et al, 2009). 
MSCs are derived from the mesoderm germ layer and in adults are found in a range 
of stem cell niches including bone marrow, synovium, umbilical cord, muscle and 
adipose tissue (Kolf et al, 2007). MSCs are a heterogeneous population of stem cells 
and are broadly defined as cells capable of self-renewal plus having the potential to 
differentiate into osteoblasts, chondrocytes and adipocytes in vitro (Nombela-Arrieta 
et al, 2011). Due to their heterogeneous nature, there is no single cell surface marker 
for MSCs. Instead, they are identified by the presence of multiple cell surface antigen 
markers such as CD90, CD73 and CD105 whilst lacking expression of markers of other 
stem cell types such as CD45, CD34, CD14 or CD11b, CD79-alpha or CD19, and HLA-
DR surface molecules. MSCs must also adhere to standard tissue culture plastics. 
These criteria are stipulated by the International Society for Cellular Therapy (Dominici 
et al, 2006) and cells must meet these criteria to be classed as MSCs. Additional to 
the common characteristics mentioned, MSCs from different stem cell niches can show 
different antigen markers or vary in the level of cell marker expression which may affect 
differentiation potential of the MSC. For example, cells that have a high expression of 
CD105 have an increased osteogenic potential (Maleki et al, 2014). Bone marrow 
derived MSCs (BM-MSCs) are rare, only comprising around 1 in 10,000 cells in bone 
marrow whereas adipose tissue can yield 500 times this amount (Williams et al, 2013; 
Kolaparthy et al, 2015). Despite their rarity, BM-MSCs are relatively easy to isolate and 
are commonly used in stem cell research. BM-MSCs have been shown to have greater 
chondrogenic and osteogenic potential compared to adipose derived MSCs (AD-
MSCs; Li et al, 2015). Therefore, BM-MSCs are the better choice for studies into 
cartilage and bone. 
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As well as the cell types already mentioned, MSCs have the potential to differentiate 
into other lineages including tenocytes (Wang et al, 2005), myocytes (Singh et al, 
2016) and neural cells (Scuteri et al, 2011). They have been studied extensively for 
the purpose of tissue engineering and regeneration due to their vast differentiation 
potential. For example, studies investigating the use of MSCs for tendon repair have 
been promising. Tendon is a connective tissue that connects muscle to bone and 
consists of tightly packed collagen fibrils in parallel to each other. Tendon has an 
inherently low regeneration capacity and healed injured tendon leaves tough, fibrous 
scar tissue that affects the physical properties and function of the tendon. The impaired 
function of the tendon increases the risk of further injury (Butler et al, 2004).  
Incorporation of MSCs into injured tendon resulted in improved repair in a rabbit model 
of Achilles tendon regeneration (Young et al, 1998). Other studies have also shown 
use of MSCs increased tendon repair in mice (Hoffman et al, 2006) and horses 
(Carvalho et al, 2013).  
 
MSCs have been used for regeneration of bone. In adults, the skeleton is slowly and 
continuously remodelled; a process mediated by osteoblasts and osteoclasts. These 
are bone forming and bone resorbing cells originating from MSCs and HSCs 
respectively. Comparative to other tissues, in healthy individuals bone heals itself 
adequately in most cases (although bone repair is a slow process). However, bone 
regeneration is impaired with age and in diseases such as osteogenesis imperfecta 
(Gil et al, 2017) and osteoporosis (Tarantino et al, 2011). MSC grafts to the site of 
damaged bone increased repair in rat calvarial bone (Agacayak et al, 2012).  
 
MSCs are also extensively used in cartilage repair studies. Like tendon, cartilage is a 
connective tissue and is dense in ECM (Section 1.1). Similar to tendon, cartilage 
possesses very limited regeneration capabilities in adults. Adult cartilage forms a 
fibrocartilage scar upon injury healing. Accordingly, cartilage repair faces many similar 
challenges to tendon repair. Clinical trials have shown that application of autologous 
MSCs to injured cartilage improved repair (Wang et al, 2017). A review of multiple 
animal and human studies of MSC use in cartilage repair identified different outcomes 
depending on the methods and conditions used and a lack of standardisation in 
measuring outcomes (Goldberg et al, 2017).  
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Figure 1.5 – Basic principle of stem cell transplantation. Stem cells can be extracted from the patient 
(autologous stem cell transplant) or a healthy donor, they can then be expanded or differentiated in vitro and 
transplanted to the site of injury or disease.  
 
As well as directly using MSCs for tissue regeneration, MSCs can also be differentiated 
into the desired cell type to create artificial tissues in vitro. Tissue engineering 
approaches revolve around isolating MSCs from donors or patients and differentiating 
them under laboratory conditions before transplanting the differentiated cells back into 
the patient (Fig. 1.5). Differentiating isolated MSCs has advantages to simply 
implanting MSCs to the site of injury or disease. The injured or diseased tissue may 
not have conditions ideal for MSC differentiation into the required cell type, or MSCs 
may not stay at the site of injury (Haque et al, 2015). In this case, differentiating stem 
cells in vitro before transplanting may be the more effective method. Creating cells and 
tissues from isolated MSCs is a complex task. Depending on the tissue, it may be 
advantageous to grow cells in 3D scaffolds rather than monolayer cell cultures. Cells 
such as chondrocytes, tenocytes and osteoblasts exist in vivo surrounded by networks 
of extracellular matrix. They are sensitive to external stimuli such as weight loading 
which affects the integrity of cartilage, tendon and bone. Both over and under loading 
can negatively impact the structure and strength of the tissue (Sun, 2010; Galloway et 
al, 2013; Klein-Nulend et al, 2012). 3D scaffolds offer cells a more natural environment 
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to grow compared to monolayer dishes; MSCs grown in 3D scaffolds show increased 
proliferation compared to those grown in monolayer cultures (Meng et al, 2014). 
Materials for stem cell scaffolds, particularly for bone and cartilage regeneration, have 
been widely researched. Scaffolds usually contain various growth factors and other 
proteins necessary for optimal attachment, proliferation and differentiation of MSCs. 
Collagen containing scaffolds have been shown to increase MSC proliferation (El-
Jawhari et al, 2015). Scaffold-free methods have also been developed and these are 
reviewed in section 1.5. 
 
As well as finding suitable materials for cell scaffolds, there has been research into 
engineering cultured MSCs to be more robust or more capable of differentiating into 
the desired cell type (Park et al, 2015). Stem cells proliferate at different rates and they 
may be more likely to differentiate into some cell lineages than others. Age is a major 
factor that negatively affects the rate of stem cell division and differentiation (Sharpless 
and DePinho, 2007). In healthy adults, MSCs divide and differentiate in both in 
response to tissue injury and as part of normal tissue homeostasis.  With age, 
proliferation of MSCs decreases and MSCs tend to differentiate into adipocytes at the 
expense of osteoblastogenesis (Bethel et al, 2013). Studies into age related effects of 
MSC chondrogenesis have yielded conflicting outcomes with some showing that 
chondrogenesis is impaired with age (Kretlow et al, 2008) whereas others have shown 
no difference (Scharstuhl et al, 2007; Payne et al, 2010).  Increasing the shelf life of 
extracted MSCs is also important. MSCs that have been cultured and passaged 7-12 
times display reduced differentiation capacity and enter replicative senescence 
(Wagner et al, 2008). Similarly, MSCs extracted from aged mice show reduced function 
compared to young and adult mice (Bruna et al, 2016). Age was also found to 
negatively impact extracted human MSCs; genes related to oxidative stress were 
upregulated in aged MSCs (Peffers et al, 2016). Therefore, the age of stem cell donors 
is an important factor to consider when using MSCs in regenerative medicine and 
tissue engineering.  
 
Regulation of gene expression in stem cells both in vivo and in vitro is mediated by 
multiple genetic, epigenetic and environmental factors. Understanding these 
mechanisms is key to developing new regenerative medicine solutions for injury and 
disease.  The use of MSCs for tissue repair has been extensively studied and results 
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have been positive. However, application of this technology to treat human patients is 
not widespread and is limited to clinical trials or research settings. Optimisation of such 
techniques is far from complete and there are still many questions to be answered 
before the use of stem cells to treat human injury and disease becomes routine. Further 
research is required to perfect existing techniques and develop new methods. 
Regenerative medicine using stem cells is a powerful tool to treat a wide range of 
diseases; in theory, stem cells can be used to regenerate any somatic cell type in the 
body. This is particularly paramount for cells and tissues that are not easily replaced 
or repaired by the body.  
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1.5 Scaffold-free in vitro models of chondrogenesis 
 
To study chondrogenesis, many in vitro models have been developed (Yu et al, 2012). 
Chondrogenesis can be studied in animal models but it is not feasible to investigate 
human chondrogenesis in vivo. Therefore, in vitro models offer a valuable method of 
studying chondrogenesis of human cells. They are also a step towards developing 
usable cartilage for transplantation.  
 
hMSCs can be extracted from various tissue sources such as adipose tissue and bone 
marrow. BM-MSCs are superior to AD-MSCs for chondrogenesis (Li et al, 2015). Once 
extracted, BM-MSCs proliferate well in culture and can be stimulated to differentiate 
into its cell lineages by the addition of growth factors into the cell media (Fig. 1.6). 
MSCs can also be maintained in the stem cell state by culturing in media containing 
fibroblast growth factor 2 (FGF2), ascorbic acid and platelet-derived growth factor 
(PDGF; Gharibi and Hughes, 2012). FGF2 promotes the proliferation of MSCs while 
inhibiting differentiation (Lai et al, 2011). Cultured MSCs can be induced to differentiate 
by replacing MSC maintaining media with differentiation media. Differentiation media 
is designed to simulate the changes in the environment that occur in vivo to drive MSCs 
down a particular cell lineage. For example, supplementation with BMP2 induces 
osteoblastogenesis (Westhrin et al, 2015) whereas indomethacin and 3-isobutyl-1-
methylxanthine (IBMX) induces adipogenesis (Scott et al, 2011). For chondrogenesis 
to occur in cultured MSCs, TGFβ supplementation is essential (Worster et al, 2000; 
Bian et al, 2011). Addition of other supplements such as dexamethasone, ascorbic 
acid and insulin aids the in vitro differentiation process (Solchaga et al, 2011).  
 
Successful differentiation of MSCs into the desired cell type is usually measured by 
the upregulation of cell type specific genes and the downregulation of genes involved 
in other cell lineages, including MSC markers. Phenotypic and cell morphology 
changes can also be measured using other methods such as cell staining and flow 
cytometry.   
 
Osteoblastogenesis results in the upregulation of osteoblast markers such as RUNX2, 
BGLAP and COL1A1 (Huang et al, 2007). Positive adipocyte markers include the 
ADIPOQ and LEP genes (Houde et al, 2014). MSC differentiation into chondrocytes is 
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marked by induction of a chondrogenesis specific gene set such as SOX9, COL2A1 
and ACAN (Solchaga et al, 2011) and downregulation of osteoblast genes such as 
RUNX2 before the hypertrophic stage (Lengner et al, 2005). Quantification of such 
markers allows for the assessment of differentiation.   
 
 
Figure 1.6 – In vitro MSC differentiation into osteoblasts, adipocytes and chondrocytes. Cultured MSCs can be 
stimulated to differentiate into osteoblasts by adding growth factors such as BMP2 and β-glycerophosphate 
into the cell media. Gene markers of osteoblasts include RUNX2, BGLAP and COL1A1. Addition of indomethacin 
and IBMX in cell media promotes adipogenesis; characterised by expression of ADIPOQ and LEP. For 
chondrogenesis to occur, MSCs must be grown in the presence of TGFβ. Chondrocyte markers include an 
upregulation of COL2A1, ACAN and SOX9 
 
In vitro models of chondrogenesis vary and there are methods that utilise scaffolds and 
scaffold-free methods. Scaffold-free methods have advantages over scaffold based 
techniques as they are relatively simple to execute and do not rely on artificial scaffold 
material of varying quality. Furthermore, scaffold-free chondrogenesis mimics more 
closely the process that occurs during native development; the chondrocytes are 
seeded at high density which resembles the condensation step and the cells 
themselves create their own scaffold through expression and secretion of ECM 
proteins (Whitney et al, 2012).  
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The simplest scaffold-free chondrogenesis model involves differentiation of high 
density MSCs in pellet culture. During incubation of MSCs in chondrogenic cell media, 
cells differentiate into chondrocytes and form a pellet of ECM resembling cartilage. The 
micromass model is an adaptation of the pellet culture model whereby MSCs are 
differentiated into chondrocytes within the wells of 24 48 or 96-well plates without 
centrifugation of MSCs. The two chondrogenesis models are similar although the 
micromass model was found to be more cartilage-like compared to the pellet model 
(Zhang et al, 2010). The transwell model of chondrogenesis is another scaffold-free 
model of chondrogenesis (Murdoch et al, 2007). This model involves seeding MSCs 
at high density into tissue culture treated transwell inserts containing a porous 
membrane.  Chondrogenic differentiation media is added into and around the 
transwell. Over time, a cartilaginous disc forms at the base of the transwell insert. The 
ECM within the transwell chondrogenesis model was found to be more homogenous 
than pellet cultures (Murdoch et al, 2007). Previous studies using the transwell 
chondrogenesis system has yielded gene expression changes similar to in vivo 
chondrogenesis (Murdoch et al, 2007; Barter et al, 2015).  
 
The stages of chondrogenesis can be investigated by stopping in vitro differentiation 
at different time points. The challenges involved in differentiating MSCs into 
chondrocytes in vitro include avoiding the terminal hypertrophic fate of chondrocytes. 
In development, the majority of chondrocytes apoptose after hypertrophy during 
endochondral ossification. Articular cartilage is formed from chondrocytes that do not 
undergo this stage. Whilst cultured MSCs can produce a cartilage-like tissue with 
similar gene expression profiles, a model that can result in cartilage exactly like native 
cartilage has yet to be developed. Articular cartilage in the body is characterised with 
zones at different depths in the cartilage. At each zone, the ECM composition and 
chondrocyte morphology varies. In vitro models struggle to replicate the complex 
layers found in endogenous cartilage.  Furthermore, MSCs extracted from donors are 
heterogeneous and can exhibit varied proliferation and differentiation potential 
(Somoza et al, 2014). Selecting MSCs for in vitro experiments can therefore be biased 
towards those that grow well in culture and can successfully differentiate in the model 
used by the researcher.   
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It is important to develop better cartilage constructs with the properties of endogenous 
articular cartilage for tissue regeneration purposes. It has been proposed that MSC 
chondrogenesis may be enhanced by using epigenetic modulators (Patel et al, 2015; 
Yapp et al, 2016). Therefore, improvement of cartilage constructs may be 
accomplished by engineering the cells themselves. Manipulating MSC differentiation 
can be achieved with the use of epigenetic modifying enzymes or using the CRISPR-
cas9 system. However, more knowledge of how the differentiation process is regulated 
is required.   
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1.6 Epigenetics 
 
1.6.1 Definition of epigenetics 
 
Epigenetics (from the Greek prefix “epi” meaning above or over plus the word genetics) 
describes the changes and alterations around the genome that have an effect on 
transcriptional activity without changing the underlying nucleotide sequence of the 
genome itself. Epigenetic modifications can be hereditary and some definitions state 
that an epigenetic trait must be heritable, either to daughter cells or progeny (Berger 
et al, 2009). However, some traits which are non-heritable may also be classed as 
epigenetic (Bird, 2007). In this project, epigenetics is taken to mean any heritable or 
non-heritable change which does not change the genome sequence.  
 
Definitions of epigenetics do not distinguish between mitotic and meiotic inheritance. 
Transgenerational epigenetic mechanisms are important for controlling normal cell 
processes such as development whereas many epigenetic marks can also be 
influenced by environmental factors and are not passed on to the next generation 
(Slatkin, 2009). This is an important distinction as acquired epigenetics can contribute 
to the development of disease.  
 
Epigenetic changes may regulate gene transcription and are therefore a powerful 
mechanism for modulating gene expression in disease. Epigenetic marks regulate 
gene transcription partly by altering the structure of chromatin into transcriptionally 
permissible or repressed states. Epigenetic marks such as histone modifications can 
also attract specific transcription factors to regulate gene expression. The two major 
epigenetic mechanisms regulating gene transcription are histone modifications and 
DNA methylation (Fig. 1.7). Non-coding RNAs (ncRNAs) are also classed an as 
epigenetic mechanism (Peschansky and Wahlestadt, 2011), as are prions (Halfmann 
and Lindquist, 2010) but these are beyond the scope of this project and are not 
discussed further.   
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Figure 1.7 - Packaging of DNA into chromosomes in the nucleus. DNA wraps around histone proteins in a 
nucleosome unit to form chromatin. Chromatin is further condensed and packaged into a chromosome. 
Chromatin structure is determined by epigenetic marks such as DNA methylation and histone modifications. 
Histone tails may be modified by the addition of a chemical group, e.g. methylation. DNA methylation occurs on 
the cytosine base of CpG sites. These two epigenetic components can alter the structure of chromatin. (Image 
adapted from Sadava et al, 2012). 
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1.6.2 Histone modifications 
 
1.6.2.1 Chromatin structure 
 
DNA in the nucleus is compacted into chromatin by histones; chromatin is usually 
grouped into transcriptionally repressed heterochromatin or transcriptionally active 
euchromatin. Constitutive heterochromatin is found at centromeres and telomeres and 
consists of repeating sequences of DNA that are not transcribed. Facultative 
heterochromatin is usually transcriptionally silenced although may become active 
depending on signalling cues (Trojer and Reinberg, 2007). Transcriptionally active 
genes are typically found in euchromatin, which is not as tightly compacted as 
heterochromatin. The open structure of euchromatin is usually described as 
resembling beads on a string, with the string representing DNA and the histone 
proteins represented by beads. Not all genes in euchromatin are constitutively 
expressed and regions with inactive genes are closed to restrict accessibility to the 
transcription machinery. Regions of transcriptionally inactive euchromatin is 
condensed into facultative heterochromatin, with the process reversed upon activation 
of gene transcription. Repression of transcription exists on a continuum and genes 
may be partially or fully repressed. Studies in yeast show that the complete silencing 
of genes is a gradual process and occurs over multiple cell divisions (Katan-
Khaykovich and Struhl, 2005). Furthermore, the spatial organisation of chromatin can 
affect gene transcription. Genes in euchromatin that are in close proximity to 
heterochromatin may also be silenced, a phenomenon termed position effect 
variegation (PEV). PEV was originally identified in Drosophila although it has also been 
demonstrated in mammals (Kleinjan and Heyningan, 1998). This demonstrates how 
the structure of chromatin can influence whether a gene is transcribed.  
 
Post-transcriptional modifications to histone proteins provide a method of 
epigenetically altering gene expression. Histones are highly conserved proteins that 
DNA wrap around in a nucleosome, subsequently compacting it into chromatin. There 
are four core histones, H2A, H2B, H3 and H4. Each nucleosomes unit consists of 
146bp DNA wrapped around two of each of the four core histones forming an octamer. 
Nucleosomes are joined by two linker histones H1 and H5.  
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1.6.2.2 Chromatin remodelling and histone modifications 
 
The amino acids of core histone N-terminal tails can be chemically modified in a 
number of ways, the most common being methylation and acetylation. These marks 
have the potential to change the structure of chromatin and accessibility of the DNA to 
the transcriptional machinery. Histone marks regulate transcription by recruiting 
chromatin modelling complexes change the configuration of chromatin to allow or block 
the accessibility of the transcriptional machinery to genes. Specific histone 
modifications may be represented in text in short form. The nomenclature of histone 
modifications notation begins with the histone number followed by the modified residue 
and type and number of chemical groups added. For example, H3K4me3 conveys that 
histone H3 is modified on the fourth lysine residue with three methyl groups. 
 
Besides methylation and acetylation, other histone modifications include ubiquitination, 
sumoylation and phosphorylation. This short review focuses on methylation and 
acetylation as other types of modifications are beyond the scope of this project. Histone 
marks that influence gene transcription are found throughout the genome including at 
regulatory elements and within gene bodies (Hon et al, 2009). Methylation of histones 
may lead to transcriptional repression or activation of genes depending on the specific 
mark. For example, H3K4me3 is associated with gene transcription whereas 
H3K27me3 is usually linked to transcriptional repression. Methylation of histones 
involves the covalent addition of a methyl group (-CH3) to lysine or arginine residues 
on histone tails. S-Adenosylmethionine is the main methyl donor in many organisms 
including humans (Detich et al, 2003). Lysines may be mono-, di- or tri-methylated. 
Arginine residues may be mono- or di-methylated (Bannister and Kouzaridas, 2011). 
These modifications are mediated by either lysine or arginine methyltransferases. It 
was originally thought that histone methylation was an irreversible process. However, 
histone demethylation enzymes have been identified, the first of which was KDM1A 
(Shi et al, 2014).  Histone demethylases act in complexes in order to demethylate 
nucleosomal histones.  
 
Histone acetylation is associated with transcriptional activation (Eberharter and 
Becker, 2002). Acetylation of histones is mediated by histone acetyltransferases 
(HATs) and removed by histone de-acetylases (HDACs). HATs catalyse the addition 
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of an acetyl group to lysines on histone tails, although sites within globular histone core 
can also be acetylated, such as H3K56 (Yuan et al, 2009). In contrast to methylation, 
lysines can only be acetylated once. Acetylation of histones leads to remodelling of 
chromatin into an open conformation. Acetylation is also proposed to neutralise the 
positive charge on the lysine, which weakens the bond between the histone and DNA. 
This opens the chromatin to transcription factors that can then bind to DNA to initiate 
transcription. HDACs remove acetyl groups from lysine, restoring the charge difference 
between histone and DNA (Bannister and Kouzarides, 2011).  
 
 
Figure 1.8 – Chromatin remodelling by ATP-dependent chromatin remodelers mediated by histone 
modifications. Specific histone modifications attract remodelers to alter the structure of chromatin. Some 
chromatin remodelers e.g. Swi/Snf are involved in both opening and closing chromatin whereas others only 
remodel in one direction.  Image adapted from Tsukiyama, 2002.  
 
Chromatin remodelling enzymes reposition histone proteins, changing the 
conformation of chromatin. A number of chromatin remodelling complexes have been 
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identified (Fig. 1.8) but a comprehensive review is beyond the scope of this project. 
Chromatin remodellers interact with histone modifying enzymes to couple histone 
modifications and chromatin remodelling (Felisbino et al, 2013). Repressive histone 
marks are known to silence gene expression by recruiting polycomb group protein 
containing complexes (PRCs). Histone marks H3K9me3 and H3K27me3 are both 
found in heterochromatin. H3K9me3 marks are abundant throughout constitutive 
heterochromatin and H3K27me3 is common in facultative heterochromatin. The PRC1 
complex is able to recognise and dock at H3K27me3 sites and subsequently 
ubiquitinate H2A, which in turn attracts PRC2. PRC2 catalyses the transfer of methyl 
groups to H3K27, creating a positive feedback loop. These two complexes work 
together to remodel chromatin into higher order structures to silence transcription 
(Blackledge et al, 2014). 
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1.6.2.3 Regulatory elements and the histone code  
 
The histone code is the hypothesis that histone modification patterns can determine 
whether a gene is switched on or off. It is proposed that gene expression can be 
predicted by the histone modifications surrounding a gene (Jenuwein, 2001). 
Interpreting this code could help elucidate how transcription is regulated via histone 
modifications. The histone code hypothesis is more complex than originally thought. 
Histone modifications can indeed determine whether genes are transcribed. However, 
combinations of histone modifications often exist and different combinations have 
different meanings in the context of gene regulation.  
 
Distinct histone modifications mark cis-regulatory regions in the genome such as gene 
promoters and enhancers. Different histone modifications may be site specific or found 
genome wide. The core or minimal promoter of genes generally consists of its 
transcriptional start site (TSS), binding sites for RNA polymerases and general 
transcription factors and a 5'-TATAAA-3' motif known as a TATA-box. The proximal 
promoter is the region outside of the core promoter that contains further transcription 
factor binding sites. Promoters are located upstream of genes but can also overlap the 
TSS and 5’UTR at the start of genes. The size of promoters varies but can range from 
100bp to over 1kb (Kanhere and Bansal, 2005). Although histone methylation generally 
silences transcription of genes, some methylation marks can also be active.  H3K4me3 
is associated with the promoters of transcriptionally active genes. Regulatory elements 
can also contain bivalent domains, where both active and repressive marks are 
present. Bivalency is common in stem cell promoters, which often become monovalent 
after differentiation (Mikkelsen et al, 2007). H3K4me3 and H3K27me3 co-localisation 
are a bivalent state often seen in stem cell promoters. It is thought that H3K27me3 
represses activation of lineage specific genes whereas H3K4me3 readies the gene for 
activation upon differentiation (Bernstein et al, 2006), however, others have shown that 
bivalently marked genes may be expressed at low levels (De Gobbi et al, 2011). Upon 
differentiation, promoters may lose either H3K27me3 or H3K4me3 marks, or remain 
bivalent (Cui et al, 2009). Bivalent modifications can also be established upon entering 
a differentiation lineage (De Gobbi et al, 2011).  Genome wide histone marks H3K9ac 
and H3K14ac are usually associated with active and bivalent promoters alongside 
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H3K4me3, and show a strong correlation with the CpG content of promoters 
(Karmodiya et al, 2012). 
 
H3K27me3 marks are associated with transcriptional repression and can be found 
throughout the genome. However, in rare cases H3K27me3 may also correlate with 
active transcription. H3K27me3 marks were enriched in the promoter of genes that 
were transcriptionally active in mouse embryonic and progenitor cells (Young et al, 
2011). This adds an extra layer of complexity to the histone code hypothesis, as there 
is some degree of plasticity to whether a histone mark is repressive or active depending 
on the gene and/or cell type. H3K9me3 is another example of a transcriptionally 
repressive mark. Whilst typically found in constitutive heterochromatin in contrast to 
H3K27me3 which marks facultative heterochromatin, H3K9me3 also plays a role in 
cell type specific gene regulation (Becker et al, 2016).  
 
Gene enhancers are distal regulatory elements that can regulate their target gene over 
long distances and do not necessarily act on its nearest gene. Enhancers can be found 
1Mbp away from the gene it regulates (Cho, 2014). Sizes of enhancers show more 
variation than promoters and can range from 50bp to many thousands of bases. 
Enhancers are typically found upstream of genes but may also be downstream or 
within gene bodies. Active enhancers are proposed to interact with their target 
promoters through a chromatin looping mechanism (Fig. 1.9). The enhancer-promoter 
interaction initiates gene transcription by attracting the components of the transcription 
machinery such as RNA polymerase II.  Like promoters, enhancers also contain 
binding sites for transcription factors and co-activators. H3K27ac is a marker of active 
promoters and active enhancers. H3K4me1 is associated with poised enhancers when 
alone and active enhancers alongside H3K27ac (Creyghton et al, 2010). As well as 
H3K27ac, the Mediator 1 coactivator protein (MED1) is often used as a marker for 
active enhancers. MED1 is a subunit of the Mediator transcriptional co-activator 
complex. The p300 co-activator is an active enhancer marker and can also be used to 
define super enhancers (Pott and Lieb, 2015). Enhancers tend to be cell type specific 
and regulate genes involved in cell type specific processes rather than genes involved 
in general maintenance of the cell (Ong and Corces, 2011).  
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Individual enhancers may regulate multiple genes and the same enhancer may 
regulate different genes in different cell types. There are far more enhancers present 
in the genome compared to genes. Redundancy of enhancers is proposed to aid in 
fine tuning the regulation of gene transcription (Guerrero et al, 2010).  
 
A subgroup of enhancers called super enhancers have been identified. These are 
defined as multiple neighbouring enhancers that exhibit high levels of enhancer 
markers such as H3K27ac and MED1. Super enhancers are reported to increase the 
upregulation of genes compared to typical enhancers. Stretch enhancers, another 
subgroup of enhancers, are defined as long enhancers associated with cell type 
identity. Stretch and super enhancers share many similarities and may be largely 
synonymous (Pott and Lieb, 2015). 
 
 
Figure 1.9 – Schematic of regulatory elements in the genome. (A) General layout of cis-regulatory elements 
surrounding genes; enhancers are typically located distal to the gene TSS whereas promoters are proximal to 
the gene TSS. (B) Enhancer-promoter looping model. Enhancers may be bound by transcription factors that 
facilitates enhancer binding to a target promoter to activate gene transcription by recruiting RNA polymerase II 
and transcription initiation factors. Enhancers do not necessarily target the nearest gene and can act on genes 
over 1Mbp away.  
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Histone modifications can occur both at regulatory elements of genes and within gene 
bodies. H3K36me3 is a transcriptionally permissive mark found in actively transcribed 
genes. The histone methyltransferase SET2 catalyses the addition of methyl groups 
H3K36 within genes and interacts with RNAPII, leading to the coupling of H3K36me3 
marks and transcription elongation (Kizer et al, 2005). SET2 physically binds to gene 
bodies but not gene promoters (Schaft et al, 2003). This demonstrates that gene 
transcription is not only regulated at promoters and enhancers but relies on a co-
ordinated effort across the gene.  
 
Histone methylation and demethylation is proposed to affect diseases such as cancer 
and also in ageing and cell senescence by switching on and off relevant genes. This 
makes histone methyltransferases and demethylases attractive drug targets (Cloos et 
al, 2008). HDAC inhibitors (HDACi) are inhibitors of HDAC and prevent HDAC activity 
by binding to the catalytic domain of HDACs. Targeting of HDACs with HDACi has 
been used as a therapeutic for diseases such as cancer. Cancers caused by abnormal 
HDAC recruitment to promoters of oncogenes can potentially be treated with HDACi. 
Furthermore, HDACs are up-regulated in a number of cancers. Treatment with HDACi 
results in cell cycle arrest and apoptosis (Marks et al, 2000). Use of HDACi in cancer 
has been promising and a number of drugs have been licenced for this purpose. For 
example, vorinostat is a HDACi used to treat cutaneous T cell lymphomas and has 
also been used in HIV research (Archin et al, 2009). The use of HDACi’s has also been 
explored as therapeutics for OA. Recent studies have shown that treatment with 
HDACi can have a chondroprotective effect by repressing MMP expression induced 
by cytokines (Young et al, 2005; Culley et al, 2013). Despite encouraging outcomes 
so far, there are still some issues with specificity and cardiotoxicity (Gryder et al, 2012) 
associated with the therapeutic use of HDACi. The use of HDACi to modify gene 
expression in disease illustrates how important histone modifications are in regulating 
gene expression. HDACi’s may also be used to regulate chondrogenesis in vitro. An 
HDACi, trichostatin A, was shown to be able to inhibit hMSC chondrogenesis through 
suppression of the Sp1 transcription factor (Wang et al, 2011). These studies show 
that the epigenome can be modified to alter gene transcription.  
 
As well as using enzymes to modulate epigenetic marks, the use of genome editing 
methods to alter epigenetic marks has been investigated. The versatile CRISPR-Cas9 
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technique can be used to engineer non-coding as well as coding regions of the 
genome. Epigenome editing can be achieved by targeting activator or repressor 
proteins to promoters or enhancers of genes (Hilton et al, 2015).  Functional roles of 
enhancers have been elucidated by targeting Cas9 to transcription factor binding sites 
within enhancers (Korkmaz et al, 2016).  
 
Groupings of histone modifications can define regulatory elements and regulate genes 
through modulating chromatin remodelling to allow or block access of transcription 
factors. However, histone modifications also rely on other epigenetic mechanisms such 
as DNA methylation. Histone modifications rely on DNA methylation and vice versa 
(Cedar and Bergman, 2009). Crosstalk between the two epigenetic mechanisms 
allows for greater control of gene transcription and it is important to consider histone 
modifications in the wider context of the whole epigenome.  
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1.6.3 DNA methylation 
 
DNA methylation is an important epigenetic mark influencing gene transcription. 
Methylation of DNA is generally a repressive mark although there are exceptions 
(Halpern et al, 2014). DNA methylation is important in mammalian development in 
controlling the expression of imprinted genes and aiding in X-chromosome inactivation. 
Imprinted genes are genes that are expressed depending on their parental origin. 
Autosomal genes in diploid organisms possess two copies or alleles inherited from 
both parents and gene expression usually occurs equally from both. However, a small 
number of imprinted genes are only expressed from just one allele. For example, the 
IGF2 gene is only expressed from the paternally inherited allele and the maternal allele 
is silenced (Giannoukakis et al, 1993). Genomic imprinting also affects tissue specific 
genes (Gregg et al, 2010). During early embryonic development, the majority of DNA 
methylation is erased and re-established with imprinted genes programmed to only 
express one allele, in part due to DNA methylation of the silenced allele. In females, 
one X-chromosome is randomly inactivated so that genes on the X-chromosome have 
the same level of gene expression as the single X-chromosome present in males 
(Sharp et al, 2011). The XIST non-coding RNA gene initiates X-chromosome 
inactivation which is maintained by DNA methylation (Plath et al, 2002). More 
generally, DNA methylation acts alongside other epigenetic mechanisms to control 
gene transcription.   
 
DNA may be methylated at CpG sites, typically clustered together to form CpG islands 
near gene promoters (Illingworth and Bird, 2009). Specifically, the cytosine base within 
CpG sites are methylated to form 5-methylcytosine (5mC). More rarely than cytosine, 
adenine bases can also be methylated (Wu et al, 2016). DNA methylation is mediated 
by DNA methyltransferase (DNMTs) enzymes which catalyse the addition of a methyl 
group to the cytosine base. In mammals, three active DNMTs have been found - 
DNMT1, DNMT3A and DNMT3B. DNMT3A and DNMT3B can target promoters as a 
complex along with HDACs and other transcriptional repressors, illustrating the 
crosstalk between histone modifications and DNA methylation (Arzenani et al, 2011; 
Smith and Meissner, 2013).  
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At CpG islands in promoters of actively transcribed genes, hypomethylation is 
achieved by preventing DNA methyltransferases from accessing the CpG sites. 
Housekeeping genes possess promoters that are constitutively hypomethylated, 
reflecting the continual transcription of these genes. Transcription factor binding at 
promoters help block DNA methyltransferases from methylating and thus repressing 
gene transcription. The Sp1 transcription factor was found to prevent methylation of 
CpG islands. Removal of transcription factor binding sites in gene promoters lead to 
higher methylation levels at CpG sites in the promoter, suggesting that DNA 
methylases and transcription factors compete for binding (Brandeis et al, 1994; 
Macleod et al, 1994). DNA methylation also plays a role in alternative splicing by 
inhibiting CTCF binding at exons; CTCF promotes the inclusion of exons by stalling 
RNA polymerase II (Shukla et al, 2011).   
 
Methyl groups can be removed from DNA by demethylase enzymes in a multistep 
process (Pfeifer et al, 2013). 5mC can become oxidised to form 5-hydroxycytosine 
(5hmC), a process mediated by the TET family of proteins. 5hmC is an intermediate 
modification formed during the demethylation of 5mC. The existence of 5hmC was first 
discovered in bacteria and was confirmed to be present in mammalian cells in 2009 
(Kriaucionis and Heintz, 2009; Tahiliani et al, 2009).  
 
Interestingly, promoters of housekeeping genes and some development genes remain 
hypomethylated even when transcriptionally silent (Weber et al, 2007). This suggests 
other regulatory mechanisms are also involved in modulating gene expression. 
Although early studies on DNA methylation have focused on gene promoters, gene 
enhancers may also be methylated. In general, promoters show a lower level of DNA 
methylation compared to enhancers. DNA methylation at enhancers is associated with 
regulation of genes involved in cell specific processes. Hypomethylation of gene 
enhancers and super enhancers is correlated with increased cell specific gene 
expression in muscle cells (Ehrlich et al, 2016). It was shown in cancer cells that 
hypomethylation of enhancers more closely correlated with gene expression than 
hypomethylation of promoters (Aran et al, 2013). Therefore, associating DNA 
methylation at promoters to gene transcription without considering methylation at other 
regulatory elements may be overly simplistic.  
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1.7 Bioinformatics  
 
 
1.7.1 High throughput sequencing 
 
High throughput sequencing, also called next-generation sequencing (NGS; although 
this term has fallen out of use), is one of the methods commonly used in ‘omics studies. 
High throughput sequencing encompasses the newer, high throughput methods of 
DNA sequencing that have been developed after the original Sanger sequencing 
method. Sanger sequencing was developed in 1977 by Frederick Sanger and for many 
years it was the sole method of sequencing DNA. The dye terminator Sanger 
sequencing method determines the sequence of a DNA template using DNA 
polymerase, a DNA primer, deoxynucleosidetriphosphates (dNTPs) and di-
deoxynucleotidetriphosphates (ddNTPs). Briefly, the primer binds to the ssDNA 
template and the DNA polymerase extends the primer using dNTPs. In current Sanger 
sequencing, the sequence is determined and reaction terminated when a fluorescently 
labelled ddNTP binds to the elongating strand and emits light; each of the four ddNTPs 
are labelled with fluorescent dyes that emit light at different wavelengths. Owing to the 
reaction being terminated by the incorporation of a ddNTP, a large amount of starting 
DNA template is required to fully determine the DNA sequence as many reactions are 
needed. This is one of the limitations of Sanger sequencing; it is not possible to 
sequence rare DNA samples using this method. Furthermore, it can be a slow process 
requiring many reactions to determine the full sequence of a length of DNA. Although 
Sanger sequencing for genomics applications has been largely replaced by newer 
methods, it is still widely used for small scale DNA sequencing such as determining 
the sequence of plasmids. It is also used when longer reads are required; one of the 
main advantages of Sanger sequencing is that it can generate reads of up to 1000bp. 
In contrast, many high throughput methods typically only manage 50-150bp reads 
(Hodkinson and Grice, 2015).  
 
High throughput sequencing methods can sequence many DNA templates 
simultaneously multiple times. Massively parallel sequencing can generate millions of 
reads in a comparatively short time. This allows for deep sequencing of DNA where 
bases are sequenced multiple times, reducing the potential for sequencing errors. High 
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throughput sequencing generates large amounts of data which presents challenges 
for storage and analysis. 
There are a selection of high throughput sequencing methods developed by different 
life science companies including SOLiD sequencing, pyrosequencing, Ion Torrent 
sequencing and Illumina sequencing. Each has its own advantages and disadvantages 
and have enjoyed varying popularity over the years. As of 2015, Illumina’s sequencing 
by synthesis platforms dominate the high throughput DNA sequencing market and their 
success is predicted to continue (Goodwin et al, 2016).  Illumina’s sequencing by 
synthesis method is an adaptation of dye terminator Sanger sequencing using non-
terminating ddNTPs. The cost of high throughput sequencing has dramatically fallen 
in recent years, making it more accessible to researchers. Accordingly, increasingly 
sophisticated bioinformatics tools have been developed to cope with the large influx of 
sequencing datasets and the various needs of different research groups. In general, 
more bioinformatics resources are required to store and analyse high throughput 
sequencing data compared to array data.  
 
From high throughput DNA sequencing, a number of derivative methods have been 
developed to assay various biological molecules and features. Originally, sequencing 
methods were used to determine the sequence of genomic DNA. Nowadays, there are 
adapted methods to assay the transcriptome, exome and epigenome.  
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1.7.2 ‘Omics methods 
 
1.7.2.1 Transcriptome 
 
The transcriptome is the full repertoire of RNA transcripts transcribed by the genome. 
This includes messenger RNA (mRNA), ncRNA, ribosomal RNA (rRNA) and small 
nucleolar RNA (snoRNA). The types of RNA have different functions; mRNA is 
important as it may be translated into protein. Other species of RNA may be involved 
in regulation of transcription or translation. To quantify the transcriptome, RNA is 
extracted from the cells or tissue of interest and cDNA synthesised from the RNA. The 
relative amounts of cDNA are used to assess transcript levels. There are two main 
methods of assaying the transcriptome, microarrays and RNA-seq. Gene expression 
microarrays consists of a DNA chip bound with nucleotide probes. Microarrays rely on 
complementary probes that bind fluorescently labelled cDNA to measure gene 
expression. The level of fluorescence is assessed to quantify relative abundance. 
 
RNA-seq may also be used to determine the abundance of RNA transcripts in the 
transcriptome. The cDNA can be prepared into a cDNA library and sequenced in the 
same way as genomic DNA. Analysis of RNA-seq usually involves mapping reads to 
a reference genome, quantifying and normalising reads within a transcript and testing 
for differential gene expression between multiple conditions. RNA-seq has a larger 
dynamic range compared to DNA microarrays and can more accurately detect both 
very rare and highly abundant transcripts (Zhao et al, 2014). Gene expression 
microarrays have largely fallen out of fashion in favour of RNA-seq. Unlike DNA 
microarrays which depend on using probes to known transcripts to assay gene 
expression, RNA-seq has the ability to detect novel transcripts, splice sites and 
alternative splicing events.  
 
1.7.2.2 DNA methylome 
 
Whole genome methylation assays are used to characterise the DNA methylome 
during biological processes including disease and development. Like transcriptomics 
methods, the DNA methylome may be assayed using array based or sequencing 
based methods. To determine methylation, DNA is extracted and denatured and 
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treated using sodium bisulfite which leads to the deamination of unmethylated 
cytosines to uracil. Methylated cytosines, 5mC or 5hmC, remain intact. Subsequent 
PCR amplifies uracil bases as thymine and 5mC or 5hmC as cytosines thus allowing 
for discrimination between methylated and unmethylated cytosines bases.  
 
DNA methylation arrays are a popular method of investigating the methylome and are 
based on DNA gene expression microarray technology. It is carried out using a 
microarray chip containing probes that bind to bisulfite converted DNA sequences. The 
array probes incorporate a fluorescently labelled ddNTP and the intensity of the 
fluorescent signal represents the quantity of methylation. Methylation probes are 
designed to bind to specific CpG sites in the genome. Initially, 27K probe methylation 
arrays were offered by Illumina but this has expanded to 450K and beyond - the 
number of CpG sites that can be quantified has increased up to more than 850,000 in 
Illumina’s new MethylationEPIC BeadChip. Only CpG sites with probes designed can 
be quantified; the use of probes is a major limitation of array-based methods because 
only designated sites can be assayed, an issue which also affects gene expression 
microarrays. Although methylation arrays are commonly described as a genome wide 
method, they are not truly genome wide and are biased towards regions with a high 
density of probes. Despite this, DNA methylation arrays remain popular whereas gene 
expression microarrays have given way to RNA-seq.  
 
Whole genome bisulfite sequencing can also be used to assay DNA methylation. In 
this method, a DNA sequencing library is prepared from bisulfite treated DNA and 
sequenced. Subsequent bioinformatics analysis differentiates between thymines, 
which may be derived from normal thymines or unmethylated cytosines, and cytosines, 
derived from methylated cytosines. This approach does not rely on probes and can 
quantify methylation anywhere in the genome.  Like DNA methylation arrays, bisulfite 
sequencing is unable to distinguish between 5mC and 5hmC. One of the major 
challenges with bisulfite sequencing is the bisulfite conversion of DNA which can lead 
to excessive DNA degradation. Incomplete conversion can lead to false positives if 
unmethylated cytosines are not converted to uracil (Leontiou et al, 2015). Another 
issue is inaccurate alignment of reads after conversion, read aligners designed for 
bisulfite sequencing data must allow for mapping asymmetry and a degree of possible 
errors (Chatterjee et al, 2012).  
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1.7.2.3 Histone modification assays 
 
Chromatin immunoprecipitation coupled with high throughput sequencing (ChIP-seq) 
can be used to determine all the sites a DNA binding protein binds to in the genome. 
Transcription factors are commonly assayed although any protein that binds to DNA 
can be investigated using this method (TF ChIP-seq). Briefly, this technique involves 
cross-linking DNA to proteins, extracting chromatin from cells or tissues and sonicating 
the DNA with endogenously bound proteins then performing an immunoprecipitation 
using an antibody to bind the protein of interest. A DNA sequencing library is then 
prepared using immunoprecipitated DNA fragments (Fig. 1.10).  
 
 
Figure 1.10 – Overview of the ChIP-seq technique. Chromatin is extracted from cells or tissues, proteins are 
crosslinked with DNA before sonication of the chromatin. Chromatin fragments are immunoprecipitated using 
an antibody against a protein or histone modification. The immunoprecipitated chromatin fragments are 
reverse crosslinked and the DNA is prepared into a sequencing library.  
 
Bioinformatics analysis is used to identify regions of the genome enriched with the 
protein after high throughput sequencing.  Histone modifications in the genome can 
also be studied with this method (histone ChIP-seq) using antibodies against the 
histone modification of interest. Although similar, TF and histone ChIP-seq present 
with different challenges.  Both rely on the availability of a good quality antibody for the 
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protein or histone mark studied, however, the quality control and analysis of data post-
sequencing is different. TF ChIP-seq produce short, sharp peak signals (narrow peaks) 
whereas histone ChIP-seq generally produce wider enrichment peak signals (broad 
peaks). This difference in signal length means different parameters are required when 
assessing the data and during peak calling. 
 
Different ChIP-seq datasets can be analysed together to assess co-binding of 
transcription factors or generate chromatin states using multiple histone modifications. 
Co-occurrence of histone modifications may be used to define chromatin states (Ernst 
and Kellis, 2012). Promoters, enhancers, active and repressed regions can be 
determined using a panel of histone modifications assayed using ChIP-seq. The 
Encyclopaedia of DNA Elements (ENCODE) and Roadmap Epigenomics projects 
have used the ChIP-seq technique extensively to characterise the epigenomes of 
many human cell types and tissues. ENCODE, one of the early pioneers of large scale 
epigenomics, has published a set of guidelines for optimal ChIP-seq performance 
(Landt et al, 2012).  
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1.7.2.4 Chromatin interactome 
 
Epigenomic marks influence the structure of the chromatin and chromatin interactions, 
these interactions can indicate target genes of regulatory elements. The 3D chromatin 
interactions in the genome can be assayed using chromatin conformation capture 
assays. Coupled with high throughput sequencing, methods such as Hi-C can detect 
all chromatin interactions present in the genome. 4C is a similar method whereby a 
region of the genome, e.g. a promoter or enhancer, is used as a bait to determine 
chromatin regions that interact with the bait region. Establishing the physical 
interactions in the genome can help to define enhancer-promoter pairings and identify 
trans-acting regulatory elements. Chromatin conformation assays can also be used to 
help define topologically associated domains (TADs). Regions of chromatin within the 
same TAD are likely to physically interact whereas separate TADs rarely interact 
(Pombo and Dillon, 2015).  
 
Chromatin interactions differ between cell types and large-scale changes are seen 
during differentiation of stem cells (Dixon et al, 2015). TAD boundaries between cell 
types are largely conserved, however, interactions within and between TADs are cell 
type specific (Smith et al, 2016).  
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1.8 Bioinformatics and the ‘omics revolution 
 
Modern bioinformatics is an interdisciplinary field that has developed over the past two 
or three decades to analyse and interpret biological data generated by new high-
throughput technologies such as high throughput sequencing. Bioinformatics 
incorporates elements of computer science, mathematics and statistics and applies 
methods derived from these areas to biological research. In particular, in silico tools 
and methods have facilitated genome wide ‘omics research, allowing researchers to 
manage vast amounts of information at once. These computational approaches have 
greatly advanced our knowledge of the genome, transcriptome and the epigenome. 
The Human Genome Project (HGP; Lander et al, 2001), completed in 2003, signified 
the advent of the ‘omics era. Since then there have been many large-scale projects 
designed to interrogate various aspects of the human genome and its derivative ‘omes.   
 
As well as the human genome, the genomes of model organisms and other species of 
interest have been determined. Since the HGP, thousands of prokaryote, viral and 
eukaryote genomes have been sequenced. The US National Centre for Biotechnology 
Information (NCBI), Ensembl consortium and University of California, Santa Cruz 
(UCSC) provide online public databases of annotated genomes and reference genome 
sequences. In the UK, the 100,000 genomes project orchestrated by Genomics 
England and the NHS aims to sequence the individual genomes of patients and their 
families with rare diseases and cancers.  
 
Epigenomics projects usually incorporate DNA methylation, histone modification, 
transcription factor binding and chromatin conformation capture assays. The ENCODE 
project was initiated shortly after the conclusion of the HGP (Dunham et al, 2012). The 
ENCODE project is a worldwide consortium which aims to characterise all the 
regulatory elements in the human genome and to provide a public repository of data 
generated as part of this project. The project is currently ongoing and has progressed 
through three phases - the pilot phase, the production phase and the data analysis 
phase. As of 2017, the project has entered into its fourth phase which focuses on 
further data acquisition and analysis.  The Roadmap Epigenomics project is a similar 
initiative to ENCODE and has so far characterised over 111 epigenomes of different 
human cell types and tissues (Romanoski et al, 2015). The Blueprint consortium is 
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another large scale epigenomics project that has characterised over 100 epigenomes 
from haematopoietic cells. The epigenomes of some model organisms have also been 
investigated. For example, ModENCODE is a side project of ENCODE whose objective 
is to determine the functional elements within the Caenorhabditis elegans and 
Drosophila melanogaster genomes (Muers, 2011). The mouse also has a similar 
epigenome project, mouse ENCODE (Stamatoyannopoulos et al, 2012).  
 
Sharing data is encouraged and some journals stipulate that data be made publically 
available once the manuscript has been published. Journals encourage authors to 
upload accompanying data into online repositories such as the NCBI databases 
sequence read archive (SRA) or gene expression omnibus (GEO). The European 
Bioinformatics Institute (EBI) hosts ArrayExpress, another data repository, which 
accepts sequencing as well as array data. The generation and sharing of large 
amounts of biological big data has led to new methods of analysing and interpreting 
results. Integration of ‘omics data allows researchers to bring together different aspects 
of biology to form a bigger picture. This is especially beneficial when investigating the 
interplay between multiple biological mechanisms that are assayed using different 
methods.  
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1.9 Rationale for PhD 
 
Chondrocytes are the sole cell type in articular cartilage and are responsible for 
homeostasis of the surrounding ECM. Mutations in genes and regulatory regions of 
genes can lead to impaired chondrogenesis and cartilage abnormalities. It is becoming 
increasingly apparent that epigenetic regulatory mechanisms play important functions 
in all biological processes including chondrogenesis. Histone modification changes 
have been observed in MSC differentiation into chondrocytes in an alginate scaffold 
model (Herlofsen et al, 2013). Epigenetic mechanisms may be used to modulate gene 
expression in chondrogenesis for tissue engineering purposes and have therapeutic 
potential for treating OA (Huang et al, 2015; Yapp et al, 2016). Furthermore, OA 
chondrocytes undergo changes similar to hypertrophic chondrocytes in development 
(van der Kraan and van der Berg, 2012). Investigation of the epigenome during 
chondrogenesis will lead to a better understanding of gene transcription regulation in 
chondrocytes. This may facilitate engineering of chondrocytes and hMSCs better 
suited to tissue regeneration and implantation in diseased or injured cartilage. 
Epigenome editing is possible using modifying enzymes and the CRISPR-Cas9 
technology. However, more knowledge of cis-regulatory regions and how they 
crosstalk with other epigenetic mechanisms such as DNA methylation during 
chondrogenesis is required.  
 
Chondrogenesis in human cells is possible with the use of in vitro models. The scaffold-
free transwell model of chondrogenesis has proven to be a good model for the study 
of hMSC differentiation into chondrocytes. Scaffold-free models are more likely to 
represent the chondrogenesis process that occurs during development. The initial 
objective of this project is to generate genome wide histone modification data during 
MSC chondrogenesis in the transwell model.  
 
The use of histone ChIP-seq allows the genome wide investigation of multiple histone 
marks. By assaying a range of histone marks, we can observe patterns of co-
occurrence and infer regulatory functions from existing knowledge. For this reason, we 
chose histone marks to reflect a range of regulatory states (Table 1.1). These histone 
marks were included in the ENCODE and Roadmap projects and are well 
characterised.  
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Table 1.1 – Histone modifications selected for ChIP-seq 
Histone modification Regulatory role 
H3K4me3 Active promoter 
H3K4me1 Active/poised enhancer 
H3K27ac Active promoter and active enhancer 
H3K27me3 Transcriptionally repressive 
H3K36me3 Transcriptionally permissive 
 
 
Previously, our research group has generated microarray, RNA-seq and DNA 450k 
methylation array data using the transwell model of chondrogenesis. We observed 
gene expression and DNA methylation changes between day 0 and day 14 of MSC 
differentiation into chondrocytes. We hypothesise that by generating histone ChIP-seq 
data of the same model and integrating histone modification data with existing data, 
we will be able to define regulatory regions in the genome. DNA methylation and 
histone modifications often depend on each other and integrating these will lead to a 
greater insight into the interplay between these important epigenetic mechanisms. This 
will increase our understanding of chondrogenesis and identify potential targets for 
experimental validation. Furthermore, chondrogenesis ChIP-seq is a pre-requisite for 
performing similar studies in normal human articular chondrocytes, OA chondrocytes 
and other conditions. It has been proposed that epigenetic mechanisms may be used 
to enhance chondrogenesis. Therefore, better characterisation of the epigenome may 
lead to the development or improvement of in vitro models which could have 
therapeutic value for cartilage repair.  
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1.10 Project aims 
 
• Generate histone ChIP-seq data for histone marks H3K4me3, H3K4me1, 
H3K27ac, H3K27me3 and H3K36me3 in an in vitro transwell model of 
chondrogenesis at day 0 and day 14. Make data publically available once 
published.  
 
• Analyse histone ChIP-seq data and generate chromatin states from the histone 
marks assayed, identify regulatory regions such as enhancers and promoters. 
 
• Integrate ChIP-seq data to chondrogenesis RNA-seq and DNA 450K 
methylation datasets. 
 
• Identify epigenetic changes between hMSCs and differentiated chondrocytes. 
 
• Experimentally test selected regulatory elements identified from epigenomic 
data. 
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Chapter 2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Equipment 
 
ABI PRISM® 7900HT Sequence Detection System 
Applied Biosystems™ QuantStudio 3 
Applied Biosystems® Veriti® 96-Well Fast Thermal Cycler 
Diagenode Bioruptor Standard 
Diagenode Bioruptor Pico 
Promega Glomax-Multi+ Detection System 
NanoDrop 2000 
Qubit™ 3.0 Fluorometer 
 
2.1.2 Kits 
 
iDeal Histone ChIP-seq kit (Diagenode, cat. no. C01010050) 
PureYield™ Plasmid Miniprep System (Promega, cat. no. A1223) 
PureYield™ Plasmid Midiprep System (Promega, cat. no. A2495) 
Dual-Luciferase® Reporter Assay System (Promega, cat. no. E1960) 
NucleoSpin Gel and PCR Clean-up (Macherey-Nagel, cat no. 740609) 
Qubit dsDNA high sensitivity (HS) assay kit (Life technologies, cat. no. Q32851) 
 
2.1.3 Antibodies 
 
ChIP-seq grade polyclonal rabbit H3K4me1 (Diagenode, cat. no. C15410194) 
ChIP-seq grade polyclonal rabbit H3K27ac (Diagenode, cat. no. C15410196) 
ChIP-seq grade polyclonal rabbit H3K27me3 (Diagenode, cat. no. C15410195) 
ChIP-seq grade polyclonal rabbit H3K36me3 (Diagenode, cat. no. C15410192) 
SOX9 antibody, source rabbit (Millipore, cat. no. AB5535) 
HRP-conjugated goat anti-rabbit secondary antibody (Millipore, cat. no. 12384) 
IgG (included in Diagenode iDeal Histone ChIP-seq kit) 
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2.1.4 Enzymes 
 
For cell culture: trypsin-EDTA (Life Technologies, cat. no. 25300054) 
For digestion of cartilage discs: Hyaluronidase, trypsin, collagenase (all Sigma Aldrich) 
RT-qPCR Taqman Gene Expression Master Mix (Applied Biosystems, cat. no. 
4369510) 
In-Fusion HD Enzyme Premix (Clontech, cat. no. CL639647) 
Phire Hot Start II DNA Polymerase (Thermo Scientific) 
Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase (Life Technologies) 
 
2.1.5 Immunoblotting reagents 
 
TEMED (NNNN-Tetramethylethylenediamine; Sigma Aldrich) 
Tween-20 (polyoxyethylene sorbitan monolaurate, Sigma Aldrich) 
APS (Ammonium persulphate; BDH Chemicals) 
37:5:1 Acrylaminde/bis-acrylamide (Amresco) 
PVDF membrane (Immobilon-P polyvinylidene difluoride, 0.45µm, Millipore) 
ECL (Enhanced chemiluminescence, Amersham Biosciences) 
SeeBlue Plus 2 pre-stained protein standards (Invitrogen) 
Instant dried skimmed milk powder (Tesco)  
Triton X-100 (Sigma Aldrich) 
 
2.1.6 General reagents, chemicals and alcohols 
 
Molecular biology grade water (Sigma Aldrich, cat. no. W4502) 
Formaldehyde (Sigma Aldrich, cat. no. F8775) 
FuGENE® HD Transfection Reagent (Promega, cat. no. E2312) 
Lipofectamine® 2000 (Life Technologies, cat. no. 11668019) 
Agarose (Severn Biotech, cat. no. 301050) 
Luria-Broth EZMixTM powder (LB; Sigma Aldrich, cat. no. L7658) 
Bacto-Agar (BD, cat. no. 214010) 
Phenol:chloroform (Sigma Aldrich, cat. no. P2069) 
Methanol, ethanol, isopropanol (Molecular biology grade, all Sigma Aldrich) 
GlycoBlue (Invitrogen, cat. no. AM9616) 
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HyperLadder I and 5X sample loading buffer (Bioline, cat. no. BIO33053) 
HyperLadder 100bp and 5X sample loading buffer (Bioline, cat. no. BIO33053) 
Agencourt AMPure XP beads (Beckman Coulter, cat. no. A63881) 
Random hexamers p(dN)6 (Integrated DNA technologies, IDT-DNA) 
Loading buffer (5X) and Hyperladder I (Bioline) 
 
2.1.7 Tissue culture media/plastics 
 
DMEM-12 by Gibco, life technologies (cat no. 11320-074) 
DMEM by Gibco, life technologies (cat no. 41965-039) 
MSCBM + hMSC SingleQuot kit (LONZA PT-3238 & PT-4105) + Fibroblast growth 
factor 2 (FGF2; R&D systems) 
Chondrogenic media - made from DMEM medium with 100μg/ml sodium pyruvate 
(Lonza), 10ng/ml TGFβ3 (Peprotech), 100nM dexamethasone, 1x ITS-1 premix, 40 
µg/ml proline, and 25 µg/ml ascorbate-2-phosphate (all from Sigma-Aldrich, Poole, 
UK), L-glutamine (Sigma Aldrich). 
Tissue culture flasks/dishes, CORNING 
Dulbecco’s phosphate buffered saline (PBS; Sigma Aldrich) 
 
2.1.8 Antibiotics 
 
Ampicillin, penicillin, streptomycin (all Sigma Aldrich) 
 
2.1.9 Other 
 
DH5α competent cells (Invitrogen, cat. no. 18265017) 
Stellar competent cells (Clontect, cat. no. 636766) 
PGL3-promoter vector (Promega) 
Renilla pRL-TK (Promega) 
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2.2 Laboratory methods 
 
2.2.1 Primary hMSC culture 
 
Bone marrow aspirates were obtained from LONZA (Table 2.1) and hMSCs were 
cultured by Dr. Matt Barter (Newcastle University). Cells were phenotyped by flow 
cytometry and tri-linage differentiation potential was assessed by Dr. Matt Barter and 
Dr. Ruddy Gomez-Bahamonde (Newcastle University). Isolated hMSCs were cultured 
in LONZA MSCBM media supplemented with hMSC SingleQuot kit (containing L-
glutamine, MSC growth supplement and Gentamicin/Amphotericin) + hFGF2. Cells 
were incubated at 37oC and passaged (using trypsin) every 3-4 days as necessary.  
 
Table 2.1 – Primary hMSC donors from LONZA 
Donor ID Sex Age 
071508A Female 22 
2454e Female 24 
071671B Female 24 
071607A Male 21 
 
2.2.2 hMSC differentiation into chondrocytes 
 
hMSCs were cultured in chondrogenic medium comprising of Dulbecco’s modified 
Eagle’s medium with 100μg/ml sodium pyruvate (Lonza), 10ng/ml TGFβ3 (Peprotech), 
100nM dexamethasone, 1x ITS-1 premix (Insulin, transferrin, selenium+ Linoleic acid; 
CORNING), 40 µg/ml proline, and 25 µg/ml ascorbate-2-phosphate (all from Sigma-
Aldrich, Poole, UK). For chondrogenesis, 5x105 or 1x106 hMSC were placed into 
6.5mm diameter, 0.4-µm pore size polycarbonate Transwell filters (Merck Millipore) in 
200µl media; the filters were placed into a 24-well plate, centrifuged at 200g for 5mins 
before 0.5ml chondrogenic medium was added to the well. Medium was changed every 
2/3 days as necessary. hMSCs differentiated into chondrocytes and form a 
cartilaginous disc over time (Murdoch et al, 2007; Barter et al, 2015).  
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2.2.3 Cartilage disc digestion and isolation of chondrocytes 
 
Cartilage discs were digested at day 14 of chondrogenesis. At 14 days, the 
chondrocytes were found to be fully differentiated in a pellet model of chondrogenesis 
(Johnstone et al, 1998). The following steps were optimised and these steps are the 
final optimised protocol. After transwell chondrogenesis and removal of cartilage discs 
from the transwells, the cartilage discs were chopped into ~2mm3 pieces using a 
scalpel. Multiple discs (6-8) were digested in 2ml tubes simultaneously. Discs were 
digested first with 1000µl hyaluronidase (1mg/ml in sterile PBS) for 15mins at 37oC 
and then centrifuged at 1500g for 5mins. The supernatant was discarded, and digested 
cartilage were washed with PBS before being centrifuged again as above. The discs 
were then enzyme digested with 1000µl trypsin (2.5mg/ml in sterile PBS) at 37oC for 
30mins. An equal amount of FBS containing media was used to inactivate the trypsin. 
The discs were centrifuged as above and the supernatant removed. The discs were 
finally digested with 1000µl collagenase (2mg/ml in DMEM media) for 1-1.5hrs at 37oC 
until fully digested and matrix was no longer visible. The digested cartilage containing 
media was passed through a 100µm cell strainer to collect any remaining pieces of 
matrix. Cells were counted using a haemocytometer and centrifuged at 1500g for 
5mins.  
 
2.2.4 Chromatin extraction and sonication of hMSCs and differentiated 
chondrocytes 
 
hMSCs were harvested from monolayer culture using trypsin, counted and 10 million 
cells were pelleted by centrifugation at 1500g for 5mins. Differentiated chondrocytes 
were isolated as above (section 2.23) and 10 million were pelleted by centrifugation at 
1500g for 5mins. Chromatin from hMSC and MSC-derived chondrocytes were 
extracted using step 2a of the Diagenode iDeal ChIP-seq kit (Cat. No. C01010050). 
Briefly, 10ml ice cold lysis buffer iL1 was added to pelleted cells and resuspension 
achieved by pipetting, cells were incubated for 10mins at 4oC in lysis buffer. Cells were 
centrifuged at 500g at 4oC and the supernatant discarded. Cells were resuspended by 
pipetting in 10ml lysis buffer iL2 and incubated for 10mins at 4oC. Cells were 
centrifuged as above and supernatant discarded. Protease inhibitor (200x) was added 
to shearing buffer iS1 and 1ml shearing buffer mix was added to chromatin, mixed by 
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pipetting and incubated on ice for 10mins. Chromatin was stored at -80oC until further 
use. Sonication of chromatin was performed on the same day as the 
immunoprecipitation.  
 
Chromatin was sonicated using a Bioruptor Standard or a Bioruptor Pico by 
Diagenode. A range of cycles was used to optimise this step (1 cycle 30s on/20s off 
for Bioruptor Standard, 30s on/30s off for Bioruptor Pico). The number of sonication 
cycles ultimately used was 15 for both hMSC and chondrocytes. The size of chromatin 
fragments was assessed by reverse cross linking the chromatin by adding proteinase 
K and incubating samples at 65oC for 4 hours or overnight and running the DNA 
fragments on a 1.5% (w/v) TAE-agarose gel (see section 2.2.8). Unused chromatin 
was stored at -80oC.  
 
2.2.5 Histone ChIP 
 
Following chromatin extraction, the Diagenode iDeal ChIP-seq kit protocol step 3 was 
followed using H3K4me3 and IgG antibodies included with the kit. Diagenode’s ChIP-
seq grade H3K4me1, H3K27ac, H3K27me3 and H3K36me3 antibodies were also 
used. Total volume was 300µl per IP. Samples were incubated at 4oC overnight on a 
rotating wheel (40rpm). For ChIP-seq, two IPs were performed for each antibody and 
immunoprecipitated DNA was pooled together post purification.  
 
All ChIP-seq grade antibodies were validated for specificity and cross-reactivity by 
Diagenode using ChIP-qPCR, ChIP-seq, Dot Blot, Western blot and 
immunofluorescence. More information on antibody validation is available from the 
manufacturer.  
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2.2.6 Agencourt bead purification (for ChIP-seq) 
 
Agencourt AMPure XP beads were used to purify immunoprecipitated DNA because 
the magnetic beads included in the Diagenode iDeal ChIP kit did not yield any DNA 
after purification. The volume of Agencourt beads used per purification was 45µl per 
100µl of sample and a modified manufacturers protocol was followed to purify DNA. 
Briefly, 187.2µl Agencourt beads were added to each 416µl ChIP sample tube, mixed 
by pipetting and incubated at room temperature for 5min. Tubes were placed into a 6-
tube Ambion magnetic stand for 2-5mins until the beads magnetized to the stand and 
the solution cleared. The cleared solution was discarded and the beads were washed 
twice with 200µl 70% (v/v) ethanol. Finally, immunoprecipitated DNA was eluted with 
40µl molecular biology grade water (Sigma). 
 
2.2.7 Phenol:chlorophorm DNA extraction (for ChIP-qPCR) 
 
An equal volume of phenol:chlorophorm solution was added to immunoprecipitation 
samples and mixed by vortexing. The sample was then centrifuged for 5mins at 1500g. 
The aqueous layer of the sample was transferred to a new tube containing double the 
volume of 100% ethanol and mixed by vortexing. A 10µl aliquot of GlycoBlue 
Coprecipitant (Life Technologies) was added and samples were incubated at -20oC for 
30mins. The samples were then centrifuged at 1500g at 4oC for 30mins. The 
supernatant was removed and the pellet resuspended in 70% (v/v) ethanol. Samples 
were centrifuged again as above and the supernatant discarded. Any remaining 
ethanol was left to evaporate and DNA was resuspended in 50µl molecular biology 
grade water.  
 
2.2.8 Agarose gel electrophoresis 
 
1-1.5% agarose gels were made by weighing out the appropriate amount of agarose 
and 1X TAE buffer. The solution was heated until the agarose was completely 
dissolved. 0.01% (v/v) ethidium bromide was added. Gels were electrophoresed at 50-
100V until a sufficient level of nucleic acid separation was achieved. Loading buffer 
(5X, Bioline) was added to samples prior to loading on gel. Hyperladder I (Bioline) 
molecular weight marker was also loaded alongside samples. 
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2.2.9 ChIP-qPCR 
 
To investigate H3K4me3 histone mark enrichment in promoter regions by qPCR, 
primers were designed that span the promoters of selected human genes (Table 2.2). 
The region 500bp upstream of the TSS of the gene was used to design promoter 
primers. Primers were also designed for the COL2A1 intronic enhancer. Primer pairs 
were designed using the universal probe library assay design centre tool on the Roche 
life science website (https://lifescience.roche.com/en_gb/brands/universal-probe-
library.html).  
 
Table 2.2 – Gene promoter primers for ChIP-qPCR 
Region Forward Primer (5’–3’) Reverse Primer (5’-3’) Probe 
COL2A1 promoter tccgctgctcctttctacc cctagaccaaggacggaaaa 52 
TAGLN promoter ccccctcttctcaaactcg gaccctgcccggacttac 68 
GAPDH promoter caccagccatcctgtcct cctgataattagggcagacaatc 23 
HBB promoter cagtggggctggaataaaag tgtgagcttgcttctactctgtg 62 
TNF promoter taccgcttcctccagatgag cattcaaccagcggaaaact 22 
FN1 promoter cttcgcttcacacaagtcca cctttgcggtcatcaaactt 28 
COL2A1 intron enhancer gtgaggaaggtgtgggagag gggtgggctctcctgtagt 19 
 
 
2.2.10 qPCR analysis of immunoprecipitated DNA 
 
TaqMan (Life Technologies) qPCR reactions with TaqMan Gene Expression Master 
Mix were performed according to manufacturer’s instructions. An ABI PRISM® 
7900HT Sequence Detection System was used with default cycle temperature 
settings; qPCR cycles were repeated 40-45 times. Enrichment of histone marks was 
calculated as a percentage of input as shown below: 
 
Adjusted input = 1% input Ct – 6.644 
100*2^(Adjusted input - Ct (IP) = percentage of input 
 
A positive histone enrichment was defined as a percentage of input greater than 5% 
(Diagenode recommendation). 
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2.2.11 Quantification of nucleic acids 
 
For expected DNA/RNA concentrations of > 10ng/µl, a NanoDrop 2000 
spectrophotometer was used. A Qubit™ 3.0 dsRNA HS assay was used to quantify 
DNA samples prior to DNA library preparation and sequencing.  
 
2.2.12 Histone ChIP-seq 
 
Two different hMSC donors were used for ChIP-seq experiments, 017508A and 2454e. 
DNA library of ChIP-seq using donor 071508A was generated using Diagenode 
MicroPLEX v2 kit and single ended reads of 50bp length were generated on an Illumina 
HiSeq 2500. Each sample was sequenced on one lane on the flowcell. Library 
preparation and sequencing was performed by Diagenode, Belgium. For ChIP-seq 
replicate 2454e, DNA libraries were prepared using the NEBNext Ultra II kit and 
sequenced using an Illumina NextSeq 500, generating 75bp single ended reads. Each 
sample was sequenced over 4 lanes. For these samples, library preparation and 
sequencing was performed at the Genomics Core Facility at Newcastle University by 
Dr. Jonathan Coxhead. Fragment sizes of samples were assessed on a Bioanalyzer 
prior to sequencing. All samples were re-sheared after ChIP and before DNA library 
preparation due to fragment sizes being larger than expected. To achieve a sufficient 
number of reads, the following samples were sequenced twice: 071508A MSC input, 
071508A MSC H3K36me3, 071508A CHON input, 071508A H3K36me3, 2454e 
CHON H3K4me3. Re-sequenced samples were merged with the original prior to 
alignment. IgG controls were also sequenced for donor 071508A but were not used in 
the final analysis.  
 
2.2.13 Generation of chondrogenesis RNA-seq 
 
hMSCs (donor 2454e) were differentiated into chondrocytes over 14 days. RNA was 
extracted from hMSCs (day 0) and differentiated chondrocytes at days 3 (not used in 
this project), 6 and 14. RNA was riboRNA depleted and library preparation performed 
after using the Ribo-Zero rRNA kit (Illumina). Paired end sequencing was performed 
on an Illumina HiSeq 2000 platform by GATC. Collection of RNA was performed by Dr. 
Matt Barter (Newcastle University).  
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2.2.14 Luciferase enhancer reporter assay 
 
A selection of 6 potential super enhancers were selected for further validation; these 
were chosen based on their proximity to chondrogenesis related genes. Super 
enhancer regions were cloned into a PGL3-promoter vector (Fig. 2.1) to assess their 
enhancer activity. The PGL3-promoter vector is a plasmid construct containing the 
luciferase reporter gene (luc+) downstream of a minimal SV40 promoter. Suspected 
enhancers can be cloned upstream of the SV40 promoter, the construct is then 
transfected into cells and luciferase activity measured to assess the enhancer potential 
of the cloned insert.  
 
 
Figure 2.1 – Plasmid map of the PGL3-promoter vector comprising the luc+ gene, SV40 promoter, restriction 
enzyme sites and ampicillin resistance gene.  
 
As only a limited size can be cloned into a PGL3-promoter vector, only a region 
containing a SOX9 peak within a chosen super enhancer was amplified and cloned 
(Table 2.1).   
 
  
 
 
 55 
2.2.14.1 PGL3-promoter vector expansion 
 
The PGL3-promoter vector was expanded by transforming into Subcloning Efficiency 
DH5α competent cells (Invitrogen). Briefly, 50µl DH5α cells were thawed on ice before 
1ng PGL3 promoter vector was added and gently mixed. The sample was incubated 
on ice for 30mins and heat shocked at 37oC for 20secs. The sample was placed back 
on ice for 2mins before 950µl pre-warmed LB added and incubated at 37oC for 1hr. An 
aliquot of 150µl transformed bacteria was plated onto an LB-agar + Amp plate and 
incubated overnight at 37oC. The next day, one colony was picked and grown in 150ml 
LB broth + Amp. The plasmid was purified the subsequent day using the Promega 
Plasmid Midiprep System, quantified using a Nanodrop 2000 and stored at -20oC until 
further use. Primer extensions for In-Fusion cloning were designed using Clontech In-
Fusion primer design web tool. The PGL3-promoter vector was inputted into the tool 
along with BglII restriction enzyme to generate primer extensions.  
 
2.2.14.2 Enhancer PCR primers 
 
Primers for regions containing SOX9 binding sites within a super enhancer were 
designed using Primer3web (version 4.0.0). Primer extensions for InFusion cloning 
into the PGL3-promoter vector designed previously were added to the forward and 
reverse primers for enhancer regions (Table 2.3). Phire hot start II DNA polymerase 
(Finnzymes) was used to amplify super enhancer regions. Each PCR reaction was 
prepared as follows: 0.4µl 5X Phire enzyme (1000 units/1.25ml), 50ng genomic DNA 
extracted from SW1353 cell line, 1µl forward primer (10µM), 1µl reverse primer (10µM), 
1.6µl dNTP (2.5mM), Sigma water up to 20µl. A range of annealing temperatures were 
used – 61oC, 65oC, 69oC. PCR cycle conditions were as follows: 98oC for 30s, then 
cycle 35 times at 98oC for 5s – range of annealing temperatures for 5s – 72oC for 30s, 
final step 72oC for 1min. PCR products were electrophoresed on a 1% (w/v) agarose-
TAE gel to check expected sizes of enhancer inserts.  
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Table 2.3 – Super enhancer In-Fusion primers for cloning into PGL3-promoter vector. InFusion primer extensions 
are highlighted in bold 
SOX9 peak locus 
(hg19) 
Forward primer + 
extension 5’-3’ 
Reverse primer + 
extension 5’-3’ 
Predicted 
gene target 
Insert 
ID 
Chr2:74810421-
74811389 
CCCGGGCTCGAGATCCCC
CTTATAGTAGAGAACCAA
GC 
 
TGCAGATCGCAGATCgcCT
CGGTTGCATTGCTTTA 
 
LOXL3 1 
Chr16:69957777-
69959206 
CCCGGGCTCGAGATCTGT
TCCTTTGCCTCTGTTGC 
 
TGCAGATCGCAGATCAGG
GAATGCAGTGGGACTTT 
 
WWP2 2 
Chr16:69924387-
69924932 
CCCGGGCTCGAGATCGCT
TTGTGTCCAGCTACTCC 
 
TGCAGATCGCAGATCACAC
CCTTCTCTGGACCATC 
 
WWP2 3 
Chr16:17452680-
17453167 
CCCGGGCTCGAGATCCAT
GGTCTGGGGAAGGTCTT 
 
TGCAGATCGCAGATCTGAA
TGGCAGCTCACCTAGA 
 
XYLT1 4 
Chr12:104879495-
104880612 
CCCGGGCTCGAGATCTCC
CTGACATTGCCAGTCTT 
 
TGCAGATCGCAGATCCATG
TTCAGCTGCAATGGGA 
 
CHST11 5 
Chr1:183922069-
183922664 
CCCGGGCTCGAGATCGG
TCATGCCTCATCCCCTAA 
 
TGCAGATCGCAGATCTCTC
TCGGTTCCCTAGGTGA 
 
COLGALT2 6 
 
PCR products displaying the correct expected size were purified using the Nucleospin 
gel and PCR cleanup kit (Macherey-Nagel) following manufacturers protocol for PCR 
purification; PCR reactions from different annealing temperatures showing the same 
size were pooled prior to purification. Briefly, the volume of each PCR sample was 
adjusted to 100µl before 200µl buffer NT was added in a spin column and collection 
tube. Samples were centrifuged at 11,000g and the flowthrough was discarded, 650µl 
buffer NT3 was added to the spin column and samples were centrifuged again as 
above. The flowthrough was discarded and samples were centrifuged dry as above. 
Spin columns were placed into a new 1.5ml tube and 25µl buffer NE added directly to 
the spin column filter. Samples were incubated for at least 1min at room temperature 
before eluting by centrifuging for 1min at 11,000g. DNA was quantified using a 
Nanodrop 2000.  
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2.2.14.3 PGL3-promoter vector linearization and purification 
 
The PGL3-promoter vector was linearised using restriction enzyme BglII. The reaction 
was prepared as follows: 5µg PGL3-promoter vector, 5µl buffer M (Roche), 2µl BglII 
(Roche), dH2O (Sigma Aldrich) up to 50µl. The reaction was incubated at 37oC 
overnight. The total reaction was subsequently electrophoresed on a 1% w/v TAE 
agarose gel. The correct band size was excised under UV light and DNA was extracted 
using the Nucleospin gel and PCR cleanup kit following instructions for gel extraction. 
The protocol is the same for PCR extraction except for the initial step –the excised gel 
band was weighed and 200µl buffer NT1 was added for every 100mg gel, samples 
were incubated at 50oC until fully dissolved.  
 
2.2.14.4 Cloning of enhancer insert into linearised PGL3-promoter vector 
 
The Clontech InFusion cloning kit was used to insert an enhancer region into linearised 
PGL3-promoter vector. The reaction was prepared as follows: 2µl 5X InFusion HD 
enzyme premix, 100ng linearised PGL3-promoter vector, 100ng purified enhancer 
insert, dH2O (Sigma Aldrich) up to 10µl. The reaction was incubated at 50oC for 
15mins.  
 
2.2.14.5 Expansion of cloned vector construct and purification 
 
To expand the cloned vector, the construct was transformed into Stellar competent 
cells (Clontech) using manufacturers protocol. Briefly, an 50µl aliquot of Stellar 
competent cells were thawed on ice and mixed gently with 2.5µl InFusion reaction 
product and incubated on ice for 30mins. Cells were heat shocked at 42oC for 45secs 
and placed back on ice for 2mins before 450µl pre-warmed SOC (37oC) was added to 
the cells. Cells were incubated at 37oC for 1hr; after incubation, 100µl transformed 
cells were spread onto LB+ampicillin plates and incubated overnight at 37oC. The 
following day, 4-6 colonies were picked and each grown in 3ml LB broth plus ampicillin 
for 16 hours at 37oC in a shaking incubator at 200rpm. A 1.5ml aliquot was pelleted, 
plasmid extracted in a quick miniprep and restriction enzyme digested to check 
whether the enhancer insert was successfully cloned into the vector. Cells were 
pelleted by centrifuging for 15secs, the supernatant removed and pellet resuspended 
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in 100µl Qiagen plasmid prep buffer P1, 200µl buffer P2 and 150µl buffer P3 were 
subsequently added to the sample. The sample was mixed by inversion (10X) and 
centrifuged at maximum speed for 3mins. The supernatant was transferred to a new 
tube with 1ml 100% ethanol and vortexed before centrifuged for 10mins. The ethanol 
was removed and sample left to air dry for approximately 10mins. The plasmid was 
then resuspended in 50µl water (Sigma Aldrich). Restriction enzyme digestion was 
performed as follows: 10µl miniprep plasmid, 1.5µl buffer 2.1 (NEB), 0.5µl HindIII 
enzyme (20,000 units/ml, NEB), 0.5µl XhoI enzyme (20,000 units/ml, NEB), 11.5µl 
water (Sigma Aldrich). The reaction was incubated at 37oC for 2hr. The digested vector 
was electrophoresed on a 1% w/v TAE agarose gel for 30mins at 100v. Samples 
showing the correct insert size were purified from the original overnight culture using 
the Promega PureYield Miniprep system following manufacturers protocol. Briefly, 
1.5ml bacterial culture was pelleted at maximum speed using a microcentrifuge, the 
supernatant was discarded and the pellet was resuspended in 600µl water (Sigma 
Aldrich). Cell lysis buffer was added at 100µl and mixed by inversion (6X), 350µl cold 
(4-8oC) neutralisation solution and mixed by inversion. Samples were then centrifuged 
at maximum speed for 3mins, the supernatant was then transferred into a spin column 
plus collection tube and centrifuged again for 15secs and the flowthrough discarded. 
The samples were washed by adding 200µl Endotoxin Removal Buffer and 
centrifuging at maximum speed for 15secs, 400µl Column Wash Solution was added 
and the samples centrifuged again for 30secs. The spin column was then placed into 
a clean 1.5ml tube and 30µl water (Sigma Aldrich) added directly to the spin column 
filter. The samples were incubated at room temperature for 1min before eluting by 
microcentrifugation for 15secs at maximum speed. A Nanodrop 2000 was used to 
measure plasmid construct concentration. Samples were stored at -20oC until further 
use.  
 
2.2.14.6 Plasmid transfection 
 
SW1353 cells were seeded into 96-well plates at a density of 5000-6000 cells per well 
in 100µl medium. The following day at approximately 50% confluency, cells were 
transfected as follows: 25ng enhancer PGL3 construct, 50ng SOX9 overexpression 
plasmid (pUT-FLAG-SOX9; Lefebvre et al, 1997) or empty vector control, 2.5ng Renilla 
control plasmid and 3µl:1µg FuGENE transfection reagent to total DNA per 100µl total 
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volume of DMEM (nil). The transfection mix was prepared and incubated at room 
temperature for 15mins prior to transfection. Transfected cells were incubated at 37oC 
for 24hrs. Replicates were performed at n = 6 for each enhancer vector construct. The 
transfection experiment was repeated in HEK293T cells as above, but using 
transfection reagent Lipofectamine 2000.  
 
To measure luciferase activity, the Promega Dual Luciferase Reporter Assay System 
kit was used. The buffers were prepared as follows: Luciferase Assay Reagent was 
prepared by resuspending luciferase assay substrate in 10ml luciferase assay buffer 
and Stop & Glo reagent was prepared by adding 1 volume of Stop & Glo substrate to 
50 volumes Stop & Glo buffer. Reagents were stored at -80oC when not in use and 
covered at all times to protect from light. To measure luciferase activity in transfected 
cells, media was aspirated away and 30µl 1X lysis buffer (Promege Dual Luciferase 
Reporter kit) was added to each 96-well and the samples placed on a rocker for 
15mins. After lysing, 10µl of each lysed cell sample was transferred to a 96-well black 
and white domino plate. A Glomax luminometer was used to measure luminescence. 
The conditions were used as follows: dual luciferase two injections setting, 0.5s delay, 
speed 200µl/s, 40µl per injector. Injectors were primed one at a time before use and 
cleaned using default cycles after use. To normalise, sample values (measured by 
injector containing Luciferase Assay Reagent) were divided the background Renilla 
control (measure by the injector containing Stop&Glo reagent). The mean was 
calculated from replicate samples. A two sample T test with a Welch’s correction was 
performed to test for significance (p < 0.05).  
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2.2.15 Western blot 
 
A protein immunoblot was performed to assess SOX9 overexpression in transfected 
cells. To confirm overexpression of SOX9, cells were transfected as described in 
section 2.2.14.6. Cell numbers and volumes of reagents were scaled accordingly to 6-
well plate format.  
 
2.2.15.1 Cell lysis method 
 
Medium was aspirated from transfected cells in 6-well plates. The plate was placed on 
ice and cold PBS was added to each well and the plate swirled. All PBS was then 
aspirated from the wells and 150µl magic lysis buffer ((50mM Tris-HCl, pH 7.4, 10% 
(v/v) glycerol, 1mM EDTA, 1mM EGTA pH 8.0), 1mM Na3VO4, 5mM NaF, 10mM β-
glycerol phosphate, 5mM Na4P2O7, 1% (v/v) Triton X-100, 1μM microcystin-LF and 1 
Complete protease inhibitor Mini tablet (Roche)) was added. Cells were scraped from 
the plate using a cell scraper and cell lysate was mixed by pipetting before transfer into 
a cooled 1.5ml tube and rotated at 4oC for 20mins. Lysates were centrifuged at 10,000g 
for 3mins at 4oC. The supernatant was then removed, snap frozen on dry ice and 
stored immediately at -80ºC until further use. 
 
2.2.15.2 Protein concentration quantification 
 
A Qubit protein assay (Life Technologies) was used to quantify protein samples. 
Protein standards were prepared following manufacturers method. All solutions were 
prepared in Qubit Assay tubes. Qubit working solution was prepared by adding Qubit 
Protein Reagent to Qubit Protein Buffer at a ratio of 1:200. Each of the 3 standards 
weas prepared by adding 190µl Qubit working solution to 10µl standard. Protein 
samples were prepared by adding 10µl protein lysate and 190µl Qubit working solution.  
All prepared standards and samples were vortexed and incubated at room temperature 
for 15mins. The protein assay protocol on the Qubit 2.0 Fluorometer was selected and 
calibrated using the standards before measuring sample concentrations.  
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2.2.15.3 SDS-PAGE and immunoblot 
 
Cell lysates were thawed on ice and Laemmli sample buffer (0.1 M Tris-HCl, pH 6.8, 
0.35M SDS, 20% (v/v) glycerol, 0.01% bromophenol blue and 10% (v/v) β-
mercaptoethanol) added to 1/5 of the volume.  The resulting mixtures were heated to 
100ºC for 5 minutes, cooled on ice, and then electrophoresed on a 12.5% SDS (w/v) 
polyacrylamide gel. The separating gel was prepared as follows: 3ml dH2O, 1.5ml 
lower gel buffer (1.5M Tris-Base pH8.8, 0.4% SDS (w/v)), 1.5ml acrylamide/bis 40% 
solution, 30µl APS, 10µl TEMED (added last). The stacking was prepared as follows: 
5ml stacking solution (0.5M Tris- HCl pH 6.8, 0.4% (w/v) SDS), 30µl APS, 10µl TEMED 
(added last). Gels were set up in a Bio-Rad PROTEAN gel electrophoresis unit and 
electrophoresed for approximately 1hr at 120V. Samples were then transferred to 
PVDF membrane by electroblotting in a Scie-Plas V20-SDB 20 x 20cm semi-dry blotter 
for 1-1.5 hours at 1mA/cm2 in transfer buffer. Membranes were then covered in 
blocking buffer (TBS-T & 5% w/v non-fat dry milk powder (w/v)) for 1 hour at room 
temperature.  The membranes were washed 3 times for 5mins each in TBS-T.  Washed 
membranes were incubated overnight at 4ºC with SOX9 primary antibody, diluted 
1:1000 in primary antibody dilution buffer (TBS-T & 5% w/v non-fat dry milk powder), 
with gentle agitation. The membrane was washed 3 times for 10mins each and then 
incubated with 5ml secondary antibody (HRP-conjugated) diluted 1/1000 in TBS-T and 
5% milk for 1hr. After incubation, the membrane was washed again as above. The 
membrane was developed using ECL plus solution (Promega), made up by adding 
25µl solution A to 1ml solution B. The prepared ECL plus solution was added to the 
membrane and incubated at room temperature for 5mins. ECL solution was removed 
and the membrane was visualised on a ChemiGenius II BioImager.  
 
2.2.16 siRNA depletion of LOXL1-4 genes 
 
2.2.16.1 Transfection of hMSCs 
 
siRNAs targeting LOXL1, LOXL2, LOXL3 and LOXL4 were purchased from 
Dharmacon (ON-TARGETplus SMARTpool siRNA). SMARTpool siRNAs are a mix of 
4 siRNAs designed to the region of interest to maximize potency and minimize off-
target effects. siRNAs were prepared to a stock concentration of 20µM by adding 250µl 
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siRNA buffer (Dharmacon). hMSCs (donor 2454e) were transfected with siRNAs for 
48hrs before differentiation into chondrocytes. For each siRNA transfection, 250,000 
cells were seeded onto 6cm tissue culture dishes in 3ml hMSC medium. After 24hrs, 
cells were transfected with 50nM siRNA using Dharmafect 1 transfection reagent 
according to manufacturers instructions. Briefly, for each siRNA pool, 50nM siRNA was 
added to serum free medium to a volume of 200µl. A siRNA control was included. In a 
separate tube, 4µl Dharmafect 1 was added to 196µl serum free medium. Both 
solutions were mixed, incubated at room temperature for 5mins and then combined for 
20mins before 1600µl hMSC media added. hMSC medium was aspirated from the 6cm 
dishes containing seeded hMSCs and replaced with 2ml transfection media. After 
48hrs, hMSCs were differentiated into chondrocytes using the transwell insert model 
of chondrogenesis. Prior to differentiation, 50,000 hMSCs from each siRNA experiment 
were pelleted and frozen in 1.5ml tubes at -20oC to be processed at the same time as 
differentiated chondrocytes to reduce technical effects. 
 
2.2.16.2 RNA extraction and reverse transcription 
 
RNA from transfected hMSCs and differentiated chondrocytes at day 7 was extracted. 
RNA was extracted from cartilage discs and hMSCs (frozen previously) using TRIzol 
reagent (Invitrogen). Briefly, 250µl TRIZol was added to cartilage disc and hMSC 
samples in a 1.5ml tube and incubated at room temperature for 5mins.  Cartilage discs 
were ground using a pestle until disintegrated, 50µl chloroform was added to each 
sample and mixed thoroughly by shaking. Samples were incubated at room 
temperature for 2 mins before centrifugation at 2,000g for 15mins at 4oC. The aqueous 
phase was transferred to a fresh 1.5ml tube containing 125µl isopropanol and 
vortexed. Samples were incubated at room temperature for 10mins before centrifuging 
as above for 10mins. The supernatant was removed and the pellet washed with 250µl 
75% (v/v) ethanol. Samples were centrifuged as above for 5mins, ethanol was 
removed and the pellet air dried until ethanol was fully removed. RNA was 
resuspended in 20µl water (Sigma Aldrich) and the concentration determined using a 
Nanodrop 2000.   
 
RNA was reverse transcribed into cDNA using reverse transcriptase. The protocol per 
reaction was as follows: 500ng RNA in 8µl water (Sigma Aldrich), 3µl dNTPs (10mM) 
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and 1µl random hexamers (1µg/µl; IDT-DNA) were heated to 70oC for 5mins before 
being chilled on ice. 4µl 5X RT buffer (Invitrogen), 2µl 0.1M DTT (Invitrogen), 0.25µl 
MMLV (200 units/l Invitrogen) and 1.75µl water (Sigma Aldrich) was added to each 
sample. Samples were heated to 37oC for 50mins and 75oC for 15mins before 30µl 
water (Sigma Aldrich) was added. Samples were frozen at -20oC until further use.  
 
2.2.16.3 RT-qPCR 
 
Gene expression assayed using TaqMan RT-qPCR with probe library primers (Table 
2.4), normalized against 18S expression. RT-qPCR cycles were as follows: 95oC for 
10mins, 40 cycles of 95oC for 30sec, 60oC for 30sec and 72oC for 30sec.  
 
Table 2.4 – Roche universal probe library LOXL1-4 primers and ABI assays for SOX9 and ACAN used for TaqMan 
RT-qPCR  
Gene Name Forward 5’ – 3’ Reverse 5’ – 3’  Universal probe 
library no. or 
sequence 
LOXL1 accagggcacagcagactt gtggctgcatccagtaggtc 87 
LOXL2 ggatctggcacgactgtca accttggtgccattgagg 62 
LOXL3 caggaccagcactcttctcc cactgacaggtcgcatgg 15 
LOXL4 ccagcttctgtctggaggac 
 
aagttggcacatgcgtagc 
 
43 
SOX9 acttgcacaacgccgag ctggtacttgtaatccgggtg 5'-FAM-
TCTGGAGACTTCT
GAACGAGAGCGA-
IABkFQ-3' 
ACAN agcgagttgtcatggtctg 
 
tgtgggactgaagttcttgg 
 
5'-FAM-
CTGGGTTTTCGTG
ACTCTGAGGGT-
IABkFQ-3' 
18S cgaatggctcattaaatcagttatg
g  
 
tattagctctagaattaccacagtta
tcc  
 
5’FAM-
TCCTTTGGTCGCT
CGCTCCTCTCCC0
-TAMRA 3’  
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2.2.17 GAG assay 
 
2.2.17.1 Pellet culture chondrogenesis 
 
hMSCs were differentiated into chondrocytes using a pellet culture. hMSCs were 
seeded into wells of a 96-well tissue culture plate at a density of 50,000 cells per well 
in PBS. The 96-well plate was centrifuged at 200g for 5mins to pellet hMSCs in the 
wells. PBS was aspirated and replaced with 150µl chondrogenic media and the cells 
incubated at 37oC. Medium was refreshed every 2-3 days as necessary.  
 
2.2.17.2 GAG assay 
 
Medium was aspirated from cartilage pellets at 7 days. To digest cartilage pellets, 70µl 
phosphate buffer and a pre-mixed solution of 20µl papain, 10µl cys-HCl and 10µl EDTA 
was added to each 96-well containing a pellet and incubated at 65oC for 2-4hrs. 
Chondroitin sulphate standards at concentrations of 0-40µg/ml were prepared with 
phosphate buffer. Dimethyl-methylene blue (DMB) reagent was prepared as follows: 
3.04g glycine, 2.37g NaCl, 95ml 0.1M HCl, up to 1l dH2O and 16mg DMB. To a fresh 
96-well plate, 40µl digested cartilage pellet or standard was added to each well in 
duplicate and 250µl DMB solution was added to each well. Absorbance was measured 
using a plate reader at 530nm. A standard curve was created using the known 
concentrations of chondroitin sulphate and the concentrations of samples were 
determined using the standard curve. 
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2.3 Bioinformatics Methods 
 
2.3.1 Software  
 
If the software has an associated published paper this is referenced, otherwise links to 
the main website/manual page are given. Website links current as of August 2017.  
 
Scripts are deposited into GitHub at:  
https://github.com/kathleencheung/PhD_Young_lab 
 
2.3.1.1 List of software used in no particular order: 
 
Fastqc v0.11.5 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) 
MultiQC v0.8 (http://multiqc.info/) 
FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) 
Bowtie2 v2.2.4 (Langmead and Salzberg, 2012) 
HISAT2 v2.0.4 (Pertea et al, 2016) 
SAMtools v1.6 (Li et al, 2009) 
BEDtools v2.26.0 (Quinlan and Hall, 2010) 
UCSC utilities (https://genome.ucsc.edu/) 
ENCODE tools (https://www.encodeproject.org/software/) 
Ngs.plot v2.61 (Shen et al, 2014) 
HOMER v4.7 (http://homer.ucsd.edu/homer/) 
MACS2 v2.1.0.20150731 (Feng et al, 2012) 
Salmon v0.7.2 (Patro et al, 2015) 
ChromHMM v1.12 (Ernst and Kellis, 2012) 
Picard tools v1.130 (https://broadinstitute.github.io/picard/) 
PETModule (Zhao et al, 2016) 
GREAT v3.0.0 (McLean et al, 2010) 
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2.3.1.2 Bioconductor packages: 
 
DiffBind v 2.2.12 (Stark and Brown, 2011) 
SPP v1.13 (Kharchenko et al, 2008) 
Tximport v1.6.0 (Soneson et al, 2015) 
Minfi v.1.20.2 (Aryee et al, 2014) 
Missmethyl v0.99.0 (Phipson et al, 2016) 
Limma v3.30.13 (Ritchie et al, 2015) 
Sva v3.22.0 (Leek et al, 2012) 
 
2.3.1.3 Genome browsers: 
 
Integrative Genome Viewer v2.3.91 (Robinson et al, 2011) 
UCSC genome browser (Kent et al, 2002) 
 
2.3.2 QC and alignment of ChIP-seq reads 
 
For quality control of raw sequencing reads, the FastQC tool was used. Aggregation 
and summarisation of multiple FastQC reports was performed using MultiQC. 
Alignment of sequencing reads to human reference genome hg38 was performed by 
bowtie2. A bowtie2 index for hg38 was generated using the bowtie2-build indexer with 
default settings. Reference genome hg38 in fasta format was downloaded from UCSC, 
as were chromosome size and annotation files.  
 
2.3.3 Normalisation of aligned ChIP-seq reads 
 
Output SAM alignment files from bowtie2 were converted to sorted BAM files using 
samtools view and sort respectively. For genome browser visualization, BAM files were 
then normalised to reads per million (RPM) scaled genome coverage files in bedgraph 
format using bedtools genomecov, using the -scale option with RPM values. RPM 
scales for each sample were calculated by finding the total aligned reads using 
samtools flagstat and dividing 1 million by this number. Bedgraph files were converted 
to bigwig format using the bedGraphToBigWig program from ENCODE. 
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2.3.4 Peak calling and peak annotation 
 
Peaks were called using MACS2 peak caller using input samples as background 
controls with the --broad option turned on, a q value cutoff of 0.05 and the effective 
hg38 genome size given as 3.05x109. The effective genome size represents the 
portion of the genome to which sequencing reads can be mapped. This was calculated 
using UCSC tool faCount to determine the total number of mapped bases and 
unmapped bases (denoted by N) in hg38, the number of unmapped bases was 
subtracted from the total number of bases to give the effective genome size. For hg38, 
3.05x109 represents 95% of the total genome size. Peaks were annotated by HOMER 
annotatePeaks.pl which associates peaks to the nearest gene and overlapping 
genomic feature.  
 
2.3.5 ChIP-seq sample QC metrics 
 
Quality metrics calculated for ChIP-seq samples were PCR bottleneck coefficient 
(PBC), fraction of reads in peaks (FRiP), normalized strand cross-correlation 
coefficient (NSC) and relative strand cross-correlation coefficient (RSC).  PBC was 
calculated by dividing uniquely mapped reads by total mapped reads. Duplicated and 
unique reads were found using Picard tool MarkDuplicates. FRiP was calculated using 
the Bioconductor package DiffBind in RStudio. NSC and RSC were calculated using 
ENCODE tool Phantompeakqualtools and SPP. 
 
2.3.6 Comparison and correlation of ChIP-seq replicates 
 
Bioconductor package DiffBind was used to generate a correlation heatmap of ChIP-
seq replicates from hMSC donor 2454e and 071508A. Overlap of peaks was also 
assessed using DiffBind and Venn diagrams created using the Venneuler package in 
RStudio.  
 
2.3.7 RNA-seq expression quantification and analysis 
 
QC of raw RNA-seq reads was performed using Fastqc and summarised using 
MultiQC. To improve quality scores, reads were subject to a hard trim (101bp to 90bp) 
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using fastx_trimmer (Appendix ii, Fig. 1). For hMSCs at day 0, 52.8 million paired end 
reads were achieved and 47.5 million paired end reads were achieved for day 14 
chondrocytes (Appendix ii, Table 1).  Gene abundance in transcripts per million (TPM) 
was quantified using Salmon in quasi-mapping mode. A hg38 Salmon transcriptome 
index was generated using the Salmon indexer with default settings. Transcripts were 
summarized to gene level using the tximport Bioconductor package in RStudio. Hg38 
reference genome files were downloaded from UCSC. TPMs were extracted using 
Bioconductor package tximport in R. Gene expression plots were generated using the 
ggplot2 package in R. Genes with a log2 fold change > 1.5 (actual fold change 2.83) 
were considered to be differentially expressed. Log2 fold change was calculated as 
follows: log2(day14 TPM + 1) – log2(day0 TPM + 1). A value of 1 was added to all 
TPM values to avoid negative logged values; this also removes undue influence of very 
small expression values. GO terms were found using DAVID gene list analysis. Log2 
fold change TPM values were correlated with changes from chondrogenesis cDNA 
microarray data (Barter et al, 2015) and a Pearson’s correlation test performed. 
 
2.3.8 Correlation of histone mark enrichment to RNA-seq data 
 
Read counts per million for each histone mark were plotted against subsets (high, 
medium and low expressed) of genes to explore the association of histone mark 
enrichment and gene expression.  Genes with a TPM < 2 were considered low 
expressed; a density plot of TPM values was created and a gene expression cut off of 
2 was chosen; this was the threshold where the highest density peak sharply 
decreases (Appendix ii, Fig. 2). Genes with medium expression had a TPM of between 
2 and 16.7; 16.7 was the mean TPM in day 0 and day 14 samples. Genes with a TPM 
higher than the mean were considered highly expressed. Read counts per million 
mapped reads (reads per million; RPM) were plotted against genes in each expression 
level set. Plots were generated using ngs.plot. Histone peaks were associated to the 
nearest gene using HOMER annotatepeaks.pl. The BiomaRt package was used to 
query the BioMart database in order to annotate genes.  
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2.3.9 Differential histone binding analysis 
 
Significant differential binding sites for H3K4me1 and H3K4me3 samples between 
hMSCs and differentiated chondrocytes were determined using the DiffBind package 
in RStudio. hMSC and differentiated chondrocyte samples from both replicates were 
combined in this analysis. The default DESeq2 method was used. More information is 
available in the DiffBind vignette.  
 
2.3.10 Chondrogenesis DNA microarray 
 
Chondrogenesis microarray data was kindly provided by Dr. Matt Barter (Newcastle 
University) who carried out the experiment and analyzed the data. Correlation plots 
and tests were performed using RStudio.  
 
2.3.11 Chromatin State Learning using ChromHMM 
 
BED alignment files were used as input into the software ChromHMM. ChromHMM 
uses a multivariate Hidden Markov Model (HMM) to compute emission probabilities of 
histone marks in a chromatin state by modelling the presence or absence of histone 
marks in 200bp bins across the genome. The collective ChIP-seq alignment tracks can 
be considered a multivariate sample i.e. each 200bp bin in the genome displays a set 
of observations, in this case the observations are the read counts from each histone 
mark sample. If available, the read counts are normalised using a control. ChromHMM 
trains a model using the input data to calculate the probability of a set of observations 
that are present in an unknown (hidden) state. The program takes the number of 
hidden states from the user and calculates the emission and transition probabilities for 
those states. A full description of the method is available in Ernst and Kellis, 2010.  
 
To identify chromatin states, the following subcommands were performed. Briefly, the 
BinarizeBed command was used to convert aligned read coordinates into a binarised 
data format for chromatin state learning. Alignment files from all ChIP-seq samples 
(both replicates) were used along with their controls. The command LearnModel was 
then used to compute chromatin states from the binarised alignment data. The number 
of states specified to the program started at 8 and increased by increments of 2 until 
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there was a sufficient separation of distinct states. The final state number used was 
16. Chromatin states were annotated using information from the Epigenomics 
Roadmap project and the Reorder command was used to re-label, re-order and assign 
track colours to chromatin states. The MakeBrowserFiles, MakeSegmentation, 
NeighbourhoodEnrichment and OverlapEnrichment commands were then used to 
create associated plots and browser tracks with the annotated chromatin state names. 
Chromatin state browser tracks (BED format) were visualised in IGV genome browser. 
 
2.3.12 Assessing chromatin state changes 
 
Genomic co-ordinates were split into 200bp bins using BEDTools window. The hMSC 
and differentiated chondrocyte chromatin state at each 200bp bin was noted and the 
frequency of change between hMSCs and differentiated chondrocyte was calculated. 
A frequency plot was generated using ggplot2 and a corresponding Sankey plot 
created using the riverplot package in RStudio. 
 
2.3.13 Analysis of DNA 450k methylation arrays 
 
An Infinium HumanMethylation450 BeadChip array was used to quantify DNA 
methylation of known CpGs in the human genome. hMSCs from four donors were 
differentiated into chondrocytes (Table 2.5) using the transwell model of 
chondrogenesis. A total of 12 samples were included in the chondrogenesis 450K 
array, 7 hMSC samples and 5 chondrocyte samples. Adipogenesis and 
osteoblastogenesis DNA 450k methylation was performed at n = 3 (Table 2.6). 
Laboratory work and data collection was performed by Dr. Matt Barter (Newcastle 
University; chondrogenesis), Catherine Bui (Newcastle University; chondrogenesis) 
and Dr. Ruddy Gomez-Bahamonde (Newcastle University; chondrogenesis, 
adipogenesis and osteoblastogenesis).  
 
Raw files were pre-processed using the Bioconductor package minfi. Data were 
normalised using the functional normalisation algorithm developed for 450k analysis 
(Fortin et al, 2014). Significantly differentially methylation CpGs positions (DMPs) 
between hMSCs and chondrocytes were determined using the lmfit()  and ebayes() 
functions in limma. The experiment design included both paired and unpaired samples 
 
 
 71 
and this was reflected in the phenotable. DMPs were calculated using a mixed paired 
and unpaired analysis in limma after applying SVASeq batch correction (Leek et al, 
2012). 
 
Table 2.5 – hMSC donors and samples used for chondrogenesis DNA 450K methylation array.  
Donor ID Sample ID Cell type Sex Age 
071508A MSC0_8A_1 hMSC Female 22 
071508A MSC0_8A_2 hMSC Female 22 
071508A MSC0_8A_3 hMSC Female 22 
071508A MSC14_8A_1 Chondrocyte Female 22 
071508A MSC14_8A_2 Chondrocyte Female 22 
071508A MSC14_8A_3 Chondrocyte Female 22 
2454E MSC0_ruddy_2454E hMSC Female 24 
071508A MSC0_ruddy_8A hMSC Female 22 
071671B MSC0_ruddy_1B hMSC Female 24 
071607A MSC14_7A Chondrocyte Male 21 
2454E MSC0_2454E hMSC Female 24 
2454E MSC14_2454E Chondrocyte Female 24 
 
Table 2.6 – hMSC donor and samples used for adipogenesis and osteoblastogenesis DNA 450k methylation 
array 
Donor ID Sample ID Cell type Sex Age 
3728A R01C01 hMSC Female 19 
3728A R02C01 hMSC Female 19 
3728A R03C01 hMSC Female 19 
3728A R04C01 Adipocyte Female 19 
3728A R05C01 Adipocyte Female 19 
3728A R06C01 Adipocyte Female 19 
3728A R01C02 Osteoblast Female 19 
3728A R02C02 Osteoblast Female 19 
3728A R03C02 Osteoblast Female 19 
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2.3.14 GO term analysis 
 
The Bioconductor missMethyl package was used to find GO terms for the top 500 
hypomethylated CpG sites. The GREAT GO ontology webtool was used to associate 
GO terms to chromatin states after conversion from hg38 to hg19 using UCSC liftover. 
GREAT default settings associates genomic features to the nearest genes using a 
basal plus extension rule. Genes are assigned a regulatory feature area which is 
extended 5kb upstream and 1kb downstream of the gene, until it meets another gene. 
This area is extended up to a maximum of 1000kb if no nearby genes are found in the 
initial search area. This extended area is defined as the region where regulatory 
features are likely to be found and genes may share regulatory regions. The inputted 
chromatin states (or other regulatory features) are associated by overlap to the 
extended gene regulatory area. More than one gene may be assigned to a regulatory 
feature. Default basal plus extension settings were used to associate enhancer states 
to nearby genes and a simple nearest gene approach (within 1000kb) was used to find 
GO terms for all other chromatin states. Chromatin states may be associated with 
multiple genes if they overlap more than one gene regulatory region. The whole 
genome was used as a background control. GREAT output was viewed in the 
Significant By Region-based Binomial setting recommended for large datasets. The 
top 20 significant (p < 0.05) GO terms were selected for visualisation.  
 
2.3.15 Comparison of chondrogenesis chromatin states to Roadmap states 
 
Chondrogenesis chromatin state genome co-ordinates were converted from hg38 to 
hg19 using UCSC’s liftover tool for this analysis. Equivalent chromatin states between 
Roadmap’s extended 18 state model and chondrogenesis 16 state model were 
compared. To determine similarity between chromatin states, the Jaccard index was 
used. This calculates a similarity co-efficient between 0 and 1, with higher values 
indicating more similarity.  
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The Jaccard index is calculated as follows: 
 
 
 
 
 
 
 
 
 
 
  J = Intersection between A and B 
Union 
 
All possible pairwise comparisons between the 98 Roadmap cell types and hMSCs 
and chondrocytes were performed for the eight equivalent chromatin states. The 
BEDtools Jaccard tool was used to calculate similarity coefficients. GNU Parallel was 
used to parallelise the process. Scripts from http://quinlanlab.org (lead developer for 
BEDtools) were adapted for this analysis. The princomp() function in R was used for 
principal component analysis (PCA).  
 
2.3.16 Correlation of DNA methylation to chromatin states 
 
Chromatin states for CpG sites in the 450K methylation array were found using 
BEDtools intersect. UCSC liftover was used to convert hg19 probe genome co-
ordinates to hg38. Of the total 485513 probes in the 450K array, 485438 (99.99%) 
lifted over successfully including all significant CpG sites (q < 0.05 and 10% ∆β). 
Jaccard statistics was performed for significant CpGs and all CpGs in chondrogenesis 
chromatin states using BEDtools. The average length of each chondrogenesis 
chromatin state was found by dividing the total size by the number of states.  
 
  
 
 
 74 
2.3.17 Generation of plots 
 
Chromatin state plots were generated by ChromHMM. DNA methylation plots were 
generated using built in function in minfi. Violin and PCA plots were created using the 
ggplot2 package in RStudio. Correlation heatmaps with hierarchical clustering based 
on Euclidean distance were constructed from a matrix of Jaccard index values using 
the pheatmap() function; all heatmaps were drawn using the same scale. Pie charts 
and bar plots were created using Microsoft Excel. Data wrangling was performed using 
R and Shell languages.  
 
2.3.18 Analysis of SOX9 and JUN ChIP-seq datasets 
 
Mouse rib chondrocyte SOX9 and JUN ChIP-seq data were downloaded from the GEO 
database (accession GSE69109 and GSE73372 respectively). Fastq files were 
converted from sequence read archive (SRA) files using the fastq-dump tool from the 
SRA toolkit. Both datasets were aligned to mouse reference genome mm10 
(downloaded from UCSC) using Bowtie2 (default settings) after generating a Bowtie2 
index. Aligned reads were converted into hg38 coordinates using the UCSC liftover 
tool. Peaks were called using MACS2 peak caller using input samples as a control with 
a q value cutoff of 0.05 and the effective hg38 genome size given as 3.05x109. De 
novo motif discovery was performed using the top 500 significant peaks in each 
peakset using the MEME ChIP tool (default settings); the TOMTOM utility within the 
MEME suite was used to compare discovered motifs to known human transcription 
factor binding motifs. An E-value (FDR) < 0.05 was considered to be significant.  
 
2.3.19 Identification of super enhancers 
 
Super enhancers in chondrocytes were identified in our dataset based on the method 
described in Pott and Lieb, 2014. Regions identified as strong enhancers (13_EnhS; 
chromatin states computed by ChromHMM) in differentiated chondrocytes were used. 
We stipulated that strong enhancers states in our chondrocytes must also be an 
enhancer state in Roadmap E049 chondrocytes (9_EnhA1 or 10_EnhA2). Strong 
enhancer states were stitched together if they were less than 12.5kb apart. Significant 
SOX9 and JUN peaks (q value > 0.05) were intersected with stitched enhancers and 
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enhancers were ranked by SOX9 signal value (from MACS2 peak caller). A SOX9 
signal value cutoff was defined by finding the point of the curve where the slope = 1. 
Enhancers with SOX9 peaks above this value were designated as super enhancers. 
Super enhancers must have an overlapping SOX9 and JUN peak. HOMER 
annotatepeaks.pl was used to associate super enhancers to the nearest gene. The 
GREAT GO ontology tool was used to retrieve GO terms for super enhancers.  
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Chapter 3. Histone ChIP-seq quality control, alignment and peak 
calling 
 
3.1 Introduction 
 
Histone modifications regulate gene transcription by recruiting chromatin remodellers 
to restructure chromatin to alter the accessibility of genes to transcription factors. 
Regulatory elements of genes may be marked by active or repressive histone 
modifications. Histone ChIP-seq is a high-throughput method of assaying genome 
wide histone modifications. A principal aim of this project was to generate a histone 
ChIP-seq dataset for the transwell in vitro model of chondrogenesis. We aimed to 
elucidate epigenomic changes important for chondrogenesis by investigating histone 
modifications at day 0 and day 14 of differentiation. 
 
We selected five histone modifications to assay in our ChIP-seq experiment. These 
were H3K4me3, H3K4me1, H3K27ac, H3K27me3 and H3K36me3. These were 
selected to offer a broad range of representation of regulatory elements in the genome. 
H3K4me3 marks are enriched in active gene promoters (Guenther et al, 2007). 
H3K4me1 and H3K27ac both mark gene enhancers although H3K27ac is more 
indicative of an active enhancer (Creyghton et al, 2010) whereas high H3K4me1 levels 
denotes poised enhancers (Heinz et al, 2015). H3K27me3 is typically a repressive 
mark and is found within transcriptionally inactive genes and heterochromatin (Boros 
et al, 2014) athough a study found that H3K27me3 may be associated with active 
transcription in some genes (Young et al, 2011). H3K27me3 may also be present 
alongside H3K4me3 in gene promoters, which signifies a bivalent state. H3K36me3 
modifications within genes are associated with active transcription (Vakoc et al, 2006). 
H3K36me3 can mark both introns and exons although at lower levels in introns and 
alternatively spliced exons, which suggests this histone mark could have a role in the 
regulation of splicing (Kolasinska-Zwierz et al, 2009). These five histone modifications 
were also included in ChIP-seq experiments in the ENCODE (Dunham et al, 2012) and 
Epigenomics Roadmap projects.  H3K4me3, H3K4me1, H3K27me3 and H3K36me3 
were included as core marks in the Epigenomics Roadmap project and H3K27ac was 
an additional mark in some datasets (Kundaje et al, 2015).  
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The inclusion of a negative control is highly important to ChIP-seq experiments in order 
to assess protein or histone mark enrichment and the signal to noise ratio. Options for 
ChIP-seq controls are a mock IgG control, input control and for histone ChIP-seq, a 
H3 antibody control may also be used. The IgG control involves using an IgG antibody 
to serve as a mock immunoprecipitation with the DNA fragments pulled down used as 
the background noise. An input control is the DNA used in the immunoprecipitation 
experiment but is not immunoprecipitated itself so it represents non-enriched DNA 
fragments. Although an IgG control mimics more closely an immunoprecipitation 
experiment, it can be difficult to recover enough DNA for sequencing and the limited 
material recovered may lead to PCR bias during the library preparation step (Kidder et 
al, 2011). Furthermore, input controls provide a greater coverage of noise over the 
genome (Kidder et al, 2011) and peak calling algorithms are usually designed with 
assumptions appropriate with using an input control (Boer et al, 2014). Therefore, input 
controls are preferred over IgG controls for ChIP-seq. For histone ChIP-seq a general 
H3 antibody can be used to generate the background noise. A study found that there 
was no difference in the use of an H3 control or an input control (Flensburg et al, 2014). 
In this project, an input control was generated.  
 
The ENCODE project has published a set of guidelines for generating and assessing 
optimal ChIP-seq data (Landt et al, 2012). These guidelines were considered during 
the design and optimisation of the chondrogenesis ChIP-seq workflow. The 
differentiated chondrocytes form a cartilage-like disc in the transwell model of 
chondrogenesis. One of the challenges involved was the extraction of cells from the 
ECM-dense disc. Before ChIP-seq was attempted, the protocol was optimised using 
ChIP coupled with quantitative PCR (ChIP-qPCR). After histone ChIP-seq, quality 
control (QC) of the samples was performed and a range of quality metrics was 
calculated. These metrics were part of ENCODE guidelines for assessing the quality 
of ChIP-seq data. For each sample, we calculated the PCR bottleneck coefficient 
(PBC), normalised strand coefficient (NSC), relative strand coefficient (RSC) and the 
fraction of reads in peaks (FRiP). The PBC measures library complexity and whether 
duplicate reads are overrepresented. RSC, NSC and FRiP are measures of 
enrichment.  
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3.2 Aims: 
 
• Differentiate hMSCs into chondrocytes over 14 days using the transwell model 
of chondrogenesis. Optimise chondrocyte isolation and chromatin extraction 
from cartilage discs.  
 
• Assess histone mark enrichment for the in vitro model of chondrogenesis 
(hMSC at day 0 vs chondrocytes at day 14) using ChIP-qPCR.  
 
• Generate a histone ChIP-seq dataset for the same model using antibodies 
against histone marks H3K4me3, H3K4me1, H3K27ac, H3K27me3 and 
H3K36me3 including an input control, and assess the quality of the data and 
reproducibility of biological replicates. 
 
• Call peaks and annotate peaks in the ChIP-seq dataset. 
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3.3 Results 
 
3.3.1 Sonication of extracted hMSC and chondrocyte chromatin 
 
hMSCs were differentiated into chondrocytes in transwell inserts over 14 days and 
chromatin extracted at days 0 (hMSCs) and day 14 (differentiated chondrocytes). 
Chromatin was extracted from hMSCs and differentiated chondrocytes using 
Diagenode’s iDeal histone ChIP-seq kit. Differentiated chondrocytes were first isolated 
from the cartilage-like disc formed over the chondrogenesis process using enzyme 
digestion before chromatin was extracted. After crosslinking with formaldehyde, the 
chromatin was sonicated. Sonication of chromatin is an important step in the ChIP 
protocol. Adequate fragmentation of chromatin is required for a high resolution of 
protein enrichment. Diagenode recommended an ideal average fragment size of 100-
600bp for histone ChIP-seq. Sonication cycles were optimised for hMSC and 
chondrocyte chromatin using a Biorupter Standard (Diagenode). Chromatin from 
hMSCs was sonicated with a range of cycle numbers and the DNA fragment size (after 
reverse crosslinking) was visualised using agarose gel electrophoresis (Fig. 3.1A). 
 
 
Figure 3.1 – (A) Sonication of hMSC chromatin using 0, 5, 10, 15 and 20 cycles (Diagenode standard; 30s on/20s 
off. (B) DNA fragment sizes from chromatin extracted from hMSCs and isolated differentiated chondrocytes 
sonicated at 15 cycles.  
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We observed that as the cycle number increased, the average DNA fragment size 
decreased. DNA fragments without sonication and at 5 and 10 sonication cycles were 
too large for ChIP as bands exceeding 10kb were present. We observed that 15 
sonication cycles (30s on/20s off; Diagenode Standard) gave a DNA fragment size 
range of 150-800bp with the majority of the DNA at ~250bp. Chromatin extracted from 
differentiated chondrocytes was also sonicated for 15 cycles and this gave similar sizes 
to hMSC with an average of ~250bp (Fig. 3.1B).  Whilst chromatin sonicated for 20 
cycles also yielded fragment sizes of ~150-600bp, over sonication leads to reduced 
ChIP efficiency (Pschelintsev et al, 2016) so the lowest sonication cycle with the same 
size range was chosen. Thus 15 cycles were decided to be optimal.  
 
For each ChIP-seq replicate experiment, chromatin from hMSC and differentiated 
chondrocytes was extracted and sonicated at the same time. Immunoprecipitations 
using different histone modification antibodies were carried out using chromatin from 
the same batch to minimise technical variation. Similarly, the input controls were from 
the same chromatin used for immunoprecipitations.  
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3.3.2 ChIP-qPCR 
 
3.3.2.1 H3K4me3 ChIP-qPCR 
 
ChIP-seq grade antibodies and histone mark enrichment of hMSCs and differentiated 
chondrocytes were assessed using ChIP-qPCR. The H3K4me3 antibody was tested 
using ChIP-qPCR prior to performing experiments for sequencing. H3K4me3 is found 
in the promoters of actively transcribed genes. Enrichment for H3K4me3 marks were 
assayed using primers designed to promoter regions of actively expressed genes in 
hMSCs and chondrocytes (Fig. 3.2). Gene expression abundance in transcripts per 
million (TPM) in RNA-seq data of the same in vitro model of chondrogenesis was used 
as a reference for expression levels. Genes that change during chondrogenesis were 
selected to elucidate whether the change in H3K4me3 enrichment was associated with 
gene expression change.  
 
A positive enrichment was defined as a percent of input greater than 5% (Diagenode 
recommended threshold). Enrichment was normalised using an input control because 
at this stage we had determined that future ChIP-seq experiments would include an 
input control. However, IgG immunoprecipitations were included in initial ChIP-qPCR 
experiments and the percent of input of IgG calculated as an extra negative control. 
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Figure 3.2 – H3K4me3 enrichment for hMSCs and day 14 differentiated chondrocytes (labelled CHON) at gene 
promoters. H3K4me3 enrichment at promoters of genes COL2A1, TAGLN, GAPDH, HBB, SOX9, MATN3 and 
RUNX2 were assayed using ChIP-qPCR (technical replicates n = 3). A positive enrichment was defined as a 
percent of input above 5%, an IgG control was included but this was not used in the final analysis. Error bars 
represent the standard deviation. TPM of genes assayed by RNA-seq are shown below the bars. 
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Increased enrichment of H3K4me3 at gene promoters was seen for genes that were 
upregulated from day 0 to day 14 of chondrogenesis based on TPM. COL2A1, SOX9 
and MATN3 showed both increased gene expression and promoter H3K4me3 
enrichment in chondrocytes compared to hMSCs. The opposite was seen for TAGLN, 
a gene which is down regulated during chondrogenesis. However, RUNX2 which is a 
marker of osteoblastogenesis and is downregulated during chondrogenesis, shows an 
enrichment of H3K4me3 at the gene promoter that is absent in hMSCs. GAPDH was 
used as a positive control gene and H3K4me3 enrichment was observed as expected 
in both hMSCs and chondrocytes. As a housekeeping gene, expression of GAPDH 
was not expected to change during chondrogenesis but it appears to increase in 
chondrocytes. It is unknown whether this change is significant because differential 
testing could not be performed for RNA-seq samples due to low sample size (n = 1). 
However, chondrogenesis microarray data (kindly provided by Dr Matt Barter, 
Newcastle University) confirmed that GAPDH is upregulated (log2 fold change 1.4; q 
value < 2.37 x 10-10) in differentiated chondrocytes compared to hMSCs. Nonetheless, 
GAPDH remains highly expressed in both cell types and this is reflected in the 
enrichment of H3K4me3. The negative control gene, HBB, was neither expressed nor 
was enriched for H3K4me3 in hMSCs and differentiated chondrocytes. These initial 
findings show that upregulation of gene expression during chondrogenesis is 
accompanied with an increase in H3K4me3 enrichment at promoters.  
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3.3.2.2 H3K4me1 and H3K27ac ChIP-qPCR 
 
Designing primers for ChIP-qPCR to assay other histone marks proved challenging. 
H3K4me3 marks active promoters and was therefore a simple matter of designing 
primers upstream (0-500bp) of the TSS of genes. Other histone marks we were 
interested in included the poised and active enhancer marks H3K4me1 and H3K27ac 
respectively, active gene body mark H3K36me3 and repressive mark H3K27me3. 
Enhancers can be located long distances from genes and gene body modifications can 
be found anywhere within the gene body. For non-promoter histone modifications, we 
were limited to genomic regions that were known to be marked by specific histone 
marks. For this reason, gene body modifications were not assayed using ChIP-qPCR 
and enhancer modifications were only assessed in a known enhancer. H3K4me1 and 
H3K27ac histone modifications in the COL2A1 enhancer located within the first intron 
of the COL2A1 gene (Krebsbach et al, 1996) was assayed using ChIP-qPCR. In 
MSCs, there was a marginal positive enrichment of the poised enhancer mark 
H3K4me1 and no enrichment of the active enhancer mark H3K27ac. Both 
modifications are positively enriched in chondrocytes, defined as a percentage of input 
greater than 5% (Fig 3.3). 
 
Overall, for the genes that were assayed, a change in gene expression occurred with 
the expected change in H3K4me3 enrichment at the gene promoters. Both enhancer 
marks were enriched in a known intronic COL2A1 enhancer in chondrocytes whereas 
only the poised mark H3K4me1 was enriched in hMSCs, illustrating an activation of 
this enhancer in chondrogenesis.  
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Figure 3.3 – Enrichment of H3K4me1 and H3K27ac histone modifications within the COL2A1 intronic gene 
enhancer in hMSCs and chondrocytes (CHON) assayed using ChIP-qPCR (n = 3). A positive enrichment was 
defined as a percent of input greater than 5%, an IgG control was included but not used in the final analysis. 
Error bars represent the standard deviation.  
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3.3.3 Read QC and ChIP-seq quality metrics 
 
After optimisation of the ChIP protocol using ChIP-qPCR, ChIP-seq was performed for 
hMSC and differentiated chondrocytes (n = 2 for each cell type, hMSC donors 071508A 
and 2454e) using antibodies against H3K4me3, H3K4me1, H3K27ac, H3K27me3 and 
H3K36me3. Input controls also were sequenced for each replicate and cell type. The 
Diagenode iDEAL histone ChIP-seq kit was used. Library preparation and high 
throughput sequencing was performed externally. ChIP-seq replicate 1 was performed 
by Diagenode and replicate 2 by the Genomics Core facility, Newcastle University. 
Replicate experiments were performed one year apart. In both cases, bioanalyzer 
results showed that DNA fragments were larger than expected and DNA required re-
sonicating as fragment sizes after immunoprecipitation were too large for library 
preparation. ChIP-seq reports from Diagenode and the Genomics Core facility are 
available at https://github.com/kathleencheung/PhD_Young_lab 
 
Sequencing reads from each ChIP-seq experiment were assessed for quality. ChIP-
seq replicate 1 (donor 071508A) samples were sequenced over one lane and 
generated 14 fastq files (2 of which were IgG controls and were not used). ChIP-seq 
replicate 2 (donor 2454e) were sequenced over 4 lanes and generated 49 fastq files 
in total (4 per ChIP sample plus 1 re-sequence) before merging. FastQC was 
performed on individual read files to assess any differences between them and to 
determine whether there were any outliers before merging. Summarised MultiQC 
reports showed that all sample reads from both replicates achieved a minimum quality 
score above 20 (Appendix i Fig. 1 and Fig.2); therefore, it was not deemed necessary 
to trim reads. MultiQC also assesses GC content and duplication of reads (Appendix 
Table 1 and Appendix Table 2). ChIP-seq samples derived from hMSC donor 071508A 
displayed high read duplication (9/14 samples failed this QC) compared to donor 
2454e (no failures). ChIP-seq samples from donor 071508A required additional PCR 
cycles after DNA library preparation in order to achieve enough DNA for sequencing.  
The high rate of duplication seen in samples from donor 071508A was likely due to the 
additional PCR cycles. In total, 1/14 fastq files from donor 071508A and 6/49 read 
samples from donor 2454e failed GC content QC. This was not considered a problem 
as GC content failures can arise from enrichment of genomic regions with high GC 
content in ChIP-seq data. Likewise, duplicated reads were not removed to avoid 
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eliminating biological effects, and so QC metrics can be calculated for the data without 
biasing the outcomes. Further QC metrics were calculated after merging fastq files 
from the same sample and aligning reads to hg38 reference genome using the Bowtie2 
short read aligner. Reference genome hg38 was the latest human reference genome 
released at the time of this project.  All samples achieved raw read numbers ranging 
from 31-84 million reads, exceeding recommended minimum read numbers for histone 
modifications (Chen et al, 2012; Jung et al, 2014). Alignment rates for replicate 1 
samples were variable ranging from 38.85% to over 98%. All samples from replicate 2 
achieved alignment rates over 97% (Appendix Table 3).  
 
Following alignment of reads to hg38, we assessed the complexity of the data by 
calculating the PBC. The PBC is a measure of DNA library complexity; values of 0-0.5 
indicates severe bottlenecking, 0.5-0.8 is moderate bottlenecking, 0.8-0.9 is mild and 
0.9-1 indicates no bottlenecking. All ChIP-seq samples from replicate 1 displayed 
severe to moderate PCR bottlenecking (PBC values between 0 and 0.8; Table 3.1) 
reflecting the high levels of duplicate reads uncovered by MultiQC. In contrast, 
replicate 2 samples displayed mild to no PCR (PBC values > 0.8) bottlenecking 
suggesting a diverse DNA library.  Samples from ChIP-seq replicate 2 did not undergo 
multiple PCR cycles prior to DNA library preparation. Histone ChIP-seq data from 
ENCODE displayed a range of PBC values from 0.19 to 0.98 with an average PBC of 
0.79. Our ChIP-seq samples displayed a range of PBC values from 0.052 to 0.97 with 
an average of 0.28 and 0.94 from ChIP-seq replicates 1 and 2 respectively.   
 
To measure enrichment prior to peak calling, the NSC and RSC (measures of 
enrichment independent of peak calling) values were calculated using ENCODE utility 
phantompeakqualtools. A range of NSC and RSC values was seen in both replicates. 
Most NSC and RSC values were low (NSC < 1.1 and RSC < 1) but apart from 
H3K27me3 and H3K36me3 samples in replicate 1, sample values were higher than 
their respective input controls. ENCODE sample NSC values ranged from 1.01 to 1.82 
and RSC values from 0.09 to 3.47. Our ChIP-seq NSC values ranged from 1 to 1.3 
and RSC from 0.17 to 1.1 (see Appendix i Fig. 6-10 for NSC and RSC plots).   
 
After broad peak calling using MACS2, the FRiP was calculated using the 
Bioconductor DiffBind package. The percentage of reads located in peaks ranged from 
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46% to 79%, much higher than the recommended ENCODE minimum of 1% (Landt et 
al, 2012). ENCODE ChIP-seq datasets do not have a FRiP value attached and instead 
used a metric called signal portion of tags (SPOT) which is analogous to FRiP. 
ENCODE’s SPOT values for histone ChIP-seq datasets range from 7% to over 89%. 
However, our FRiP values and ENCODE’s SPOT are not directly comparable due to 
the different peak callers and peak calling parameters used.  
 
ENCODE dataset quality metric values were used as a reference. Both ENCODE and 
our histone ChIP-seq metric values were varied. Quality metrics for ENCODE samples 
are available on the ENCODE website and have also been uploaded here 
https://github.com/kathleencheung/PhD_ChIP-seq/ 
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Table 3.1 – Quality metrics PBC, NSC, RSC and FRiP calculated for each histone ChIP-seq sample and input 
controls.  
  
  
Replicate 
no. 
hMSC 
Donor 
Sample name PBC NSC RSC FRiP 
1 071508A MSC_input 0.396324225 1.026624 0.2790935 N/A 
1 071508A MSC_H3K4me3 0.589673045 1.067147 0.6845061 0.67 
1 071508A MSC_H3K4me1 0.15150683 1.032418 0.2886845 0.65 
1 071508A MSC_H3K27ac 0.740986632 1.015744 0.3682942 0.64 
1 071508A MSC_H3K27me3 0.084117163 1.124742 0.2121983 0.46 
1 071508A MSC_H3K36me3 0.052449762 1.173076 0.1646135 0.63 
1 071508A CHON_input 0.261170701 1.033358 0.2738952 N/A 
1 071508A CHON_H3K4me3 0.168367456 1.095136 0.4527105 0.65 
1 071508A CHON_H3K4me1 0.24007756 1.028448 0.376056 0.69 
1 071508A CHON_H3K27ac 0.545050931 1.020625 0.3893155 0.6 
1 071508A CHON_H3K27me3 0.054636704 1.218342 0.1764161 0.51 
1 071508A CHON_H3K36me3 0.069729458 1.128785 0.2053987 0.62 
2 2454e MSC_input 0.957925977 1.007932 0.2389265 N/A 
2 2454e MSC_H3K4me3 0.858682875 1.326625 1.114411 0.79 
2 2454e MSC_H3K4me1 0.964465229 1.031276 0.8018935 0.75 
2 2454e MSC_H3K27ac 0.945940422 1.078115 0.9714882 0.71 
2 2454e MSC_H3K27me3 0.942934438 1.012197 0.3424739 0.58 
2 2454e MSC_H3K36me3 0.935295272 1.013854 0.411228 0.72 
2 2454e CHON_input 0.954169002 1.007501 0.2390396 N/A 
2 2454e CHON_H3K4me3 0.956291968 1.110019 0.9048022 0.65 
2 2454e CHON_H3K4me1 0.942191644 1.022946 0.767487 0.72 
2 2454e CHON_H3K27ac 0.942729131 1.021243 0.7790453 0.66 
2 2454e CHON_H3K27me3 0.94870526 1.013444 0.2955627 0.56 
2 2454e CHON_H3K36me3 0.929758043 1.015522 0.3025558 0.62 
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Overall mapped read density in the genome for each sample was inspected using the 
ngs.plot tool (Fig. 3.4 – 3.6; Appendix i Fig. 3-5) before peak calling. Reads for 
H3K4me3 samples were generally mapped to around the TSS of genes and the 
highest density of reads was found slightly downstream (within 1000bp) of TSS (Fig. 
3.4). This fits in line with expectations as H3K4me3 is an active promoter histone 
modification. Enhancer and gene body histone modification reads were located further 
away from the TSS. The highest density of H3K4me1 reads mapped to 2000-3000bp 
downstream from the TSS with another density peak seen a similar distance upstream 
(Fig. 3.5). H3K27ac showed the most heterogeneous read profile across samples; 
H3K27ac reads from hMSC and chondrocyte samples from donor 071508A displayed 
a read density profile comparable to H3K4me1 whereas 2454e samples were more 
alike H3K4me3. The highest read densities for gene body marks H3K27me3 and 
H3K36me3 were seen around 3000-6000bp away from the TSS (Fig. 3.6). Globally, 
for each histone modification, reads mapped to expected regions of the genome 
relative to the TSS of genes. 
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Figure 3.4 –Average read densities for active promoter mark H3K4me3 in both hMSC (A&B) and chondrocyte 
(C&D) replicates (A&C = donor 017508A; B&D = donor 2454e). Shading represents the 95% confidence intervals. 
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Figure 3.5 – Average read densities for enhancer marks H3K4me1 (A-D) and H3K27ac (E-H) in both hMSC (A&B, 
E&F) and chondrocyte (C&D, G&H) replicates. Shading represents the 95% confidence intervals. 
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Figure 3.6 – Average read densities for repressive mark H3K27me3 (A-D) and active gene body H3K36me3 (E-H) 
in both hMSC (A&B, E&F) and chondrocyte (C&D, G&H) replicates. Shading represents the 95% confidence 
intervals. 
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In addition to calculating quality metrics recommended by ENCODE, read coverages 
were also visually inspected using IGV genome browser after normalising by reads per 
million mapped reads (RPM). As examples of actively expressed genes, ChIP-seq 
reads around CD44 (a marker of MSCs) in hMSCs (Fig. 3.5) and COL2A1 in 
chondrocytes are shown (Fig. 3.6). In general, read coverages for each histone 
modification from both ChIP-seq replicates occur around the same region in the 
genome. For instance, actively expressed genes tended to exhibit H3K4me3 marks 
around their TSS and H3K36me3 marks in the gene body whereas non expressed 
genes did not.  Enhancer marks H3K4me1 and H3K27ac reads tended to be seen in 
the same regions whereas repressive H3K27me3 and active H3K36me3 did not 
overlap. Although not a quantitative assessment, visualisation on a genome browser 
proved to be a useful and intuitive method of initially surveying the data before moving 
on to further analyses.  
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3.3.4 Peak calling and annotation 
 
Peak calling identifies regions of the genome that are statistically enriched for the 
protein or histone modification assayed over a background control. The MACS2 peak 
caller was used for its option to call broad peaks, the type of peaks typically produced 
by histone modifications. To call peaks, alignment files in BAM format were converted 
into bedgraph format using the bedtools genomecov tool and the bedgraph files were 
used as input into MACS2 peak caller. Significant broad peaks were called using 
MACS2 peak caller (q value < 0.05) using the input samples as a control. Peaks were 
called separately for each ChIP-seq replicate. Numbers of peaks called for each 
histone mark were variable between cell types and donors (Table 3.2). The number of 
H3K4me3 peaks in hMSC cells from donor 071508A was roughly half of the other 
samples (33161 compared to 61348 – 69215). H3K4me1 peak numbers were 
comparable between cell types from the replicates. There were more H3K27ac peaks 
called for both hMSCs and chondrocytes from donor 2454e (60465 and 67590) 
compared to 071508A (147461 and 110775). Numbers of H3K27me3 peaks were 
variable between all four samples. More peaks were called for H3K36me3 in hMSCs 
from donor 071508A compared to chondrocytes from the same donor; in contrast, 
donor 2454e showed the opposite trend. 
 
Table 3.2 – Total number of peaks called by MACS2 (q < 0.05, broad option on, input control) for each ChIP-seq 
sample.  
 Number of peaks called by MACS2 
Replicate 
no. 
hMSC 
donor 
Cell 
type 
H3K4me3  H3K4me1 H3K27ac H3K27me3 H3K36me3 
1 071508A hMSC 33161 163717 60465 110041 138557 
1 071508A CHON 69215 145745 67590 85395 96321 
2 2454e hMSC 61348 173052 147461 151273 95744 
2 2454e CHON 69094 149400 110775 234574 131261 
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To view genome coverage of called peaks, peak density plots were created (Fig. 3.9). 
Prior to peak calling, read coverage for each histone mark was plotted and visualised 
on the IGV genome browser (Fig. 3.3 – 3.7).  However, these analyses do not 
empirically take into account the input controls and may not be a true representation 
of histone mark enrichment. For example, high sample read density in a region does 
not necessarily equate to enrichment if the input sample also exhibits many reads in 
that same region. MACS2 uses a Poisson distribution to compare the local background 
(input control) enrichment levels with ChIP-seq samples. Consequently, plotting peak 
density, as opposed to read density, gives a better insight into where specific histone 
modification enrichments are located in the genome. In a high quality ChIP-seq 
dataset, profiles of read coverage density and peak density will be very much alike. 
For our dataset, plots of read coverage and peak density around the TSS of genes (-
/+ 6kb) are similar. The highest density of H3K4me3 peaks are located around the TSS 
(Fig. 3.9A). In comparison to H3K4me3, all other histone mark peaks are at a lower 
density at gene TSSs. H3K4me1 peaks are at their highest density ~2-3kb downstream 
of TSS. The highest density of H3K27ac peaks are close to the TSS of genes but they 
are at a lower density compared to H3K4me3 peaks. In contrast, H3K27ac peaks are 
at higher densities than H3K4me3 further away from the TSS. Both gene body marks 
H3K27me3 and H3K36me3 peaks are distal to the TSS and showed a higher density 
away from the TSS compared to the promoter mark H3K4me3. The signal to noise 
ratio of reads was also evaluated independently of peak calling (Fig. 3.10), this 
corroborated the enrichment of peaks around the TSS.  
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Figure 3.9 – Histone mark peak densities at TSS -/+ 6000bp. Broad peaks were called using MACS2 and density 
plots created in RStudio. All plots are drawn with the same x and y scales. (A) H3K4me3 peak densities, (B) 
H3K4me1, (C) H3K27ac, (D) H3K27me3 and (E) H3K36me3.    
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Figure 3.10 – Signal over noise ratio of histone mark reads from combined replicate samples. The ratio of 
histone mark reads to input controls was assessed independently of peak calling. Alignment files for each 
histone mark sample were merged and plots were generated using ngs.plot.r  
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Peaks were annotated by associating to the nearest gene and overlapping genomic 
feature using HOMER software. Features available are 5’ untranslated regions 
(5’UTR), 3’UTRs, exons, introns, intergenic regions, promoters, transcriptional 
termination sites (TTS) and non-coding exons. Overlapping genomic features confirms 
that H3K4me3 peaks are found at gene start sites, with enrichment at 5’UTRs, 
promoters, introns and intergenic regions (Table 3.3). H3K4me3 peak numbers were 
relatively low at 5’UTRs (1.11%) and promoters (8.53%) compared to introns (47.1%) 
and intergenic regions (37%). Although comparatively low, percent of H3K4me3 peaks 
in these 5’UTR and promoter regions is higher than the other histone marks. The 
smaller percentage of peaks in these areas may be due to the smaller size of these 
regions relative to others. 5’UTR regions cover around 100-200bp (Mignone et al, 
2002) and HOMER defines promoter regions as -1kb to +100bp from the TSS. Introns 
and intergenic regions can span much larger areas and therefore it is likely more peaks 
will fall into these regions. All histone marks showed high percentages of peaks in 
introns and intergenic regions. Although 47.1% of H3K4me3 are located in introns, a 
high proportion of these, 51.7%, are found in the first intron. Similarly, 2.71% of 
H3K4me3 peaks are found in exons with 42.2% of these peaks in the first exons. This 
adds support that H3K4me3 peaks are mainly found around the 5’ end of genes. The 
other histone mark peaks do not display such a bias towards the first exons and introns. 
The active gene body modification H3K36me3 had the lowest percentage of peaks in 
the first intron and exon compared to the other histone marks. Enhancer marks 
H3K4me1 and H3K27ac showed similar peak percentages in each genomic feature. 
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Table 3.3 – Average percentages of all peaks from both ChIP-seq replicates for each histone mark in genomic 
features annotated by HOMER annotatepeaks.pl. Regions classed as N/A have not been annotated as any of the 
available regions. 
 
 
 
  
Percentage of peaks in genomic features Percent of 
total 
genome 
 H3K4me3 H3K4me1 H3K27ac H3K27me3 H3K36me3 
5'UTR 1.11 0.182 0.404 0.064 0.041 0.08 
3' UTR 0.947 1.19 1.50 0.363 1.20 0.72 
exon  
 
2.71 (of 
which 42.2% 
in exon 1) 
 
1.34 (of 
which 10.4% 
in exon 1) 
 
2.19 (of 
which 
13.3% in 
exon 1) 
 
0.697 (of 
which 15.3% 
in exon 1) 
 
1.77 (of 
which 2.92% 
in exon 1) 
 
 
1.09 
Intron 
 
47.1 (of 
which 51.7% 
in intron 1) 
 
54.6 (of 
which 34.0% 
in intron 1) 
 
60.8 (of 
which 
36.7% in 
intron 1) 
 
29.4 (of which 
28.1% in intron 
1) 
 
51.4 (of 
which 15.5% 
in intron 1) 
 
 
37.9 
 
intergenic 37.0 38.5 29.4 67.14 42.7 58.05 
promoter 8.53 2.18 3.46 0.818 0.534 1.02 
TTS 1.55 1.45 1.77 0.701 1.36 
0.91 
 
non-
coding 
exons 0.856 0.485 0.592 0.289 0.443 
0.17 
N/A 0.213 0.123 0.035 0.585 0.518 0.06 
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3.3.5 Correlation of ChIP-seq replicates 
 
ChIP-seq replicates of hMSC and differentiated chondrocytes were derived from two 
hMSC donors 071508A and 2454e. The replicate donor ChIP experiments and 
sequencing was performed at different times using different DNA library preparation 
kits and sequencing platforms. We sought to investigate how reproducible our ChIP-
seq experiments were and whether the two replicates were comparable. Using the 
Bioconductor package DiffBind, a correlation heatmap was generated using read count 
data (Fig. 3.11). All ChIP-seq samples of the same histone mark clustered together 
showing that samples from our two replicate experiments are comparable when 
considering histone mark alone. H3K27me3 samples clustered together on a separate 
node to the other four histone marks and are negatively correlated to enhancer marks 
H3K4me1 and H3K27ac. The highest correlation between histone marks was 
observed between H3K4me1 and H3K27ac. This indicates that H3K4me1 and 
H3K27ac are likely to co-occur in the genome whereas the presence of H3K27me3 
marks are mutually exclusive with H3K4me1 and H3K27ac.  
 
As well as clustering by histone mark, we would expect samples to cluster by cell type 
and not by replicate/hMSC donor if biological effects are greater than technical effects 
between the two experiments. This was not the case for H3K27me3 or H3K36me3; 
samples of both these marks clustered by replicate/hMSC donor before cell type 
suggesting effects between replicates are greater than the effects between cell type. 
However, this could be due to technical variation between the experiments or as a 
result of biological variation between the hMSC donors for these histone modifications. 
H3K4me3 samples did not cluster by replicate nor cell type. In contrast, both enhancer 
histone marks H3K4me1 and H3K27ac separated by cell type. This shows that 
enhancer histone marks between hMSC and chondrocytes are more dissimilar 
compared to other histone marks in this study, suggesting that the cell type specific 
effects outweigh donor variation. A PCA plot (Fig. 3.12) showed the same outcome. 
 
The proportion of overlapping peaks for each histone mark in both ChIP-seq replicates 
was found using the DiffBind package. Peaks were liberally defined as overlapping if 
they shared at least one base in common, this was the default setting in DiffBind. There 
was a 37.8% overlap of total H3K4me3 peaks from hMSC replicates and 20.3% of 
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chondrocyte H3K4me3 peaks. H3K4me1 peaks in hMSCs saw an overlap of 20% and 
32% overlapped in chondrocytes. For H3K27ac, 20.3% overlapped in hMSCs and 
21.7% in chondrocytes. Only 9% of H3K27me3 peak overlapped in hMSCs, similar to 
chondrocytes which saw an 8.5% peak overlap. Overlap in H3K36me3 peaks between 
ChIP-seq replicates was also low with 11.9% and 11.8% in hMSCs and chondrocytes 
respectively (Fig. 3.13).  
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Figure 3.11 – Correlation heatmap of histone modifications across all samples. The correlation matrix was 
generated using DiffBind with read count data and replotted using the pheatmap() function in RStudio.  
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Figure 3.12 – PCA plot of ChIP-seq peak sets. Points labelled 1 are samples from replicate 1 (hMSC donor 
071508A) and labelled 2 are from replicate 2 (hMSC donor 2454e). 
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Figure 3.13 – Overlap of histone peaks between the two ChIP-seq biological replicates (hMSC donors). 
H3K4me3, H3K4me1 and H3K27ac displayed greater overlaps between replicates than H3K27me3 and 
H3K36me3. Overlapping peaks share at least one base. Overlap analysis was performed using the DiffBind 
package and Venn diagrams created using the Venneuler package in RStudio.  
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3.4 Discussion 
 
The initial primary aim of this project was to generate histone ChIP-seq data from the 
transwell model of chondrogenesis. We developed a ChIP-seq workflow optimised for 
hMSCs and differentiated chondrocytes. At day 14 in our chondrogenesis model, cells 
form a cartilage-like disc (Murdoch et al, 2007). We expected the extraction of 
chromatin from cartilage to be difficult due to the dense extracellular matrix secreted 
by chondrocytes. In this project, extraction was achieved by first isolating chondrocytes 
by digesting the cartilage-like disc using hyaluronidase, trypsin and collagenase 
sequentially before extracting the chromatin. Previous chondrocyte ChIP studies also 
isolated cells from cartilage prior to chromatin extraction (Otero et al, 2005; Dvir-
Ginzberg et al, 2008; Herlofsen et al, 2013). Care must be taken to minimize disruption 
to cells and to ensure a high yield of chondrocytes from the discs. There is evidence 
that isolation of chondrocytes from cartilage can alter gene expression. One study 
found that shorter digestion times of cartilage explants with collagenase led to fewer 
gene expression changes. The study also concluded that longer digestion yielded 
more cells (Hayman et al, 2006). Consequently, choosing an appropriate digestion 
period is a trade-off between harvesting a high yield of cells and minimising gene 
expression changes. As gene expression and histone modifications are linked and 
highly dynamic, it would be prudent to reduce any effects which could alter gene 
expression.  
 
Sonication of chromatin is an important step in generating ChIP-qPCR/ChIP-seq data. 
Fragment sizes that are too large leads to a poor signal to noise ratio whereas over 
sonication may result in biases to certain regions in the genome (Diaz et al, 2012) or 
fragmentation of the protein bound DNA. It is particularly important to consider this 
when sonicating chromatin for histone ChIP experiments. DNA is wrapped around 
histone proteins in a unit called a nucleosome. One nucleosome is approximately 
146bp (Luger et al, 1997); in order to avoid disrupting nucleosomes, chromatin should 
be sonicated to no smaller than 150bp. There is no single standardized chromatin 
fragment size for ChIP-seq and sonication generates a range of fragment sizes. 
Biotechnology companies providing ChIP products and services recommend 200-
1000bp (ABCAM) or 100-1000bp (Diagenode). For ChIP-seq, Diagenode recommend 
sonicating chromatin to 100-600bp whereas ENCODE guidelines stipulate 100-300bp 
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(Landt et a, 2012). Smaller sizes are more appropriate for DNA library construction for 
high throughput sequencing. Although we sonicated chromatin to an average fragment 
size of ~250bp, all samples required re-sonication prior to DNA library preparation. The 
larger fragment size seen after immunoprecipitation is indicative of a bias towards 
pulling down longer fragments during immunoprecipitation. Larger fragments may 
contain more of the histone modification of interest and therefore be more likely to be 
bound by an antibody. Furthermore, sonication across the genome is not consistent, 
for example, heterochromatin is more resistant to sonication compared to euchromatin 
(Teytelman et al, 2009). Disregarding larger fragments in favour of smaller fragments 
may lead to a biased representation of the genome. One study found that repeat 
fragmentation of longer fragments after immunoprecipitation improved resolution of 
ChIP-seq and that the extra sonication step did not introduce any artefacts (Mokry et 
al, 2010). Therefore, re-shearing and including the longer immunoprecipitated 
fragments in the DNA library is the best approach in this scenario.   
 
The sequencing depth of ChIP-seq experiments is another important factor to consider. 
Histone marks spanning broader genomic regions such as gene body and enhancer 
marks require more reads to achieve sufficient coverage. The ENCODE project 
recommends at least 10 million reads for transcription factor ChIP-seq (narrow source 
peaks) and 20-40+ million reads for histone ChIP-seq (Landt et al, 2012). All our ChIP-
seq reads exceeded recommended numbers. 
 
The ENCODE consortium was one of the first large scale projects using ChIP-seq and 
many of the early bioinformatics tools developed for ChIP-seq analysis was created by 
or in collaboration with ENCODE. The initial analysis and QC steps illustrated in this 
chapter largely follows the ENCODE ChIP-seq analysis pipeline. Various metrics 
attempt to assess the technical quality of ChIP-seq data and whether the data is of 
high enough quality for downstream analysis.  The ENCODE project defined a number 
of quality metrics for ChIP-seq data and recommends that all ChIP-seq data is 
assessed using these metrics. ChIP-seq data can be assessed by QC metrics such as 
the PBC, NSC, RSC and FRiP. The PBC is a measure of DNA library complexity and 
ranges from 0 to 1, with increasing values indicating higher complexity. Diverse DNA 
libraries will have a high PBC score whereas lower scores represent PCR bias and 
read duplication. However, ChIP-seq is inherently biased as antibodies are used 
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specifically to immunoprecipitate genomic regions of interest. Therefore, low PBC 
values do not necessarily mean the ChIP-seq data is of poor quality. In fact, this can 
be a sign that certain genomic regions are overrepresented in the DNA library which 
is expected in ChIP-seq. Very high scores can indicate no enrichment of specific 
genomic regions. For example, H3K4me3 marks are located around active gene 
promoters which may share common motifs such as transcription factor binding sites 
in a specific cell type. Therefore, duplicate reads could occur if these motifs are highly 
enriched in the DNA library. Removing duplicate reads in this case may remove true 
biological information. However, very low PBC scores are undesirable and could be a 
symptom of PCR amplification bias. ChIP-seq replicate 1 (donor 071508A) exhibited 
moderate to severe PCR bottlenecking, most likely due to excessive PCR cycles.  
 
Cross strand correlation analysis assesses enrichment of the immunoprecipitated 
protein independent of peak calling using read density on forward and reverse strands. 
It is expected that in a good quality ChIP-seq dataset, there will be high densities of 
read counts on both the forward and reverse strands centred around the binding site 
of the protein. The distance between the read density peaks on the forward and 
reverse strands should reflect the size of the predominant sonicated DNA fragment. A 
cross correlation metric can be calculated by shifting the two strands by fixed, 
incremental distances in both directions and finding the Pearson’s correlation at each 
shift. The NSC is the maximum correlation value, occurring at a shift equal to the DNA 
fragment size, divided by the minimum correlation value at strand shift (the background 
cross correlation). The minimum NSC value is 1; values lower than 1.1 are considered 
low and values above 1.1 indicates higher enrichment of the bound protein. The 
correlation at the fragment length shift minus the background cross correlation shows 
a tag peak when plotted against all other distance shifts. In short read data (read length 
smaller than 100bp), which represent the majority of next generation sequencing 
datasets, of complex mammalian genomes such as human and mouse, a peak is also 
seen at a strand shift equal to the read length. This is known as a phantom peak. The 
ratio of the fragment length peak compared to the phantom peaks gives the RSC value. 
A bigger fragment length peak relative to the read length peak demonstrates more 
enrichment of the immunoprecipitated protein. The RSC value ranges from 0 to above 
1 with 0 indicating no enrichment and above 1 indicating high enrichment. Similar to 
PBC, the cross strand correlation metric values provide an indication of histone 
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enrichment and signal to noise ratio but taken alone, they do not necessarily determine 
whether ChIP-seq data is biologically meaningful. They are useful for gauging whether 
ChIP-seq data is technically sound but further analysis is needed before drawing 
conclusions. Furthermore, they are designed on the basis that enrichment of a DNA 
binding protein gives a sharp peak signal. This occurs for transcription factor ChIP-seq 
but not for proteins or histone marks that give both narrow and broad peaks such as 
RNA polymerase II and H3K27ac (Furey, 2012; Wang et al, 2016). Histones produce 
broad peaks as they tend to be enriched over a larger area compared to transcription 
factors. This enrichment profile can result in lower NSC and RSC scores. For all our 
samples, FRiP far exceeded the minimum threshold of 1% stipulated by ENCODE. 
 
Enrichment for specific histone marks was seen at expected genomic features, for 
example, H3K4me3 at gene promoters. The histone marks we assayed are very well 
characterised so this information is not novel. Nonetheless, confirming the enrichment 
profiles of individual histone marks in the genome is a fundamental initial step in the 
ChIP-seq analysis pipeline.  
 
ENCODE recommends a minimum of two ChIP-seq replicates (Landt et al, 2012) and 
therefore we generated histone ChIP-seq data for two chondrogenesis experiments 
using different hMSC donors. However, they were performed separately. For this 
reason, we assessed the similarity between the replicates. For measuring 
reproducibility of transcription factor ChIP-seq experiments, ENCODE recommends 
calculating the irreproducible discovery rate (IDR). IDR scores peaks on how 
reproducible they are between two replicates, peaks with low scores can be excluded 
from the data (Li et al, 2011). Unfortunately, this method was not designed to be used 
with histone ChIP-seq. This further highlights the limited bioinformatics tools available 
at this time to interrogate histone ChIP-seq. We examined our replicates using a 
correlation heatmap, PCA analysis and by determining overlapping peaks. 
Comparison of the two biological ChIP-seq replicates showed that whilst samples for 
the same histone marks clustered together, peak overlap between the replicates was 
generally poor. This is not surprising considering the two ChIP-seq experiments were 
performed and sequenced at different times. Other studies also found poor peak 
overlap between replicates, with high PBC values exacerbating the difference (Yang 
et al, 2014). H3K4me3, H3K4me1 and H3K27ac showed more parity between the two 
 
 
 112 
replicates compared to H3K27me3 and H3K36me3. Although the ChIP-seq replicates 
derived from the same in vitro chondrogenesis model, the experiments were carried 
out at different times and therefore are not true biological replicates. Furthermore, the 
hMSC donors were different and therefore any the differences identified could reflect 
natural biological variation. Surprisingly, there is no consensus for combining ChIP-
seq replicates from the same experiment or otherwise. Published ChIP-seq studies 
have either pooled all replicates, used ENCODE’s IDR method, selected the best 
replicate or, for experiments with n > 3, used a majority rule approach (Yang et al, 
2014). Each method has its own pros and cons; ChIP-seq analysis pipelines must be 
tailored to the project. Our peak sets were kept separate as it was unnecessary to 
combine them and peaks were not used in further analysis. With this in mind, we 
considered our ChIP-seq replicates to be sufficiently consistent for the next step in the 
data analysis. 
 
In summary, an optimised workflow for extracting chromatin from hMSCs and 
chondrocytes from a cartilage-like disc was developed. We generated a histone 
(H3K4me3, H3K4me1, H3K27ac, H3K27me3 and H3K36me3) ChIP-seq dataset for 
hMSCs and differentiated chondrocytes. Initial QC of the data showed that histone 
read enrichments were located at expected genomic regions. Further analysis is 
required to elucidate the histone modification changes during chondrogenesis.  
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3.5 Conclusions 
 
• We generated a histone ChIP-seq dataset of the in vitro transwell model of 
chondrogenesis using antibodies against H3K4me3, H3K4me1, H3K27ac, 
H3K27me3 and H3K36me3. An input control was included.  
 
• QC of our dataset established that our samples were of varying quality, with 
samples from replicate 2 showing higher quality metrics than replicate 1.  
 
• Enrichment of histone marks were seen at expected genomic features, with a 
high density of H3K4me3 present at promoters, enhancer marks H2K27ac and 
H3K4me1 were found further away from promoters and gene body marks 
H3K27me3 and H3K36me3 further still. 
 
• Analysis of peaks revealed that the same histone modifications clustered 
together and enhancer marks also showed clustering of the same cell types 
from both replicates. H3K4me3, H3K4me1 and H3K27ac peak sets showed 
more overlapping peaks between replicates compared to H3K27me3 and 
H3K36me3.  
 
  
 
 
 114 
Chapter 4. Integration of chondrogenesis histone ChIP-seq to RNA-
seq data 
 
4.1 Introduction 
 
We generated a histone ChIP-seq dataset for an in vitro model of chondrogenesis, 
described in the previous chapter. Analysis of the data showed that histone mark 
enrichments were found at expected locations in the genome.  
 
Regulation of gene transcription is partly regulated though epigenetic mechanisms 
during chondrogenesis (Furumatsu and Asahara, 2010) and is also mediated by 
transcription factors such as SOX9. SOX9 is widely considered the master 
transcription factor driving chondrogenesis and is essential for chondrogenesis 
(Akiyama et al, 2004).  Histone modifying enzymes have been found to drive SOX9 
induced gene expression during chondrogenesis (Hata et al, 2013) and play a role in 
chondrocyte maintenance (Huh et al, 2007). Histone modifications act along with other 
factors to regulate gene expression. 
 
RNA-seq is a high throughput method utilising next generation sequencing to quantify 
transcripts in a population of cells. This method offers many advantages over 
conventional gene expression assays such as RT-qPCR and microarrays. Gene 
microarrays and RNA-seq are both considered genome wide methods unlike RT-
qPCR. However, RNA-seq has a greater dynamic range compared to microarrays at 
quantifying both low and highly expressed genes. Furthermore, unlike microarrays, 
RNA-seq does not rely on transcript specific probes and can aid in the detection of 
novel genes and transcripts (Zhao et al, 2014). We generated RNA-seq data for the 
same chondrogenesis model used for histone ChIP-seq. RNA-seq was performed at 
n = 1 (hMSC donor 017508A), therefore statistical testing for differential expression 
was not possible and consequently, these results are exploratory. However, a DNA 
microarray was previously performed (n = 3) for the same chondrogenesis model and 
this was correlated with RNA-seq data to assess the similarity between the two 
datasets.  
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Both RNA-seq and microarray data were generated prior to the conception of this 
project and a full in-depth analysis of these data is beyond the scope of this PhD. In 
this chapter, the connection between histone mark enrichment and gene expression 
during the in vitro transwell model of chondrogenesis is investigated.  
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4.2 Aims 
 
• Associate histone marks (H3K4me3, H3K4me1, H3K27ac, H3K27me3 and 
H3K36me3) assayed using ChIP-seq to gene expression quantified by RNA-
seq (correlate RNA-seq to microarray data). 
 
• Explore the relationship between histone modifications and gene expression 
during chondrogenesis. 
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4.3 Results 
 
4.3.1 Chondrogenesis RNA-seq analysis 
 
Gene expression in hMSCs and differentiated chondrocytes was determined using 
RNA-seq. RNA-seq reads were assessed using FastQC and MultiQC (Appendix ii, Fig. 
1 and Table 1). Transcript isoforms were quantified using Salmon in quasi-mapping 
mode and summarised to gene level in RStudio using the tximport package. Differential 
expression tests were not possible due to insufficient sample numbers (n = 1 for both 
hMSC and differentiated chondrocytes), therefore genes were quantified in TPM and 
up- or down-regulated genes were considered as such by their log2 fold change in 
TPM.  In the absence of statistical analysis, genes with a log2 fold change (TPM + 1) 
> 1.5 were arbitrarily considered to be differentially expressed in our analysis. Using 
this fold change cut off, 447 genes were upregulated and 2771 genes were 
downregulated (Fig. 4.1).  
 
RNA-seq data was correlated to microarray data (n = 3, hMSC donor 017508A) of the 
same chondrogenesis model to confirm gene expression changes. Concordance 
between the two technologies was good and there was a significant correlation 
between gene expression changes in the RNA-seq and microarray datasets (Fig. 4.2). 
Although variation between individual genes cannot be assessed, the correlation 
between RNA-seq and microarray shows that overall, the RNA-seq dataset is similar. 
More genes were downregulated compared to upregulated in our RNA-seq data (2771 
and 447) but it is not known whether these changes are statistically significant. Our 
chondrogenesis microarray data showed that 598 genes were significantly (q < 0.05) 
upregulated with a log2 fold change > 1.5 and 562 were significantly downregulated 
by a log2 fold change < -1.5.  A separate cDNA microarray study found more genes 
were downregulated during chondrogenesis (Yoo et al, 2011).  
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Figure 4.1 – MA (log ratio vs average expression of all samples) plot of hMSC vs differentiated chondrocyte 
RNA-seq. Genes with a log2 FC (TPM + 1) > 1.5 are shown in red. The top 3 upregulated genes COL2A1, S100P 
and ACAN are labelled as are the top 3 downregulated genes TMSB4X, EFEMP1 and TAGLN. Plot generated in 
RStudio using the ggplot2 package 
 
Figure 4.2 – Correlation of gene expression changes quantified by RNA-seq (x axis) and microarray (y axis). A 
Pearson’s correlation test showed there was a significant correlation between RNA-seq and microarray data (r = 
0.75, p < 2.2x10-16). Plot generated in RStudio using the ggplot2 package.  
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RNA-seq was used to correlate histone modifications to gene expression due to it 
having a larger dynamic range than microarrays. RNA-seq determined that the most 
upregulated gene during chondrogenesis is COL2A1 with a log2 fold change of 10, 
followed by S100P with a log2 fold change of 8.9 and ACAN with 8.64. The COL2A1 
gene encodes for the alpha I chain of type II collagen, the major collagen found in 
cartilage. S100P encodes for calcium binding protein P; S100 protein family members 
are found in articular cartilage and are involved in cell proliferation and survival 
(Yammani, 2012). They are also found to have an important role in both osteoarthritis 
and inflammatory arthritis (Bertheloot and Latz, 2017). Aggrecan, encoded by the 
ACAN gene, is the main proteoglycan found in articular cartilage and was the third 
most upregulated gene in our analysis. A network of proteoglycans and collagens form 
the extracellular matrix present in cartilage (Kiani et al, 2002). The most downregulated 
gene during chondrogenesis was TMSB4X (Thymosin Beta 4, X linked); this gene is 
highly expressed in BM-MSCs and plays a role in cell migration (Huang et al, 2015). 
The second most downregulated gene was EFEMP1 which encodes for the Fibulin-3 
protein, an extracellular matrix glycoprotein. Overexpression of this gene was found to 
negatively regulate chondrogenesis (Wakabayashi et al, 2010).  The third most 
downregulated gene was TAGLN (encodes for the Transgelin protein) which is highly 
expressed in hMSCs (Silva et al, 2003). Knockout of TAGLN promoted 
chondrogenesis in vascular smooth muscle cells (Shen et al, 2011) although it is 
upregulated during hMSC differentiation into adipocytes and osteoblasts in vitro 
(Elsafadi et al, 2016). This suggests downregulation of TAGLN is required for MSCs 
to enter the chondrogenic lineage as opposed to the adipogenic or osteoblastogenic 
lineages.  
 
We also assessed up- and downregulated genes using the DAVID GO term analysis 
tool. Upregulated genes displayed GO terms relating to chondrogenesis and cartilage 
development (Table 4.1). In contrast, downregulated genes were associated with more 
heterogeneous GO terms, including those related to epigenetic regulation of gene 
expression and cell adhesion (Table 4.2). Both up- and downregulated genes shared 
the GO term osteoblast differentiation. Osteoblasts are one of the three main cell 
lineages MSCs can differentiate into and chondrocytes can transdifferentiate into 
osteoblasts during the terminal hypertrophic stage of chondrogenesis (Zhou et al, 
2014; Park et al, 2015). The mutual GO term indicates that some genes related to 
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osteoblast differentiation are upregulated and others are downregulated. The same is 
also true for the GO term cell adhesion. This illustrates the precise regulation of gene 
expression during the differentiation process.  
 
To summarise, RNA-seq of an in vitro model of chondrogenesis revealed that, by our 
definition, 447 genes are upregulated (log2 fold change > 1.5) with GO terms relating 
to chondrogenesis and 2771 genes were downregulated which had GO terms not 
related to chondrogenesis. This validates that gene expression changes in our in vitro 
model quantified by RNA-seq mimics those of developing chondrocytes in vivo.   
 
 
Table 4.1 – All significant (Benjamini-Hochberg FDR < 0.05) biological process GO terms for 447 genes 
upregulated (log2 fold change > 1.5) during chondrogenesis. GO terms found using DAVID GO analysis tool. 
TERM PVALUE BENJAMINI 
GO:0001501~SKELETAL SYSTEM DEVELOPMENT 4.40E-20 7.29E-17 
GO:0030198~EXTRACELLULAR MATRIX ORGANIZATION 4.25E-16 3.68E-13 
GO:0001503~OSSIFICATION 7.27E-11 4.02E-08 
GO:0030199~COLLAGEN FIBRIL ORGANIZATION 7.47E-10 3.10E-07 
GO:0051216~CARTILAGE DEVELOPMENT 4.06E-09 1.35E-06 
GO:0001958~ENDOCHONDRAL OSSIFICATION 7.90E-09 2.18E-06 
GO:0030574~COLLAGEN CATABOLIC PROCESS 1.00E-08 2.37E-06 
GO:0001649~OSTEOBLAST DIFFERENTIATION 2.11E-07 4.37E-05 
GO:0018146~KERATAN SULFATE BIOSYNTHETIC PROCESS 3.45E-07 6.35E-05 
GO:0030206~CHONDROITIN SULFATE BIOSYNTHETIC PROCESS 3.19E-06 5.28E-04 
GO:0042340~KERATAN SULFATE CATABOLIC PROCESS 3.71E-05 0.005580342 
GO:0002062~CHONDROCYTE DIFFERENTIATION 4.80E-05 0.006614541 
GO:0061621~CANONICAL GLYCOLYSIS 6.90E-05 0.008763528 
GO:0006094~GLUCONEOGENESIS 9.67E-05 0.011392251 
GO:0007155~CELL ADHESION 1.30E-04 0.014249007 
GO:0048706~EMBRYONIC SKELETAL SYSTEM DEVELOPMENT 1.41E-04 0.014544664 
GO:0006029~PROTEOGLYCAN METABOLIC PROCESS 1.64E-04 0.015902774 
GO:0001837~EPITHELIAL TO MESENCHYMAL TRANSITION 2.61E-04 0.023763274 
GO:0022617~EXTRACELLULAR MATRIX DISASSEMBLY 3.16E-04 0.027223699 
GO:0001502~CARTILAGE CONDENSATION 4.79E-04 0.038973293 
GO:0050679~POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 5.46E-04 0.042206073 
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Table 4.2 – Top 35 significant (Benjamini-Hochberg FDR < 0.05) biological process GO terms for 2771 genes 
downregulated (log2 fold change < -1.5) during chondrogenesis. GO terms found using DAVID GO analysis tool. 
TERM PVALUE BENJAMINI 
GO:0098609~CELL-CELL ADHESION 3.20E-13 1.77E-09 
GO:0006334~NUCLEOSOME ASSEMBLY 1.00E-10 2.77E-07 
GO:0007155~CELL ADHESION 1.91E-09 3.53E-06 
GO:0045815~POSITIVE REGULATION OF GENE EXPRESSION, EPIGENETIC 1.17E-08 1.62E-05 
GO:0000183~CHROMATIN SILENCING AT RDNA 3.96E-08 4.38E-05 
GO:0006342~CHROMATIN SILENCING 4.80E-08 4.42E-05 
GO:0006335~DNA REPLICATION-DEPENDENT NUCLEOSOME ASSEMBLY 1.39E-07 1.10E-04 
GO:0032200~TELOMERE ORGANIZATION 4.80E-07 2.65E-04 
GO:0051290~PROTEIN HETEROTETRAMERIZATION 4.40E-07 2.70E-04 
GO:0045814~NEGATIVE REGULATION OF GENE EXPRESSION, EPIGENETIC 3.95E-07 2.73E-04 
GO:0008283~CELL PROLIFERATION 7.10E-07 3.27E-04 
GO:0006915~APOPTOTIC PROCESS 6.63E-07 3.33E-04 
GO:0000086~G2/M TRANSITION OF MITOTIC CELL CYCLE 1.03E-06 4.37E-04 
GO:0048146~POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 7.33E-06 0.002890489 
GO:0008285~NEGATIVE REGULATION OF CELL PROLIFERATION 8.02E-06 0.002951469 
GO:0048661~POSITIVE REGULATION OF SMOOTH MUSCLE CELL 
PROLIFERATION 
1.08E-05 0.003734314 
GO:0045669~POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION 1.08E-05 0.003734314 
GO:0060071~WNT SIGNALING PATHWAY, PLANAR CELL POLARITY PATHWAY 1.67E-05 0.004608263 
GO:0051436~NEGATIVE REGULATION OF UBIQUITIN-PROTEIN LIGASE ACTIVITY 
INVOLVED IN MITOTIC CELL CYCLE 
1.51E-05 0.00461467 
GO:0030036~ACTIN CYTOSKELETON ORGANIZATION 1.61E-05 0.004673126 
GO:0043488~REGULATION OF MRNA STABILITY 1.79E-05 0.004690179 
GO:0051437~POSITIVE REGULATION OF UBIQUITIN-PROTEIN LIGASE ACTIVITY 
INVOLVED IN REGULATION OF MITOTIC CELL CYCLE TRANSITION 
1.50E-05 0.00485641 
GO:0051603~PROTEOLYSIS INVOLVED IN CELLULAR PROTEIN CATABOLIC 
PROCESS 
1.99E-05 0.004998955 
GO:0031145~ANAPHASE-PROMOTING COMPLEX-DEPENDENT CATABOLIC 
PROCESS 
3.00E-05 0.006604989 
GO:0016032~VIRAL PROCESS 2.99E-05 0.006857345 
GO:0007067~MITOTIC NUCLEAR DIVISION 2.93E-05 0.007025921 
GO:0090263~POSITIVE REGULATION OF CANONICAL WNT SIGNALING 
PATHWAY 
5.23E-05 0.009585958 
GO:0000226~MICROTUBULE CYTOSKELETON ORGANIZATION 5.07E-05 0.009622283 
GO:0007179~TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING 
PATHWAY 
4.97E-05 0.009756755 
GO:0006521~REGULATION OF CELLULAR AMINO ACID METABOLIC PROCESS 4.89E-05 0.009968827 
GO:0016477~CELL MIGRATION 4.76E-05 0.01007307 
GO:0001649~OSTEOBLAST DIFFERENTIATION 6.05E-05 0.010724088 
GO:0006979~RESPONSE TO OXIDATIVE STRESS 6.51E-05 0.011183195 
GO:0031047~GENE SILENCING BY RNA 7.73E-05 0.012869512 
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4.3.2 Histone modification enrichment is associated with gene expression levels 
 
Following analysis of RNA-seq data, gene expression levels were correlated to histone 
modifications. Quantified transcripts were grouped into low, medium or high expression 
genes and the profile of histone mark enrichment across the gene was plotted. Gene 
expression was measured in TPM and density plots (Appendix ii, Fig. 2) were 
generated for genes at day 0 (hMSCs) and day 14 (differentiated chondrocytes). 
Genes with a TPM < 2 were defined as low; density plots showed that the majority of 
genes had a TPM below this. The mean TPM in both hMSCs and differentiated 
chondrocytes was 16.7 and genes with a medium level of expression were defined as 
having a TPM between 2 and 16.7. Genes with a TPM > 16.7 were defined as highly 
expressed. These thresholds are somewhat arbitrary as is no consensus method of 
categorising gene expression. Using this method, 50089 and 53999 transcripts were 
defined as low in hMSCs and chondrocytes respectively. The number of medium 
genes in hMSCs was 9161 and 6581 in chondrocytes. There were 2982 genes defined 
as highly expressed in hMSCs and 1652 in chondrocytes.  
 
Normalised (RPM) read counts for all ChIP-seq samples were mapped to low, medium 
and highly expressed gene groups quantified by RNA-seq. There was good 
concordance between both ChIP-seq replicates although replicate 2454e displayed 
more variance. Highly expressed genes showed greater H3K4me3 read counts close 
to the gene TSS, followed by medium and low expressed genes (Fig. 4.2). The greatest 
density of H3K4me3 reads mapped to slightly downstream of the TSS, before dropping 
along the gene body. Histone marks H3K4me1 (Fig. 4.3), H3K27ac (Fig 4.4) and 
H3K36me3 (Fig. 4.5) displayed a similar pattern with respect to expression levels 
although these histone marks show higher enrichment further along the gene body 
compared to H3K4me3. H3K4me1 reads displayed a dip in enrichment at the TSS but 
rises along the gene body. H3K27ac displayed higher enrichment at the TSS and also 
remained high within the gene body. H3K36me3 reads are low at the TSS, gradually 
rising until the TES before decreasing again. In contrast, increased read enrichment of 
H3K27me3 is associated with genes with a low level of expression (Fig. 4.6). 
Interestingly, for H3K27me3, highly expressed genes showed greater enrichment 
compared to genes with a medium level of expression.  
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When read counts from replicate samples were merged and further normalised to the 
input control, read profiles remained the same for all marks apart from H3K27me3 
which showed that genes with a low level of expression had the highest H3K27me3 
enrichment followed by medium and highly expressed genes (Fig. 4.8). Overall, active 
histone marks in our analysis are associated with higher levels of gene expression 
during chondrogenesis. Additionally, the profile of histone mark reads in the genome 
relative to the gene TSS corroborates with the analysis performed in the previous 
chapter (Results Chapter 3). This analysis confirms expected outcomes and verifies 
that it is possible to integrate ChIP-seq and RNA-seq datasets to link gene expression 
to histone modification enrichments.  
  
 
 
Figure 4.3 – H3K4me3 read enrichment in relation to gene TSS in all ChIP-seq samples for high, medium and low 
expressed genes in chondrogenesis. Shading around the line represents the standard error from the mean. Plots 
were generated using the ngs.plot tool.  
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Figure 4.4 – H3K4me1 read enrichment in relation to gene TSS in all ChIP-seq samples for high, medium and low 
expressed genes in chondrogenesis. Shading around the line represents the standard error from the mean. Plots 
were generated using the ngs.plot tool. 
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Figure 4.5 - H3K27ac read enrichment in relation to gene TSS in all ChIP-seq samples for high, medium and low 
expressed genes in chondrogenesis. Shading around the line represents the standard error from the mean. Plots 
were generated using the ngs.plot tool. 
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Figure 4.6 – H3K36me3 read enrichment in relation to gene TSS in all ChIP-seq samples for high, medium and 
low expressed genes in chondrogenesis. Shading around the line represents the standard error from the mean. 
Plots were generated using the ngs.plot tool. 
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Figure 4.7 - H3K27me3 read enrichment in relation to gene TSS in all ChIP-seq samples for high, medium and low 
expressed genes in chondrogenesis. Shading around the line represents the standard error from the mean. Plots 
were generated using the ngs.plot tool. 
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4.3.3 Correlation of changes in histone mark enrichment to changes in gene 
expression 
 
We observed that levels of specific histone marks correlate with gene expression levels 
during chondrogenesis. We next sought to determine whether a change in histone 
mark enrichment corresponds to a change in gene expression. In the previous chapter, 
we saw that H3K4me1 and H3K27ac histone marks clustered by cell type rather than 
ChIP-seq replicate suggesting that biological differences between hMSCs and 
differentiated chondrocytes were greater than the differences between replicates or 
other technical effects. Therefore, only these two histone marks were chosen for 
differential peak enrichment analysis after combining hMSC and chondrocyte 
replicates. Significant differentially enriched peaks between hMSCs and differentiated 
chondrocytes were found for H3K4me1 and H3K27ac samples using the Bioconductor 
package DiffBind. There were 3537 significantly differentially enriched (FDR < 0.05) 
H3K4me1 peaks between hMSCs and differentiated chondrocytes (Fig. 4.9A), of which 
2939 increased in enrichment and 598 decreased in enrichment. For H3K27ac, there 
were 7004 significantly differentially enriched peaks (Fig. 4.9B), of which 6298 showed 
an increase in enrichment and 706 decreased in enrichment during chondrogenesis.  
 
All peaks were associated to the nearest gene using HOMER annotatepeaks.pl and 
the change in gene expression was plotted alongside the change in histone mark 
enrichment (Fig. 4.10).  Using this method, genes may be associated with more than 
one peak. A clear correlation between a change in H3K4me1 (Fig. 4.8A) or H3K27ac 
(Fig. 4.10B) enrichment and a change in gene expression was not apparent except for 
genes that were highly upregulated (log2 fold change > 1.5). A Pearson’s correlation 
test gave an overall significant correlation of 0.016 (p = 6.109X10-14) for H3K27ac and 
0.07 (p < 2.2X10-16) for H3K4me1. However, at such a large sample size, tests are 
more likely to yield significant p values and the effect size must be given more 
importance (Cohen, 1992). With such small effect sizes, it is difficult to conclude 
whether these correlations are of biological relevance. The correlation effect sizes 
improve when only significant differentially enriched peaks are taken into account, with 
r = 0.12 (p < 2.2X10-16) for H3K27ac and r = 0.24 (p < 2.2X10-16) for H3K4me1. 
Although small, the improvement in correlation indicates there may be a true 
correlation between change in histone mark enrichment and a change in gene 
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expression. There were many genes that were differentially expressed between 
hMSCs and differentiated chondrocytes that did not show any changes in H3K4me1 
or H3K27ac enrichment. These genes may be regulated by other histone modifications 
or by other epigenetic mechanisms.  
 
Combinations of histone marks are a better indicator of gene expression, therefore we 
sought to determine whether genes associated with both H3K4me1 and H3K27ac 
enrichment increases were more likely to be upregulated. To view the association 
between changes in histone mark enrichment and gene expression with more clarity, 
only genes with a log2 fold change > 1.5 that are also associated with a significant 
differentially enriched H3K4me1 and/or H3K27ac peak were considered (Fig. 4.11). 
Only the enrichment of the closest H3K27ac/H3K4me1 peak was considered. In this 
analysis, genes may be associated with a combination of both increased H3K27ac and 
H3K4me1 enrichment, increased H3K27ac and decrease in H3K4me1 enrichment or 
vice versa. Alternatively, they may be associated with a decrease in enrichment of both 
histone marks. Using these criteria, upregulated genes tended to exhibit increased 
enrichment of both H3K4me1 and H3K27ac marks during chondrogenesis. However, 
the enrichment of histone peaks associated with downregulated genes were more 
variable. Downregulated genes were found to be associated with all four combinations 
of H3K27ac/H3K4me1 enrichment. This suggests that other mechanisms may also be 
involved or association of histone marks to genes using the nearest gene approach 
may not be optimal.  
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Figure 4.9 – (A) significant (FDR < 0.05) differentially enriched H3K4me1 peaks and (B) H3K27ac peaks between 
hMSCs and differentiated chondrocytes. Read counts (log concentration) are log2 transformed. Significantly 
enriched peaks are coloured in pink. Differential binding analysis and MA plot generated using the DiffBind 
package in RStudio.  
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Figure 4.10 – (A) log2 fold change in H3K4me1 enrichment and (B) log2 fold change in H3K27ac enrichment 
alongside change in gene expression during chondrogenesis of the nearest gene. Significantly enriched histone 
peaks are coloured in red. A generalised additive model line was fitted to the data. Plots were built using the 
ggplot2 package in RStudio.  
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Figure 4.11 – Change in enrichment of H3K4me1 and H3K27ac peaks during chondrogenesis. Peaks were 
associated with the nearest gene using HOMER annotatepeaks.pl and only the closest peak to the gene was 
considered. Genes with a log2 fold change > 1.5 and a significant differentially enriched H3K4me1 and/or 
H3K27ac peak are shown. Upregulated genes are coloured in green and downregulated genes are coloured red. 
Plot was built using the ggplot2 package in RStudio.  
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4.4 Discussion 
 
In this chapter, gene expression measured by RNA-seq during chondrogenesis was 
correlated to histone modification enrichment. RNA-seq of hMSCs and differentiated 
chondrocytes revealed 3218 genes had a log2 fold change > 1.5. This cut off value is 
somewhat arbitrary and there is no consensus on fold change thresholds. This 
threshold was used to define differentially expression genes as statistical analysis of 
this RNA-seq dataset was not possible due to a sample number of 1 for both hMSC 
and differentiated chondrocytes. Consequently, there is no way of identifying or taking 
into account potential technical or hMSC donor effects; a gene with a high log2 fold 
change in our analysis may not be showing a true biological difference between hMSC 
and differentiated chondrocytes. However, there was a significant correlation of RNA-
seq gene expression changes to microarray data of the same chondrogenesis model 
with replicates and this and acted as an extra quality control step for the RNA-seq data 
in absence of replicates. GO terms related to chondrogenesis were detected for 
upregulated genes with a log2 fold change > 1.5. Furthermore, ACAN and COL2A1, 
the two major components of articular cartilage, were highly upregulated.  
 
Integration of expression levels to histone ChIP-seq samples yielded expected 
outcomes. Association of RNA-seq data to histone ChIP-seq data revealed a 
correlation between active histone marks and high gene expression during 
chondrogenesis. Conversely, genes with a low level of expression (TPM < 2) were 
enriched in repressive H3K27me3 marks. However, genes with a high level of 
expression exhibited greater enrichment of H3K27me3 marks compared to the 
medium expression geneset. This may be due to bivalent promoters of genes involved 
in the differentiation process. However, when reads from the two replicates were 
merged and normalised to the input control, highly expressed genes showed the least 
amount of enrichment for H3K27me3. Previous studies have found that highly 
expressed genes are likely to exhibit both active marks such as H3K4me3 as well as 
repressive mark H3K27me3. Genes with bivalent marks were more likely to change 
during differentiation (Shah et al, 2014). Bivalency is thought to allow prompt activation 
of genes upon an appropriate signal whilst maintaining the gene in an inactive state in 
the absence of signals (Voigt et al, 2013). The presence of bivalent regulatory states 
is important for embryonic stem cells where precise timely regulation of gene 
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transcription is crucial to control both maintenance of the stem cell state and 
differentiation into other cells (Bernstein et al, 2006; Vastenhouw and Schier, 2012).  
H3K27me3 marks are removed prior to gene activation when differentiating to a 
specific lineage. On the other hand, H3K4me3 marks may be removed instead to 
repress gene activation. Alternatively, the bivalent state may be maintained even post-
differentiation (Gobbi et al, 2011). ChIP-seq is commonly performed on a population 
of cells, including our chondrogenesis ChIP-seq experiments, and therefore it is 
impossible to establish whether H3K4me3 and H3K27me3 are located in the same 
genomic region of the same cell, or whether the marks occur heterogeneously between 
cells in the same population. It is possible to use single cell ChIP-seq to assay co-
occurrence of histone marks in genomic regions of the same cell but single cell ChIP 
is challenging due to the low amount of starting material which increases the level of 
background noise (Clark et al, 2016). Another method to assay histone modifications 
at the same genomic loci is to use a second ChIP assay using a different antibody to 
pull down regions of co-localisation (Furlan-Magaril, 2009).  
 
In the previous chapter, correlation of ChIP-seq replicate samples showed that only 
H3K27ac and H3K4me1 samples clustered by cell type and not by ChIP-seq 
replicate/hMSC donor. We observed that upregulated genes (log2 fold change > 1.5), 
tended to be associated with increased enrichment of both H3K27ac and H3K4me1 
marks although there were also downregulated genes with increased H3K27ac and 
H3K4me1 marks. In our analysis H3K4me1 and H3K27ac peaks were associated to 
their nearest gene. H3K4me1 marks gene enhancers whereas H3K27ac marks both 
promoters and enhancers. Enhancers can be located large distances from their target 
gene, do not necessarily target the nearest gene and not all genes have enhancers 
(Marsman and Horsfield, 2010). Therefore, linking H3K4me1 and H3K27ac peaks to 
the nearest gene is not optimal and without further data such as chromatin 
conformation assays, it is difficult to predict which genes H3K4me1 and H3K27ac 
peaks are associated with. This could explain why we did not observe a strong 
correlation between the change in enrichment of these histone marks and a change in 
gene expression except for in highly upregulated genes. This also offers an 
explanation as to why some downregulated genes appeared to also be associated with 
increased enrichment of H3K4me1 and H3K27ac marks.  
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We observed that more H3K4me1 and H3K27ac histone marks show a significant 
increase in enrichment compared to decreased enrichment during chondrogenesis. As 
these two marks are associated with active gene enhancers, an increase in enrichment 
suggests an increase of enhancer activity during chondrogenesis. Gene enhancers 
are instrumental in regulating differentiation of stem cells (Zhou et al, 2014; Cico et al, 
2016; Wu et al, 2017) including chondrogenesis (Lui and Lefebvre, 2014). A previous 
study integrating histone modifications to gene expression in a different in vitro 
chondrogenesis model showed the same outcomes as this analysis (Herlofsen et al, 
2013). Regulatory states including enhancers and the combination of histone marks 
that define them will be explored in later chapters.  
 
To summarise this chapter, changes in single histone modifications, specifically 
H3K4me1 and H3K27ac, are a poor indicator of gene expression changes in our data. 
Whilst individual histone marks can infer specific gene regulatory meanings, 
combinations of marks are often a more powerful indicator of regulatory state. There 
was a link between an increase of H3K4me1 and H3K27ac enrichment and increased 
gene expression in highly upregulated genes. Correlating histone ChIP-seq and gene 
expression in this way comes with a number of challenges and caveats, besides the 
challenges of associating histone mark peaks to genes mentioned earlier. Traditional 
ChIP-seq methods are not strictly quantitative between cell types without additional 
external controls such as the addition of an exogenous reference epigenome (Orlando 
et al, 2014). Additionally, it is unknown how enriched a ChIP-seq peak needs to be in 
order to influence gene transcriptions or whether this is consistent across cell types or 
biological processes.  
 
Integration of data from different technologies can be an arduous task; lack of 
benchmarks and consensus methodologies means analyses and interpretation of 
results can be subjective or inconsistent between researchers. Despite this, integration 
of RNA-seq and ChIP-seq data offers a high throughput, genome wide approach for 
associating gene transcription to the epigenome. With the rise of affordable ‘omics 
technologies and a growing amount of publically available data generated by large 
consortia, it has been acknowledged that methods for analysing and integrating data 
need to be improved (Gomez-Cabrero et al, 2014). There have been many studies 
involving the integration of ChIP-seq and gene expression data (Dudziac et al, 2012; 
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Angelini and Costa, 2014; Ayyapan et al, 2015), including during chondrogenesis 
(Herlofsen et al, 2013). Herlofsen et al found a high correlation between H3K4me3 and 
gene expression, as well as an enrichment of enhancer marks with chondrogenic 
genes in agreement with our study. ChIP-seq data can be used to predict gene 
expression (McLeay et al, 2012) and integration of epigenomic and gene expression 
data can be used to infer gene regulatory networks (Angelini and Costa, 2014).  With 
increasing interest in the epigenome and the regulation of gene transcription using 
genome wide methods, integration of heterogeneous datasets will become more 
commonplace.  
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4.5 Conclusion 
 
• RNA-seq determined that 447 genes were upregulated in chondrogenesis and 
2771 genes were downregulated by log2 fold change > 1.5. Upregulated genes 
displayed GO terms related to chondrogenesis and cartilage development. 
 
• H3K4me3, H3K4me1, H3K27ac and H3K27me3 ChIP-seq read enrichments 
are higher in highly expressed genes compared to genes with a lower level of 
expression. 
 
• Repressive mark H3K27me3 read enrichment is higher in low expressed genes 
than highly expressed genes.  
 
• There is a correlation between a change in histone mark enrichment and a 
change in gene expression in chondrogenesis. Multiple histone marks are better 
indicators of gene expression changes compared to single marks. 
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Chapter 5: Correlation of DNA methylation to chromatin states 
 
5.1 Introduction  
 
Histone marks around genes can influence gene transcription. The histone code is the 
theory that gene expression can be predicted simply by studying the histone 
modifications around a gene (Jenuwein and Allis, 2001). Specific marks located near 
or on genes can influence whether that gene is actively transcribed or repressed 
Previous chapters have explained that H3K4me3 marks active promoters, H3K4me1 
and H3K27ac mark gene enhancers, H3K27me3 marks repressed genes and 
H3K36me3 mark transcriptionally active gene bodies. Histone modifications attract 
other proteins including chromatin remodellers that can alter the structure of chromatin 
to make the DNA either more or less accessible to the transcription machinery. Active 
histone modifications lead to chromatin being remodelled into an open configuration, 
allowing genes within the open chromatin to be transcribed (Yan and Boyd, 2006). 
Repressive marks attract protein complexes that further compact the chromatin 
rendering genes inaccessible to transcription factors (Kadoch et al, 2016). The histone 
code is more complex than originally thought and it is now known that single histone 
marks do not often exist in isolation. In the previous chapter, we explored how single 
histone modifications are a poor predictor of gene expression. Combinations of 
different histone modifications can define gene cis-regulatory elements which give a 
better indication of whether a gene is transcribed compared to investigating individual 
histone modifications.  
 
Multiple histone ChIP-seq datasets may be integrated to define chromatin states. 
These are distinct regions of chromatin that are marked by varying levels of different 
histone modifications. Chromatin states can reflect cis-regulatory elements such as 
gene promoters and enhancers. Defining and characterising chromatin states forms 
the basis of the Epigenomics Roadmap project, a large scale project which aims to 
elucidate the epigenome of multiple cell types – similar to the premise of the ENCODE 
project. Using ChIP-seq data, the Epigenomics Roadmap project has created 
chromatin states for 127 human cell types (Kundaje et al, 2015; Romanoski et al, 
2015). The Epigenomics Roadmap project generated a 15 state model using five 
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histone marks (H3K4me3, H3K4me1, H3K9me3, H3K27me3 and H3K36me3) and an 
extended 18 state model using six histone marks for cell types with an extra histone 
modification (H3K27ac) available. Our chondrogenesis histone ChIP-seq experiment 
included all the same marks apart from H3K9me3. H3K9me3 is a marker of 
constitutively repressed heterochromatin (Saksouk et al, 2015). The Roadmap project 
used the ChromHMM software (Ernst and Kellis, 2012) to learn chromatin states from 
their data. This was also used to generate chromatin states in our chondrogenesis 
ChIP-seq data.  
 
Other epigenetic mechanisms also exist alongside histone mark defined chromatin 
states and these also contribute to the regulation of gene transcription. DNA 
methylation occurs at CpG sites within the genome, mediated by DNA 
methyltransferases. Specifically, the cytosine within a CpG site is methylated to 5-
methylcytosine. CpG sites are typically located in CpG islands near the start site of 
genes (Lim and Maher, 2010). Although DNA methylation is generally a repressive 
mark, DNA methylation of CpG sites within gene bodies is associated with active 
transcription (Yang et al, 2014). During differentiation of stem cells, large scale 
changes in DNA methylation are observed (Sheaffer et al, 2014; Altun et al, 2010). 
Both histone modifications and DNA methylation contribute to control of gene 
transcription by attracting chromatin remodellers to alter the structure of chromatin 
(Geiman and Robertson, 2002). The two mechanisms influence each other (Cedar and 
Bergman, 2009), therefore integrating information from DNA methylation and histone 
modification data could lead to new insights into gene regulation.  
 
One of the aims of this project was to generate chromatin states using our 
chondrogenesis histone ChIP-seq dataset. Our lab has also previously performed a 
DNA 450K methylation array using the same in vitro model of chondrogenesis. We 
hypothesised that by integrating DNA methylation and histone modification data, we 
would be able to identify regulatory elements important for controlling gene 
transcription in chondrogenesis. 
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5.2 Aims 
 
• Characterise chromatin states for hMSC and differentiated chondrocyte ChIP-
seq dataset using the ChromHMM software. 
 
• Compare hMSC and chondrocyte derived chromatin states to Roadmap 
Epigenomics chromatin states. 
 
• Analyse DNA 450K methylation array of hMSCs vs chondrocytes. 
 
• Correlate DNA methylation to chromatin states and identify chromatin states 
where DNA methylation is prevalent. 
 
• Carry out pathway analysis of methylated CpG sites and chromatin states. 
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5.3 Results 
 
5.3.1 ChromHMM defined 16 distinct chromatin states 
 
Chromatin states for hMSCs and differentiated chondrocytes were computed using the 
ChromHMM software in order to investigate all histone marks collectively and define 
regulatory elements in the genome. All aligned ChIP-seq reads were included in 
chromatin state learning with all input samples used as control. ChromHMM learned 
16 chromatin states from our ChIP-seq data (Fig. 5.1). The 16 state model was arrived 
at by executing ChromHMM with different numbers of states until a good separation of 
distinct states was seen. This was also the method used by the Epigenomics Roadmap 
project. Furthermore, this number also corroborates with the 18 state extended model 
from Roadmap; their extended 18 state model included one extra histone mark, 
H3K9me3. This histone mark displayed noticeable emission probabilities in only 2 
states in their 18 state model. This histone mark was not included in our experiment, 
therefore without the 2 extra states present in the 18 state Epigenomics Roadmap 
model we decided 16 would be a reasonable number for chromatin state learning. 
Chromatin states are computed as emission probabilities which indicate the likelihood 
that a specific histone mark will be present in a chromatin state and represent the 
enrichment of specific histone marks in that state.  
 
Chromatin states were annotated and named using information from published 
literature including the ENCODE and Epigenomics Roadmap projects. Active 
promoter/TSS states (1_TssA and 2_TssS) displayed high enrichment of H3K4me3 
and H3K27ac marks with low levels of other histone marks. Flanking TSS states 
(3_TssFlnk, 4_TssFlnkU, 5_TssFlnkD) also included H3K4me1 and H3K36me3 
marks. The bivalent TSS state 6_TssBiv is characterised with high amounts of active 
H3K4me3 mark as well as the repressive mark H3K27me3. Weak and strong 
transcription states (7_TxWk and 8_TxS) displayed low and high enrichment of 
H3K36me3 marks respectively. Flanking active transcription (9_TxFlnk) showed equal 
levels of H3K4me3, H3K4me1 and H3K27ac marks. Genic enhancers (10_EnhG1 and 
11_EnhG2) displayed enhancer histone marks as well as H3K36me3. In contrast, only 
enhancer histone marks were present in enhancer states (12_EnhA and 13_EnhS). 
The poised enhancer state (14_EnhP) was characterised by low levels of H3K27ac 
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marks and high levels of H3K4me1. Repressed state (15_Repr) only displayed 
H3K27me3 histone marks. The final state, 16_Quies, defines regions of the genome 
not marked by any of the five histone marks included in our ChIP-seq experiment. 
Emission parameter values are available in Appendix iii, Table 3.  
 
 
 
Figure 5.1 - State emission parameters output by ChromHMM from combined hMSC and differentiated 
chondrocyte alignments. Chromatin state learning using ChromHMM found 16 distinct states marked by 
varying levels of histone modifications. Input samples were used as controls.   All histone marks are represented 
in at least one state. 
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Figure 5.2 -  State transition probabilities output by ChromHMM from combined hMSC and differentiated 
chondrocyte alignments. Transition probabilities shows the likelihood that states in 200bp bins are adjacent to 
each other in the genome.  
 
ChromHMM also outputs transition probabilities between states (Fig. 5.2). State 
transition probabilities indicate how likely chromatin states are found to be next to each 
other in the genome. The spatial relationship between chromatin states in the genome 
also reflect the spatial changes in histone modifications and transformations of 
contiguous genomic features such as from promoters to exons and then introns, 
representing the typical structure of a gene (Ernst and Kellis, 2010). The quiescent 
state has higher transition probabilities to chromatin states typically located at the 
peripheral of genes, such as promoters and enhancers rather than states representing 
gene bodies. Therefore, it could be deduced that quiescent chromatin states may be 
more likely to fall within intergenic regions. Promoter states (1_TssA, 2_TssS and 
3_TssFlnk) are likely to be neighbours; promoter states are also likely to be next to 
9_TxFlnk (transcription flanking). The 6_TssBiv state is more likely to be found 
adjacent to the 15_Repr state. Overall, chromatin states with similar histone marks are 
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more likely to have higher transition probabilities. ChromHMM splits the genome into 
200bp bins to learn chromatin states; each chromatin state is made up of these 200bp 
sections. Identical chromatin state bins are most likely to be adjacent to each other, 
showing that all chromatin states are on average, longer than 200bp in size.  
 
ChIP-seq sample alignments from both replicates of hMSC and differentiated 
chondrocytes were used to train the chromatin state model and hence state definitions 
are the same across the two cell types. ChromHMM also overlaps defined states and 
genomic features. Overlapping states with genomic features revealed that the majority 
of the hMSC and differentiated chondrocyte genome is quiescent or unmarked (Fig. 
5.3). In hMSCs, 60.9% of the genome is quiescent whereas 65.1% of the genome is 
quiescent in chondrocytes (Appendix iii, Table 2-3). As a percentage of the genome, 
most of the other states were within 1% between hMSCs and chondrocytes. 
Exceptions were seen for 8_TxS; this state represented 7.1% of the hMSC genome 
and dropped to 2.7% in differentiated chondrocytes, suggesting that either fewer genes 
exhibited the strong transcription state or that this state is smaller in size in 
chondrocytes. Furthermore, chondrocytes displayed a slightly higher proportion of 
enhancer states (12_EnhA, 13_EnhS and 14_EnhP) compared to hMSCs.  
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Figure 5.3 - Chromatin state enrichment overlapping genomic categories in hMSCs and chondrocytes 
determined by ChromHMM. These categories were genome percentage, CpG islands, exons, genes, 
transcriptional end sites (TES), TSS and the region  +/- 2kb from TSS. 
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Active promoter states generally overlap CpG islands and gene promoters, and at 
higher proportions than other chromatin states (Fig. 5.3). The 2_TssS state is more 
likely to be found within 1kb of gene TSSs (Fig. 5.4) compared to other states. 
Promoter flanking and transcription flanking states are likely to be outside of the 1kb 
window from the start of the TSS. In general, chromatin states exhibiting high 
H3K4me3 enrichment are seen closer to the TSS. The pattern of states with a 2kb 
window from the transcriptional termination site (TTS) is less clear; the probability of 
finding the 4_TssFlnkU state in this region is greater than the other states, this could 
occur if genes are situated close together in the genome so that the TTS of one gene 
is near the TSS of a neighbour gene. Overall, the locations of chromatin states relative 
to the TSS are in accord with the enrichment peak profiles of the histone marks 
comprising the states (Chapter 3).  
  
 
Figure 5.4 – Chromatin state enrichments within 2kb of the TSS and TTS in hMSCs (A and C) and chondrocytes (B 
and D) determined by the ChromHMM software. 
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5.3.2 Chromatin state changes 
 
Chromatin state changes between hMSC and differentiated chondrocytes were 
investigated. Initially, genome browser tracks of chromatin states around specific 
genes were visualised in IGV. For example, the COL2A1 gene is highly upregulated 
during chondrogenesis (RNA-seq measured expression of 17.2 TPM in hMSCs; 16984 
TPM in chondrocytes) and the chromatin states prior and post-differentiation reflects 
its gene expression change (Fig. 5.5). In hMSCs, the COL2A1 gene promoter is 
marked by a bivalent TSS state and other regions within the gene body also display 
this state. There are large stretches of repressed states both up- and downstream of 
the gene as well as within the gene body. In contrast, in chondrocytes the COL2A1 is 
marked by active TSS states at its promoter and flanking active transcription states 
downstream of the promoter. Poised and active enhancer states are seen upstream of 
the COL2A1 gene in chondrocytes and genic enhancer states are present within the 
gene body.  
 
The TMEM016C gene is situated approximately 4kb downstream of the COL2A1 gene. 
In hMSCs, there are active promoter and transcription states within this gene 
suggesting that TMEM106C (encodes for transmembrane Protein 106C) is 
transcriptionally active.  In chondrocytes, the active promoter state is still present 
although the transcription states have switched into enhancer states. Gene expression 
measured by RNA-seq shows that TMEM106C is lowly expressed in hMSCs and is 
downregulated in chondrogenesis although expression is very low in both cell types 
(0.25 TPM in hMSCs; 0.03 TPM in chondrocytes). The two genes are separated by a 
comparatively short intergenic region; despite this, there is a quiescent chromatin state 
between them which separates the gene body chromatin states of the two genes. This 
demonstrates a segregation of histone modifications between genes in order to 
prevent the regulation of one gene being affected by a neighbouring gene. Overall, this 
example illustrates the pronounced histone modification changes surrounding genes 
that correspond with gene transcription changes.  
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The hMSC state origins of chromatin states in differentiated chondrocytes were 
determined to investigate global chromatin state changes. The frequency of which 
hMSC state each chondrocyte chromatin state originated from was calculated (Fig. 
5.6; Fig.5.7). This shows whether chromatin states in chondrocytes were derived from 
a different state in hMSC or whether the chromatin state remained stable during 
chondrogenesis. For example, the hMSC origins of the strong enhancer state 
(13_EnhS) in differentiated chondrocytes were 1% 7_TxWk, 18% 12_EnhA, 42% 
13_EnhS, 24% 14_EnhP and 14% 16_Quies. Only 1% of 1_TssA states derived from 
6_TssBiv, showing that bivalent promoters constitute a small amount of overall 
promoter activation. However, 36% of chondrocyte 6_TssBiv originated from the 
15_Repr state, demonstrating that promoters become bivalent during chondrogenesis. 
Many active chromatin states derived from 16_Quies in hMSCs; 2-48% of each active 
chondrocyte state derived from this state. These changes indicate an activation of 
genes during chondrogenesis that were previously not active in hMSCs. 
The large scale chromatin state changes observed between hMSCs and differentiated 
chondrocytes implies that the chromatin is remodelled extensively during 
chondrogenesis to alter gene transcription. Whilst we can view chromatin states 
around single genes of interest using a genome browser, it is not feasible to do this for 
all genes in the genome. Therefore, pathway analysis using GO terms for gene lists 
offers a way of associating chromatin states to groups of genes.  
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Figure 5.6 – Frequency of chromatin state changes from hMSCs to differentiated chondrocytes. Genome co-
ordinates were split into 200bp bins and the chromatin states in hMSC and differentiated chondrocytes were 
noted at each bin. Plot generated using ggplot2 in RStudio.  
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Figure 5.7 – Sankey plot representing chromatin state changes from hMSCs to differentiated chondrocytes. Each 
node is a chromatin state and the edges show the transition of states from hMSCs during chondrogenesis. 
Thicker edge lines indicate a higher observed frequency of change. Plot generated using the riverplot package in 
RStudio.  
 
 
 153 
5.3.3 GO term analysis of chromatin states 
 
Gene ontology analysis was used to characterise chromatin states and connect them 
to genes and functions. The GREAT ontology tool was used to associate 
chondrogenesis chromatin states to nearby genes and retrieve GO terms to associated 
genes. For enhancer states (10_EnhG1, 11_EnhG2, 12_EnhA, 13_EnhS and 
14_EnhP), the default GREAT basal plus extension associated method was used. 
Gene enhancers can be located long distances away from their target gene so it is 
essential that a larger region is considered. For all other chromatin states, the single 
nearest gene method was used (up to a maximum distance of 1Mb). The GREAT GO 
tool was designed to be used with cis-regulatory features such as enhancers (McLean 
et al, 2010). Using the basal plus extension method, enhancers were likely to be 
associated with multiple genes within the association area compared to the single 
nearest gene method used for other chromatin states. This method was preferred for 
enhancers because without other information, it is difficult to confirm which gene is the 
genuine target of an enhancer and this approach considers all genes in the vicinity. 
The other chromatin states were associated to genes using the single nearest gene 
method as they are more likely to be closer to or lie within their target gene.  
 
GO term analysis is a valuable method for grouping genes with similar functions. 
However, GO term analysis is not suitable or effective when numerous heterogeneous 
features comprise a dataset. For example, promoter related chromatin states (1_TssA, 
2_TssS, 3_TssFlnk, 4_TssFlnkU and 5_TssFlnkD) yielded GO terms largely related to 
the general upkeep and maintenance of the cell rather than cell type specific terms 
(Appendix iii Fig. 1-10). These chromatin states cover a broad range of genes and the 
list is too ambiguous to be able to select GO terms specific to cell type; any cell specific 
genes are diluted by those related to general function. In contrast, chromatin states 
with fewer features were associated with more cell type specific GO terms. hMSC 
bivalent promoter state yielded GO terms associated with differentiation (Appendix iii 
Fig. 1), indicating that bivalent promoters are linked to genes that are currently non-
transcribed but primed to become active depending on the cell lineage the hMSC 
enters. Interestingly, for the differentiated chondrocyte bivalent promoter state, GO 
terms were also those related to differentiation, albeit different terms with the exception 
of one. Both hMSCs and differentiated chondrocytes had a GO term of dorsal spinal 
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cord development, demonstrating that during differentiation of hMSC some bivalent 
promoters become active and others remain bivalent after chondrogenesis (Appendix 
iii Fig. 5.11). Similar to promoter related chromatin states, active transcription states 
yielded GO terms related to general cell function rather than cell specific functions (Fig. 
Appendix iii Fig. 12-16).  An exception is the hMSC transcription flanking state which 
returned three GO terms all relating to TGFβ regulation (Appendix iii Fig. 17); TGFβ 
family members mediate differentiation of hMSCs down different lineages (Roelen and 
Dijke, 2003). All genic enhancer states (except for chondrocyte genic enhancer 2 
(12_EnhG2) had general cell function GO terms. Chondrocyte 11_EnhG2 showed 
some GO terms related to cartilage function. hMSC active enhancers (12_EnhA) did 
not yield any obvious stem cell related GO terms although strong enhancers had a GO 
term of negative regulation of transforming growth factor receptor signalling pathway. 
Similar to chondrocyte 11_EnhG2, chondrocyte enhancer chromatin states returned 
GO terms related to chondrogenesis, cartilage development and MSC differentiation. 
Poised chromatin states for hMSC and chondrocytes had GO terms linked to 
development and differentiation. GO terms for repressed chromatin states were also 
non-specific, although there were some GO terms associated with development in both 
hMSCs and differentiated chondrocytes. Quiescent chromatin states encompass the 
majority of the genome and thus finding distinct genesets and GO terms is more 
challenging. See Appendix iii for figures.  
 
The locations of chromatin states in relation to the TSS determined by the GREAT tool 
corroborates with those determined by ChromHMM. Overall, GO term analysis found 
that enhancer chromatin states are more informative for inferring cell specific 
processes (Fig. 5.8 – 5.9).  
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Figure 5.8 - GREAT gene ontology analysis for hMSC 13_EnhS chromatin state. (A) number of associated genes, 
(B) distance to TSS, (C) biological process GO terms 
 
Figure 5.9 - GREAT gene ontology analysis for CHON 13_EnhS chromatin state. (A) number of associated genes, 
(B) distance to TSS, (C) biological process GO terms  
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5.3.4 Comparison of hMSC and chondrocyte chromatin states with Roadmap 
Epigenomics chromatin states 
 
A 16 state model was generated from our chondrogenesis histone ChIP-seq data using 
ChromHMM and chromatin states were annotated using information from the literature, 
including the Roadmap Epigenomics project. The Roadmap Epigenomics project 
generated a core 15 state model for 127 human epigenomes using histone 
modifications H3K4me3, H3K4me1, H3K9me3, H3K27me3 and H3K36me3. An 
additional histone mark, H3K27ac, was available for 98 epigenomes and an extended 
18 state model was trained using this extra mark. Whilst we did not assay H3K9me3, 
we did include H3K27ac in our ChIP-seq experiment and therefore we sought to 
compare our chromatin states to the 98 epigenomes with the extended 18 state model. 
The Roadmap Epigenomics project comprises a wide repertoire of cell types from 
various cell origins, including primary cells and cell lines. The full list of cells is available 
in Appendix iii, Table 2. The aim of these comparisons was to ascertain whether similar 
cell types can be classified as such by their regulatory features in the epigenome. Of 
particular interest was to compare our hMSCs and chondrocytes to those present in 
the Roadmap project to observe how alike, or otherwise, the cell types were. The 
chondrogenesis model included in the Roadmap project also differentiated bone 
marrow derived hMSC into chondrocytes, albeit using a different in vitro model 
(Herlofsen et al, 2013). We hypothesise that the epigenome of our hMSCs and 
differentiated chondrocytes would be more similar to the Roadmap hMSCs and 
chondrocytes respectively relative to the other cell types.  
 
Roadmap and our chondrogenesis chromatin state models were trained on different 
ChIP-seq samples and Roadmap chromatin states contained an extra histone mark. 
Therefore, we only compared states that appeared to have the same or similar histone 
mark emission parameters between the chromatin state models. We compared all 
equivalent states, of which there were eight (Fig. 5.10).  
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Figure 5.10 - ChromHMM emission parameters for Roadmap’s 18 state model (A) and (B) chondrogenesis 16 
state model. Roadmap’s 1_TssA state and the chondrogenesis 2_TssS state comprises equal probabilities of 
H3K4me3 and H3K27ac histone marks. Likewise, Roadmap’s 9_EnhA1 and chondrogenesis 13_EnhS have similar 
levels of H3K4me1 and H3K27ac.Other states considered comparable were Roadmap’s 5_Tx with 
chondrogenesis 8_TxS, Roadmap’s 6_TxWk with chondrogenesis 7_TxWk, Roadmap’s 11_EnhWk with 
chondrogenesis 14_EnhP, Roadmap’s 16_ReprPC with chondrogenesis 15_Repr and Roadmap’s 18_Quies with 
chondrogenesis 16_Quies.  
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To compare between equivalent Roadmap and chondrogenesis chromatin states, we 
measured the similarity by calculating the Jaccard coefficient for comparable states 
across all 98 Roadmap epigenomes, hMSCs and differentiated chondrocytes. 
Principal component analysis was performed for each comparison. PCA plots provide 
an effective method of correlating large numbers of samples and visualising related 
groups or samples. However, with many samples it can be difficult to view individual 
samples due to overlapping labels in a two dimensional plot. Therefore, we generated 
heatmaps incorporating hierarchical clustering dendrograms as well as PCA plots.  
 
When promoters were correlated, cells did not separate out by cell origin with the 
exception of primary cells. ESC derived, cell lines, primary tissue and primary culture 
cells overlapped forming one large cluster. hMSCs and differentiated chondrocytes are 
found within this large cluster. Hierarchical clustering shows that hMSCs shared the 
nearest common node with Roadmap cells E114 (lung carcinoma cell line), E118 
(hepatocellular carcinoma cell line), E116 (lymphoblastoid primary culture cells) and 
E123 (leukaemia primary culture cells). These cells bear no apparent close relation 
with hMSC respective to other cell types. However, the heatmap of Jaccard values for 
promoters showed that overall, all cell types are relatively similar. Comparison of 
Roadmap weak enhancers (11_EnhWk) and chondrogenesis poised enhancers 
(14_EnhP) displayed greater separation of cells by cell origin with high variation 
between blood cells. The closest cell type that clusters with our differentiated 
chondrocytes are Roadmap’s chondrocytes (E049). hMSCs form a cluster with 
Roadmap’s BM-MSCs (E026) and osteoblasts (E129; primary culture). Altogether, 
these cells form a larger subcluster consisting of all the cells of mesenchymal origin in 
the analysis.   
 
When the similarity of strong transcription state was investigated there appeared to be 
no apparent clustering of cells by type or cell origin. Hierarchical clustering shows that 
hMSCs were most similar to some blood (E029 – primary monocytes), skin (E061 – 
primary cultured melanocytes, E058 – primary cultured keratinocytes) and hESC 
derived cells when comparing strong transcription (E011 - hESC derived cultured 
endoderm cells, E013 – hESC derived cultured mesoderm). Chondrocytes were 
closest to blood (E038 – primary naïve T cells, E123 – primary cultured leukaemia 
cells) and HeLa cell line (E117). Interestingly, cells clustered by cell origin more by the 
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weak transcription state rather than strong transcription. Furthermore, when 
considering weak transcription states, hMSCs and differentiated chondrocytes formed 
their own cluster away from the other cell types. Jaccard similarity values for pairwise 
comparisons using weak transcriptions were lower than those of strong transcription. 
See Appendix iii for figures.  
 
A large variation between primary tissue cells was seen for active enhancer 
comparisons, with brain cells forming their own cluster away from all other cells (Fig. 
5.11A) Hierarchical clustering shows that hMSCs and differentiated chondrocytes 
formed their own cluster away from other cells (Fig. 5.12).  Correlation of strong 
enhancers showed a more distinct separation of cells by type and origin (Fig. 5.11B). 
The most similar cell type to our differentiated chondrocytes based on strong 
enhancers were hMSCs and Roadmap’s differentiated chondrocytes (E049; Fig. 5.13).  
 
When quiescent states were compared across all epigenomes, there was some 
clustering of cells by cell origin although there was a large central overlap. Correlation 
of equivalent repressed states showed no obvious clustering of cell types (Fig. 5.50B). 
In both quiescent and repressed states, hMSCs and differentiated chondrocytes 
formed their own cluster (Appendix iii).  
 
Overall, with the exception of the repressed state, more closely related cell types and 
particularly those from the same cell origin tended to cluster together, albeit loosely 
with considerable overlaps in some state comparisons. Encouragingly, blood cells from 
different cell origins were inclined to cluster together away from other cell types in 
almost all chromatin state comparisons. This demonstrates that cell types can indeed 
display distinct epigenomes. With respect to chromatin states, poised enhancer (or 
Roadmap weak enhancers) and strong enhancer states displayed a greater degree of 
clustering by cell type and origin suggesting these chromatin states are more cell 
specific compared to others. Furthermore, enhancer states (equivalent poised/weak, 
active and strong active) displayed lower similarity values across all comparisons 
demonstrating more cell type specificity. In contrast, repressed and strong transcription 
states displayed higher similarities compared to other chromatin states.  
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Figure 5.11 - Principal component analysis of equivalent active enhancer states (A) and strong enhancers (B) 
between Roadmap 18 state model and chondrogenesis 16 state model. hMSC and differentiated chondrocytes 
are circled on the plot. PCA plot was generated using ggplot2 in RStudio. 
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5.3.5 DNA is hypomethylated during chondrogenesis 
 
DNA methylation of hMSCs (n = 7) and differentiated chondrocytes (n = 5) at CpG sites 
was quantified using a 450K methylation array. Raw data was kindly provided by Dr. 
Matt Barter (Newcastle University) who also performed the data collection with Dr. 
Catherine Bui (Newcastle University).  
 
Differential DNA methylation between hMSCs and differentiated chondrocytes was 
determined using the Bioconductor package limma after pre-processing and 
normalising the data using minfi. Normalisation of samples was performed using the 
functional normalisation method (Hansen et al, 2014). Methylation plots showing 
samples before and after normalisation are available in Appendix iii, Fig 1-2. 
Differential DNA methylation tests revealed that 8837 CpG sites were significantly 
differentially methylated (q < 0.05) between hMSCs and differentiated chondrocytes. 
The vast majority of CpG sites became hypomethylated during chondrogenesis – 94% 
(8310 CpG sites). After a 10% methylation change filter was applied, the number of 
significant CpGs dropped to 6601, of which 97.7% were hypomethylated.  
 
DNA methylation is usually linked to transcriptional repression; the hypomethylation of 
DNA during chondrogenesis indicates a large scale transcriptional activation of genes 
during this process. GO term analysis using missMethyl of genes linked to significantly 
differentially methylated CpG sites showed that these genes were associated with 
extracellular matrix organisation and extracellular structure organisation (Table 5.1).  
In a 450k array, some genes have more than one probe associated with them and 
therefore may be overrepresented. The GO term analysis tool from the missMethyl 
Bioconductor package was preferred because it normalises for multiple CpG probes 
linked to the same gene (Phipson et al, 2016).  
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Table 5.1 - GO term analysis of genes associated with the top 500 most hypomethylated CpGs (q < 
0.05). GO terms were found using the missMethyl Bioconductor package. 
GO term GO term name FDR Number of 
genes 
GO:0030198 Extracellular matrix organisation 0.0067 325 
GO:0043062 Extracellular structure organisation 0.0067 326 
 
 
We next sought to determine the methylation level of chromatin states during 
chondrogenesis and where significantly hypomethylated CpGs are located.  
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5.3.6 Correlation of DNA methylation to chromatin states 
 
Chromatin states for hMSCs and differentiated chondrocytes were generated 
previously using ChromHMM (Fig. 5.1). The genomic co-ordinates of CpG 
dinucleotides were intersected with chondrogenesis chromatin states to determine 
where DNA methylation occurred in the genome. CpGs sites assayed using 450K array 
in chondrocytes were intersected with chromatin states in chondrocytes and hMSCs 
(Fig. 5.14; Fig. 5.15). Promoter and promoter flanking chromatin states displayed a 
lower overall methylation level than transcription, enhancer, repressed and quiescent 
states. To directly compare methylation levels, the methylation levels of the same 
CpGs in chondrocytes prior to differentiation were plotted (Fig. 5.14). Likewise, 
methylation of CpGs in hMSC chromatin states was plotted and for a direct 
comparison, the methylation levels of the same CpGs in chondrocytes were 
investigated (Fig. 15).  
 
 
 
Figure 5.14 – Violin plots showing the percentage of methylation (beta values) of CpGs differentiated 
chondrocyte chromatin states and prior to differentiation. DNA methylation levels of all CpGs located in hMSCs 
(B) and the same CpGs in differentiated chondrocytes (A). BEDTools intersect was used to find chromatin states 
of CpG sites. Violin plots generated using ggplot2 in RStudio. The width of each violin is the density of values 
and the box inside the violin is the interquartile range, the horizontal line within the box is the median value and 
the vertical line through the violin is the 95% confidence interval.   
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Figure 5.15 - DNA methylation levels of CpGs in hMSC chromatin states (A) and the same CpGs in differentiated 
chondrocytes (B).  
 
 
 
 
Figure 5.16 – Empirical cumulative distribution frequency plot of all DNA methylation changes in chondrocyte 
chromatin states. All CpG sites in the 450k array were intersected with chondrocyte chromatin states. The 
changes in methylation (∆β) of CpG sites within each state was plotted as an empirical cumulative frequency 
curve using ggplot2 in RStudio.  
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There was no obvious difference between methylation in chromatin states during 
chondrogenesis except the strong enhancer state (13_EnhS), where a tendency 
towards hypomethylation in chondrocytes was observed. An empirical cumulative 
distribution frequency plot showed that state with the greatest change in 
hypomethylation (mean -0.04) in differentiated chondrocytes was 13_EnhS (Fig. 5.16; 
Appendix iii, Table 5). The difference becomes more evident when CpGs in 
chondrocyte 13_EnhS are plotted side by side with their methylation levels in hMSC 
(Fig. 5.56A) and when only significant (q < 0.05) CpGs are considered (Fig. 5.17B). 
Methylation levels of significantly methylated CpGs in the chondrocyte strong enhancer 
state is ~25%, the methylation level of the same CpGs in hMSCs is over 50%.  
 
 
Figure 5.17 – DNA CpG methylation changes intersected with the day 14 chondrocyte strong enhancer state 
(13_EnhS). Violin plot showing the percentage methylation (β value) of CpGs at day 0 (hMSCs) and day 14 
(chondrocytes). (A) All CpGs and (B) significant (q < 0.05) differentially methylated CpGs only. 
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5.3.7 Strong enhancers are hypomethylated during chondrogenesis 
 
We observed that CpGs located in the chondrocyte strong enhancer state (13_EnhS) 
saw a greater change in hypomethylation compared to other chromatin states during 
chondrogenesis. We next sought to determine whether hypomethylation of the strong 
enhancer state could be explained by the number of CpG probes corresponding to this 
state by investigating the locations of CpG probes on the 450K array. In chondrocytes, 
most CpG probes on the array were located in repressed, quiescent and active 
promoter states (Fig. 5.18B). Only 4.96% of total CpG probes were located in the 
chondrocyte strong enhancer chromatin state yet 41.8% of significant hypomethylated 
CpGs were found in this state (Fig. 5.18A). This demonstrates that significant 
hypomethylated CpGs were indeed disproportionately located in the strong enhancer 
state.  
 
 
 
Figure 5.18  - Locations of significant hypomethylated CpGs (q < 0.05 & > 10% methylation change) in (A) 
chondrocyte chromatin states and (B) all CpGs. CpG co-ordinates were intersected with chondrocyte chromatin 
states using BEDTools intersect and pie charts were plotted using Microsoft Excel.  
 
Although the analysis above shows that strong enhancers contain more 
hypomethylated CpGs relative to total CpG probes on the array, this method does not 
take into account the size of chromatin state. Assuming CpG probes are randomly 
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placed across the genome, more total probes on the array and significant differentially 
methylated CpGs sites would fall into longer chromatin states by chance. Therefore, 
the Jaccard similarity index was also employed to calculate which chromatin state 
showed the most hypomethylation. This considers the size of the union between 
chromatin states and CpG sites and thus the size of the chromatin state. Higher 
Jaccard values indicate greater numbers of CpG sites in a chromatin state, taking into 
account the chromatin state size.  
 
 
 
Figure 5.19 - Jaccard similarity index was used to determine relative methylation levels of hypomethylated CpGs 
in each chondrogenesis chromatin state. (A) Significantly hypomethylated CpGs intersected with hMSC and 
differentiated chondrocyte chromatin states, (B) change in Jaccard index of significant CpGs, (C) Jaccard values 
of all CpG sites intersected with hMSC and chondrocyte chromatin states and (D) average size of chromatin 
states. 
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Overall Jaccard index values were small; this is due to the 2bp genome co-ordinates 
of CpG dinucleotides leading to small intersection values. Promoter flanking, 
transcription flanking and strong enhancer states displayed higher Jaccard values with 
significant differentially methylated CpG sites compared to other chromatin states (Fig 
5.19A); these states contain more significant CpG sites relative to chromatin state size. 
The chondrocyte strong enhancer state showed the greatest increase in Jaccard value 
and therefore hypomethylated CpGs compared to strong enhancer states in hMSCs 
(Fig. 5.19B), i.e. there are more significantly hypomethylated CpGs in chondrocyte 
strong enhancers than hMSC strong enhancers. When all CpG probes were 
intersected with hMSC and differentiated chondrocyte chromatin states, the strong 
promoter state had the highest Jaccard value (Fig. 5.19C). In the previous analysis, 
quiescent and repressed states showed a high proportion of total CpG probes with the 
quiescent state containing roughly a quarter of total probes. However, the Jaccard 
values for total CpG probes and these chromatin states were among the lowest due to 
much larger chromatin state sizes (Fig. 5.19D). To summarise, integration of histone 
ChIP-seq and DNA methylation data suggests that hypomethylation of strong 
enhancers plays a role in driving chondrogenesis.  
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5.3.8 Changes in chromatin state and DNA methylation during chondrogenesis 
are linked 
 
Previously we found that strong enhancers in chondrocytes are disproportionately 
significantly hypomethylated. The numbers of significant hypomethylated CpG sites 
and total CpG sites remain the same, yet we see different Jaccard values between 
hMSC and differentiated chondrocyte chromatin states and CpG sites (Fig. 5.19A; Fig. 
5.19C). This illustrates a shifting of chromatin states between hMSCs and 
differentiated chondrocytes which may coincide with DNA methylation changes. Of the 
total CpG sites present in the array, 52.5% were located in chromatin states that 
remained the same during chondrogenesis. In contrast, only 28.5% of significantly 
hypomethylated CpGs (q < 0.05 % 10% ∆β) were found in chromatin states that did 
not change. The overwhelming majority of hypomethylated CpGs (71.5%) were found 
in chromatin states that change during chondrogenesis. A Chi-square test showed that 
the distribution of all CpGs and hypomethylated CpGs was not the same between a) 
chromatin states that remained the same and b) chromatin states that changed during 
chondrogenesis (χ2 = 1479, df = 1, p-value = 1.48x10-323; Table 5.2). This suggests that 
the hypomethylation of CpG sites and changing chromatin state are linked.  
 
Table 5.2 – All CpGs and hypomethylated CpGs (q < 0.05 & 10% ∆β) during chondrogenesis in chondrocyte 
chromatin states that remain the same and chromatin states that change. Expected values in brackets next to 
observed values 
 
 
We previously deduced that in differentiated chondrocytes, the strong enhancer state 
contained 41.8% of hypomethylated CpGs (Fig. 5.20). We were interested to 
investigate the chromatin state changes of these CpG sites to infer how demethylation 
influences chromatin state shifting in chondrogenesis.  
 
 Total Chromatin state 
remains the same 
Chromatin state 
changes 
All CpGs 485438 255048 (253516) 230390 (231922) 
Hypomethylated 
CpGs 
6448 1835 (3367.409) 4613 (3080.591) 
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Figure 5.20  - Chromatin states prior to differentiation of hypomethylated CpG sites within chondrocyte 13_EnhS  
 
Chondrocyte strong enhancer states containing hypomethylated CpG sites originate 
from a range of chromatin states; nearly 80% originate from chromatin states other 
than strong enhancer with the largest number originating from the transcription flanking 
state (Fig. 5.59).  
 
Our integrated data shows that shifts in chromatin states during chondrogenesis are 
accompanied by DNA methylation changes. Whilst we have shown an explicit 
association between histone modification changes and DNA methylation leading to 
changes in chromatin state, the direction of these changes is less clear. From our data, 
it is not possible to deduce whether DNA methylation causes a change in chromatin 
state or whether histone modifications cause DNA methylation changes.  
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5.3.9 DNA methylation during adipogenesis and osteoblastogenesis  
 
Following the discovery that H3K27ac and H3K4me1 marked enhancers are 
hypomethylated during chondrogenesis, DNA methylation during MSC adipogenesis 
and osteoblastogenesis was investigated in order to establish whether DNA 
methylation changes were specific to chondrogenesis. DNA 450k methylation arrays 
were carried out for hMSCs and differentiated adipocytes at 14 days (n = 3) and 
differentiated osteoblasts at 21 days (n = 3). Differentiation experiments and data 
collection was carried out by Dr. Ruddy Gomez-Bahamonde. Analysis of the data was 
performed as for chondrogenesis (functional normalisation in minfi and differential 
methylation tests using limma). During osteoblastogenesis, there were 2337 
significantly differentially methylated CpGs (q < 0.05), of which 2151 were 
hypomethylated and 186 were hypermethylated. Only 2 CpGs were found to be 
significantly differentially methylated during adipogenesis and these were 
hypomethylated. GO terms associated with differentially methylated CpGs during 
osteoblastogenesis were retrieved using missMethyl (Table 5.6). There were 14 
significant GO terms (q < 0.05) found by missMethyl, of which 4 relates to ECM 
organization and 10 to cell movement. Like cartilage, bone is dense in ECM which 
provides tissue integrity and a scaffold for cells. The bone ECM is produced by 
osteoblasts and is composed of different proteins to cartilage and the primary collagen 
is type I rather than type II (Alford et al, 2015). During osteoblastogenesis, osteoblast 
precursors migrate to the site of bone formation (Thiel et al, 2017). GO terms reveal 
that differential DNA methylation occurs at genes responsible for ECM production and 
cell migration.  
 
Adipogenesis did not yield enough significantly differentially methylated CpGs for GO 
term analysis. The top 500 most hypomethylated CpGs by beta values (non significant) 
did not yield any significant GO terms nor did the 500 most hypermethylated CpGs. 
 
Histone modifications were not assayed during adipogenesis or osteoblastogenesis 
experiments and therefore chromatin states from the Roadmap 18 state model were 
used in this analysis. Roadmap primary osteoblast (cell type E129) chromatin states 
were used to determine methylated states during osteoblastogenesis. For 
adipogenesis, Roadmap primary adipose nuclei (E063) chromatin states were used.  
 
 
 174 
 
Table 5.3 – GO terms for significantly differentially methylated CpG sites (q < 0.05) during osteoblastogenesis 
found by missMethyl  
GO term GO term name FDR 
GO:0016477 cell migration 0.000320897 
GO:0005578 proteinaceous extracellular matrix 0.000320897 
GO:0030198 extracellular matrix organization 0.000482797 
GO:0043062 extracellular structure organization 0.000482797 
GO:0048870 cell motility 0.000582142 
GO:0051674 localization of cell 0.000582142 
GO:0040011 locomotion 0.000921287 
GO:0006928 movement of cell or subcellular component 0.005619566 
GO:0030334 regulation of cell migration 0.005619566 
GO:2000145 regulation of cell motility 0.008659225 
GO:0051270 regulation of cellular component movement 0.009013122 
GO:0051716 cellular response to stimulus 0.019948436 
GO:0040012 regulation of locomotion 0.021166516 
GO:0009888 tissue development 0.027323105 
 
The most hypomethylated chromatin state in osteoblasts was 9_EnhA1 (equivalent to 
13_EnhS in the chondrogenesis 16 state model), with a mean ∆β of -0.018 (Fig. 5.21; 
Appendix iii, Table 6).  In contrast, no adipocyte chromatin states showed a net 
hypomethylation during adipogenesis (Fig. 5.22; Appendix iii, Table 7). This suggests 
that osteoblast development, like chondrocyte development, is regulated by the de-
methylation of DNA in enhancers. However, DNA methylation does not appear to 
change during adipogenesis. This is corroborated by a separate study (van den 
Dungen et al, 2016). One caveat with this analysis is the use of chromatin states not 
generated from the cell types used to assay DNA methylation. The histone 
modifications profile of Roadmap primary osteoblasts and primary adipocytes may be 
different to in vitro differentiated osteoblasts and adipocytes.   
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Figure 5.21 – Empirical cumulative distribution frequency plot of DNA methylation changes during 
osteoblastogenesis within osteoblast (Roadmap E129) chromatin states. All CpG sites were intersected with 
E129 chromatin states. Plot generated using ggplot2 in RStudio.  
 
Figure 5.22 - Empirical cumulative distribution frequency plot of DNA methylation changes during adipogenesis 
within adipocyte (Roadmap E063) chromatin states. All CpG sites were intersected with E063 chromatin states. 
Plot generated using ggplot2 in RStudio.  
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5.4 Discussion 
 
Characterisation of chromatin states allows us to view combinations of histone 
modifications and their co-occurrences in the genome. This approach yields more 
information than inspecting single histone marks. From the five histone modifications 
assayed in our chondrogenesis ChIP-seq experiments, 16 chromatin states were 
characterised including promoter states denoting gene TSS and enhancer regions. We 
generated two states designated genic enhancers (7_EnhG1 and 8_EnhG2). These 
consist of enhancer marks alongside H3K36me3. Further investigation is needed to 
determine whether these states function in a different manner to conventional 
enhancer states 12_EnhA and 13_EnhS. The Roadmap project also identified genic 
enhancers but no further information on their function is available. Some chromatin 
states were more prevalent in the genome than others. The relatively high percentage 
of quiescent or unmarked state may reflect the low percentage of the genome that is 
transcribed at any given time. This abundance of quiescent states is also corroborated 
by the equivalent quiescent state in Roadmap’s extended 18 state model (Kundaje et 
al, 2015). It is thought that only 2% of the human genome codes for proteins and ~5-
10% is transcribed (Pertea, 2012). Therefore, the majority of the genome is in an 
inactive or untranscribed state. Conversely, the 16_Quies state may not be quiescent 
at all and may be marked with other histone modifications not included in our 
comparatively limited study of five histone marks. There are numerous histone 
modifications other than the marks included in our study. Furthermore, the 
modifications included in our ChIP-seq experiment, and those used to generate 
chromatin states in the Roadmap project, are only on histone H3. Considering there 
are three other core histone proteins (H2A, H2B, H4) comprising the nucleosome, our 
project and indeed even the Roadmap project, only provide a small snapshot into how 
histone modifications influence the epigenome. A much larger panel of histone 
modifications is required for a truly comprehensive study of the epigenome.  
 
ChromHMM relies on the user to annotate chromatin state names. Chondrogenesis 
chromatin state names were designated based on information from Roadmap and 
ENCODE projects. Where possible, chromatin state names and abbreviations match 
Roadmap’s extended 18 state model. An exception is Roadmap’s 11_EnhWk and 
chondrogenesis 14_EnhP. These two states both exhibit a high level of H3K4me1 
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enrichment and low enrichment for other marks. Whilst Roadmap have termed this a 
weak enhancer state, we decided to designate this state a poised enhancer. Studies 
have shown that H3K27ac marks are required to distinguish poised from active 
enhancers (Creyghton et al, 2010: Heinz et al, 2015). Therefore, a high H3K4me1 and 
low H3K27ac enrichment profile seen in chondrogenesis 14_EnhP and Roadmap’s 
11_EnhWk states corresponds to a histone mark profile more akin to poised enhancers 
than active enhancers. Chromatin state names were supported by overlap and 
neighbourhood enrichment probabilities determined by ChromHMM. ChromHMM also 
outputs transition probabilities of chromatin states which is the likelihood of states (in 
200bp bins) transitioning to another adjacent state or remaining the same. This pattern 
of transitioning states is symbolic of the spreading mechanism employed for the 
addition of post-translational modifications to histone proteins (Ernst and Kellis, 2010); 
histone modifications are added to specific amino acids on histone tails, more of the 
same modification is then added to neighbouring nucleosomes in both directions 
(Schlissel, 2004). The sequential addition of the histone mark continues until blocked 
by an insulator or boundary element (Ferrari et al, 2004; Weth et al, 2014). Insulators 
can also block the interaction between enhancers and gene promoters (Zhao and 
Dean, 2004). The transition probabilities for the chondrogenesis quiescent state 
indicates that apart from itself, it is likely to be adjacent to chromatin states that are not 
within a gene body. This is indicative of boundary elements within the quiescent state 
that stop the spreading of histone modifications from one gene into another. Boundary 
elements also lead to the formation of distinctive chromatin states by ensuring histone 
modifications do not spread along the genome unchecked.  
 
GO term analysis of genes associated with individual chromatin states reveals different 
functional characteristics of some chromatin states between hMSCs and differentiated 
chondrocytes. Enhancer chromatin states yielded more cell type specific biological 
functions than other states, suggesting that enhancers more than any other region 
regulate cell specific gene transcription during chondrogenesis. This finding fits in line 
with other studies that have found that gene enhancers drive cell specific gene 
expression, usually mediated by transcription factor binding (Heinz et al, 2015). Further 
information is required to establish whether our chondrogenic enhancers contain 
binding sites for transcription factors or other DNA binding proteins.  
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To correlate chromatin states derived from our chondrogenesis ChIP-seq and the 
Roadmap project, we calculated the Jaccard similarity coefficient between comparable 
states. There were eight chromatin states between the Roadmap’s extended 18 state 
model and our chondrogenesis model that were considered equivalent i.e. displayed 
similar emission parameters for the same histone modifications. Chromatin state 
correlations between cells showed that enhancers are more distinct between cell types 
and cell origins to a greater extent than other chromatin states. One of the aims of this 
analysis was to assess the similarity of the epigenomes of different cell types. We 
hoped to see the same cell types from different cell origins cluster together, for example 
the same cell type from primary cells and from cell lines. The use of cultured cells and 
cell lines as a proxy for cells in vivo is widespread in research. Therefore, it is important 
to investigate whether immortalising or culturing cells changes their epigenomic make 
up and to what extent. Epigenetic marks can be influenced by environmental factors 
and therefore variability in the epigenome could be introduced by culture conditions 
(McEwen et al, 2013) and number of passages (Noer et al, 2009).  
 
With the exception of blood cells, most other cell types included in the Roadmap 
Epigenomics project only derived from one cell origin. Consequently, our analysis only 
reliably shows the epigenomic relationship between cells of different cell origins rather 
than type. Our hMSC-derived chondrocytes cluster with Roadmap’s hMSC-derived 
chondrocytes on the basis on enhancers marked by H3K27ac and H3K4me1. This 
indicates that although the chondrocytes originate from different chondrogenesis 
models, research labs and ChIP-seq assays, they are nonetheless more similar to 
each other compared to other cell types. This gave us confidence that the disparate 
chondrogenesis models yielded differentiated chondrocytes that have similar 
epigenomes, at least when comparing gene enhancers. The chondrogenesis model 
from which Roadmap’s differentiated chondrocytes originated from involved the use of 
a 3D Alginate scaffold whereas our chondrocytes were differentiated in scaffold-free 
transwell cultures (Murdoch et al, 2007). Furthermore, we differentiated chondrocytes 
over 14 days whereas Roadmap’s chondrocytes were differentiated over 7 days 
(Herlofsen et al, 2013). Both chondrogenesis models utilise cultured primary hMSCs 
and therefore the in vitro chondrogenic environment is artificial. From our analysis, we 
can conclude that both chondrocytes from these two models have a similar enhancer 
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profile which may be chondrocyte specific but without further data it is unknown how 
similar they are to primary human articular chondrocytes. 
 
The Jaccard index relies on overlapping genomic coordinates to determine similarity. 
Consequently, even if a chromatin state does not overlap by 1bp in another dataset it 
will not be taken into account. Considering the plasticity and variability of the 
epigenome, not to mention the noise that is inherently present in biological data, it may 
be reasonable to recognize that chromatin states between cell types can still be 
synonymous if they are only a few bases apart as well as directly overlapping. The 
Jaccard index cannot compare chromatin states if they do not physically overlap so 
does not allow for any flexibility. Furthermore, similarity in our analysis is a relative 
term and it is unknown exactly how similar epigenomes of cell types are expected to 
be. Additionally, whilst we matched chromatin states between Roadmap and our 
chondrogenesis data, the two models are not the same and equivalent states are not 
identical. When comparing weak transcription (Roadmap 6_TxWk and chondrogenesis 
7_TxWk), active enhancers (Roadmap 10_EnhA2 and chondrogenesis 12_EnhA), 
quiescent (Roadmap 18_Quies and chondrogenesis 16_Quies) and repressed 
(Roadmap 16_ReprPC and 15_Repr) states, our hMSCs and chondrocytes formed 
their own cluster away from the Roadmap cell types. This could be due to a true 
difference in the epigenome between these cells and Roadmap’s cells or it may simply 
be due to a mismatch between the chromatin states from Roadmap and 
chondrogenesis ChromHMM models, resulting in segregation of chondrogenesis 
samples.  
 
In this chapter, we have explored the correlation between DNA methylation and histone 
modification. Whilst the DNA 450K array data was re-analysed for the purpose of this 
project, a full in depth analysis is beyond the scope of this PhD and is the focus of 
another project. We found that DNA is hypomethylated during chondrogenesis and 
that these hypomethylated CpG sites mainly occur in the strong enhancer state in 
chondrocytes. The same study that generated Roadmap’s differentiated chondrocyte 
chromatin states also assayed DNA methylation using reduced representation bisulfite 
sequencing (RRBS). Hypomethylation at CpG site dense regions during 
chondrogenesis was observed but DNA methylation at gene promoters was not found 
to correlate with gene expression (Herlofsen et al, 2013). Unfortunately, DNA 
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methylation at enhancers was not investigated. Furthermore, RRBS may not be an 
appropriate method to use to assay enhancer DNA methylation as it only measured 
DNA methylation at CpG dense regions which enhancers typically are not (Calo and 
Whysocka, 2013). In this chapter, we also found that DNA de-methylation occurs in 
enhancers during osteoblastogenesis but not adipogenesis. This suggests that DNA 
hypomethylation in enhancers may regulate enhancers in some differentiation 
processes but not others. DNA hypomethylation at enhancers also plays a role during 
intestinal stem cell differentiation into enterocytes (Sheaffer et al, 2014). Enhancer 
hypomethylation was also found to be important in T cell differentiation (Schmidl et al, 
2009). A study found that DNA hypomethylation occurring at transposable elements in 
the genome led to the gain of enhancer markers to these regions in a tissue specific 
manner (Xie et al, 2013). This suggests that DNA hypomethylation at enhancer regions 
play a role in driving cell specific gene transcription, possibly by changing histone 
modification signatures. This is important during differentiation processes when 
progenitor cells are acquiring a new cell identity.  
 
DNA methylation was investigated using a 450K methylation array which quantifies 
methylation levels using probes designed to known CpG sites. This approach is often 
described as genome wide but whilst probes cover a large degree of the genome, the 
coverage is far from comprehensive. Our analysis reveals that CpG probes are highly 
biased towards chromatin states surrounding gene promoters and the proportion of 
probes outside these regions are small. Whilst the design of CpG probes is logical as 
traditionally DNA methylation was studied at gene promoters due to CpG islands 
mainly being found at promoters (Lim and Maher, 2010), more recent research – 
including this study, has pointed towards a role for DNA methylation within gene bodies 
and enhancers (Bell et al, 2016; Yang et al, 2014). The limited CpG probes designed 
to these areas means that using this technology for investigation into enhancer 
methylation leads to an incomplete picture of DNA methylation within these regions. 
Additionally, methylation of novel CpG sites cannot be quantified using array based 
technology. The newer Illumina MethylationEPIC array provides greater coverage at 
over 850K CpG sites in the genome but whole genome bisulfite sequencing is required 
for a truly genome wide approach that also assays novel CpG sites.   
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Our data reveals a correlation between DNA methylation and strong enhancers but not 
a causation; it is unknown from our data which mechanism acts first or how DNA 
methylation affects changing chromatin states. Other research suggests that DNA 
methylation affects histone modifications and precedes histone modification changes 
(Rose and Klose, 2014; Hashimshony et al, 2003). For both ChIP-seq and DNA 
methylation experiments, populations of hMSCs was seeded into transwell inserts and 
cultured in chondrogenic media to induce chondrogenesis. Multiple transwells were 
used per sample for ChIP-seq. However, although culture conditions were the same, 
we cannot guarantee that all cells were in the same stage of differentiation when 
chromatin was harvested even within the same transwell insert. It’s likely that the final 
population of differentiated chondrocytes at day 14 were heterogeneous and even 
slight differences may affect histone modification patterns. Furthermore, the 
chondrogenesis experiments for DNA 450K array was carried out at a different time 
with extra hMSC donors. Therefore, investigating temporal changes in chondrogenesis 
using these data is not feasible.  
 
In summary, our analysis has found that gene enhancers, particularly strong 
enhancers denoted by histone marks H3K4me1 and H3K27ac, are more segregated 
by cell type and are hypomethylated in chondrogenesis. Enhancers are likely to be 
involved in the regulation of transcription of cell specific gene expression. Indeed, GO 
term analysis of enhancer chromatin states, rather than promoter or transcription 
states, revealed enrichment of terms relating to cell specific biological processes. The 
summarised evidence in this chapter so far points to a unique regulatory role of 
H3K27ac and H3K4me1 defined strong enhancers to promote cell type specific gene 
transcription. We have shown for the first time that some CpG sites within gene 
enhancers become hypomethylated during chondrogenesis. Gene transcription is 
regulated through epigenetic mechanisms which can be influenced by various factors, 
both genetic and environmental and there has been considerable interest in the 
manipulation of gene expression through epigenetic means (Hilton et al, 2015; 
Dominguez et al, 2016). Further research is needed to elucidate whether cis-regulatory 
elements such as enhancers can be exploited to control gene transcription in a 
therapeutic or tissue engineering context.    
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5.5 Conclusion 
 
 
• Chromatin state learning using ChromHMM identified 16 distinct chromatin 
states.  
 
• GO term analysis of chromatin states revealed that enhancers are linked to 
genes with GO terms related to cell specific processes. 
 
• Comparison of chondrogenesis chromatin states to the Roadmap Epigenomics 
project’s 18 state model indicates that gene enhancers are more specific to cell 
type and are more distinct between cell types compared to other chromatin 
states. 
 
• DNA is hypomethylated during the transwell model of chondrogenesis. 
 
• Strong enhancers are more hypomethylated compared to other chromatin 
states during chondrogenesis and osteoblastogenesis but not adipogenesis. 
 
• DNA demethylation during chondrogenesis is accompanied by histone 
modification changes leading to altered chromatin state. 
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Chapter 6. Identification and characterisation of super enhancers in 
chondrogenesis 
 
6.1 Introduction 
 
Cis-regulatory elements such as promoters, transcription factor binding sites and 
enhancers regulate gene transcription. Promoters are located closely upstream to the 
TSS of genes and are on average ~500bp in size (Lui and States, 2002). Conversely, 
gene enhancers can be located large distances away from start sites of genes and 
may cover large genomic areas. Furthermore, gene enhancers do not necessarily 
target their nearest gene; often they affect transcription of genes not in their immediate 
vicinity, in fact, it is thought that the majority of enhancers do not affect their nearest 
gene (Whalen et al, 2016). Enhancers physically interact with target gene promoters 
through a chromatin looping mechanism. One study found that only 22% of enhancers 
physically interact with a neighbouring active TSS (Sanyal et al, 2012). Other features, 
such as DNA binding proteins, within enhancers may give clues as to which gene 
promoter an enhancer could act on. Investigating transcription factor binding in 
enhancers will help elucidate further the regulatory mechanisms involved in 
chondrogenesis.  
 
In recent years, much attention has been given to a potentially novel subset of 
enhancers called super enhancers. Super enhancers are loosely defined as multiple 
gene enhancers in close proximity bound by high levels of active enhancer markers 
(Pott and Lieb, 2014). Enhancer markers used to define super enhancers can include 
transcription factors, transcriptional co-activators and histone modifications. H3K27ac 
is commonly used to define super enhancers, either on its own or in conjunction with 
other enhancer markers (Hnisz et al, 2013). Transcription factors known to be 
important in a particular cell type or process may be used to define super enhancers 
that drive expression of genes specific to a cell type or process. Like typical enhancers, 
super enhancers are associated with cell specific gene expression rather than 
housekeeping genes or genes necessary for general cell function. Super enhancers 
have been implicated in cancer (Sur and Taipale, 2016) and stem cell differentiation 
(Adam et al, 2015).  
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Transcription factor binding sites may be present within other cis-regulatory regions 
such as promoters and enhancers. SOX9 is commonly described as the master 
transcription factor involved in chondrogenesis.  Previous evidence has shown that 
SOX9 binds to both gene enhancers as well as promoters in chondrocytes (Ohba et 
al, 2015). SOX9 binding during chondrogenesis also coincides with binding of the AP-
1 transcription factor, which generally comprises heterodimers from the Jun and Fos 
family of proteins. The most common heterodimers are c-Jun and c-Fos, encoded by 
the JUN and FOS genes respectively (Karin et al, 1995).  Co-binding of AP-1 and 
SOX9 promotes chondrocyte hypertrophy (He et al, 2016), the terminal stage of 
chondrogenesis (Pacifici et al, 1990). Due to the importance of these transcription 
factors during chondrogenesis, they are ideal candidates for identifying super 
enhancers in chondrocytes.  
 
Previous chapters have pointed to an important role of gene enhancers during 
chondrogenesis. We observed that enhancers are more distinct between cell types 
compared to other chromatin states and that they are hypomethylated during 
chondrogenesis and osteoblastogenesis. In this chapter, we further explore the 
characteristics of gene enhancers in chondrogenesis. With the aid of external mouse 
Sox9 and Jun ChIP-seq datasets, super enhancers were identified in our differentiated 
chondrocytes and enhancer activity assessed using luciferase reporter assays. We 
identified four genes, LOXL1-4, with associated enhancers or super enhancers and 
have begun to characterize their roles in chondrogenesis.  
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6.2 Aims 
 
• Analyse mouse Sox9 and Jun ChIP-seq datasets. Convert Sox9 and Jun ChIP-
seq read co-ordinates from mouse to human.  
 
• Identify chondrocyte super enhancers using our histone ChIP-seq dataset and 
SOX9 and JUN ChIP-seq peaks.  
 
• Assess activity of identified super enhancers using luciferase reporter assays, 
with and without SOX9 overexpression 
 
• Compare chondrocyte super enhancers to known super enhancers 
 
• Deplete LOXL1-4 genes in hMSCs using siRNAs to investigate the effect on 
chondrogenesis 
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6.3 Results 
 
6.3.1 Sox9 and Jun ChIP-seq analysis 
 
Sox9 is widely considered the principal transcription factor driving chondrogenesis; 
without Sox9, chondrogenesis cannot occur (Akiyama et al, 2002). The activator 
protein 1 (AP-1) complex is also involved in promoting chondrogenesis through the 
activation of the TGFβ signalling pathway (Huang et al, 2005). The AP-1 transcription 
factor usually comprises heterodimers of Jun and Fos proteins. A study has shown 
that the Jun protein co-binds with Sox9 during chondrogenesis to promote hypertrophy 
(Ohba et al, 2015; He et al, 2016). To elucidate how transcription factor binding acts 
together with histone modifications to influence gene expression in chondrogenesis, 
we investigated the binding of SOX9 and JUN within chondrocyte chromatin states. 
Unfortunately, human SOX9 and JUN ChIP-seq data are not publically available. 
However, SOX9 and JUN ChIP-seq has been performed in mouse rib chondrocytes 
(Ohba et al, 2015; He et al, 2016). Sox9 and Jun ChIP-seq reads were converted from 
mouse (mm10) to human (hg38) using UCSC liftOver. Liftover between species can 
be problematic if the two species are separated by a large evolutionary distance 
(LoVerso and Cui, 2015). Fortunately, mice and humans are not dissimilar and the 
mouse is widely used as a model for human disease and development in research. 
Over 90% of the human and mouse genomes exhibit shared synteny (Chinwalla et al, 
2002). To confirm that liftover of SOX9 and JUN peaks to human genome coordinates 
was appropriate in our analysis, motif discovery using MEME-ChIP (default settings) 
was performed.  
 
De novo motif discovery using SOX9 peaks called from reads lifted over from mouse 
to human revealed that the top motif (Fig. 6.2A) matched to a motif belonging to EGR-
1 (early growth response protein 1) which is required for stem cell differentiation and 
has been shown to have a role in chondrogenesis (Spaapen et al, 2013), tenogenesis 
(Guerquin et al, 2013) and adipogenesis (Boyle et al, 2009). The multiple roles of EGR-
1 suggest that it is differentiation specific rather than specific to chondrogenesis alone. 
Another match for this motif included the Sp/KLF family of transcription factors such as 
Sp-1 and Sp-2 (Appendix IV, Table 1). This family of general transcription factors 
typically binds to gene promoters to regulate transcription (Voelkel et al, 2016). 
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Additional motif matches include other proteins with zinc finger motifs. Zinc finger motif 
containing proteins commonly bind to biological molecules such as other proteins, 
RNA, and DNA and have a diverse range of functions including regulation of gene 
transcription (Ravasi et al, 2003). The second top motif found by MEME belonged to 
the SOX family of transcription factors, including SOX9 (Fig. 6.1B). The third belonged 
to the AP-1 transcription factor comprised of a JUN and FOS heterodimer (Fig. 6.1C). 
The presence of other transcription factor motifs within SOX9 ChIP-seq data indicates 
a potential interaction between SOX9 and other transcription factors.  
 
 
Figure 6.1 – Motifs found in SOX9 ChIP-seq peaks, derived from lifted over mouse Sox9 ChIP-seq reads, by 
MEME. Peaks called using MACS2 after lifting over aligned reads from mm10 to hg38. (A) Top motif found by de 
novo motif discovery using MEME ChIP-seq belonged to the EGR-1 transcription factor. (B) the second motif 
matched the SOX family of transcription factors and includes SOX9 and (C) the third motif matched the AP-1 
transcription factor.    
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Figure 6.2 - Motifs found in JUN ChIP-seq peaks, derived from lifted over mouse Jun ChIP-seq reads, by MEME. 
Peaks called using MACS2 after lifting over aligned reads from mm10 to hg38. (A) Top motif found by de novo 
motif discovery using MEME ChIP-seq belonged to the AP-1 transcription factor. (B) the second motif matched 
the EGR-1 transcription factor (C) the third motif matched the EGR-2 transcription factor 
 
Motif discovery was also performed on the JUN ChIP-seq peaks called after read 
liftover from mm10 to hg38. The top motif found matched to the AP-1 transcription 
factor, of which JUN forms along with FOS (Fig. 6.2A). The second motif found by 
MEME matched to EGR-1 (Fig. 6.2B) and Sp/KLF transcription factor family members 
and zinc finger proteins (Appendix IV, Table 2). The third motif matched EGR-2; similar 
to EGR-1, EGR-2 is involved in development. Although the two EGR transcription 
factors can be involved in the same processes, they often have opposing effects (Du 
et al, 2014; Boyle et al, 2009).  
 
The presence of other transcription factor binding motifs found using SOX9 peaks 
indicates that SOX9 potentially co-binds with other transcription factors. Previous 
studies have shown that SOX9 forms complexes with other proteins before binding to 
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DNA (Jo et al, 2014). Motif discovery using SOX9 peaks yields AP-1 binding motifs. 
However, motif search with JUN peaks did not yield SOX9 binding motifs. These 
findings corroborate with motif discovery in the original mouse dataset (Ohba et al, 
2015; He et al, 2016) and shows that liftover of ChIP-seq reads achieved expected 
outcomes. He et al found a high degree of overlap between Sox9 and Jun ChIP-seq 
peaks in chondrocytes. To investigate whether this was the case in our lifted over data, 
we assessed the overlap rate between hg38 SOX9 and JUN peaks.  There were 51082 
significant (q < 0.05) peaks in the lifted over JUN ChIP-seq data and 39465 significant 
peaks in the lifted over SOX9 ChIP-seq data. There were 26413 SOX9 peaks with one 
or more overlapping JUN peaks; a total of 28602 JUN peaks overlapped a SOX9 peak 
with some overlapping more than one (Fig. 6.3).  
 
 
 
Figure 6.3 – Overlapping SOX9 and JUN peaks. Mouse rib chondrocyte SOX9 and JUN ChIP-seq data (along with 
respective input controls) were aligned to mouse reference genome mm10; aligned reads were converted into 
hg38 coordinates using the UCSC liftOver tool. Significant peaks (p < 0.05) were called on lifted over reads using 
MACS2 peak caller (default settings). Overlapping peaks were assessed using BEDTools intersect and Venn 
diagram created using the Venneuler package in RStudio.  
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Peak overlaps suggest that SOX9 and JUN do indeed co-bind, as suggested by de 
novo motif analysis on SOX9 peaks yielding AP-1 motifs, or at least share common 
binding sites. Transcription factor ChIP-seq was performed on a population of cells 
and therefore overlapping peaks may reflect heterogeneity of SOX9 and JUN binding 
in different cells rather than co-binding on the same genome. However, in situ 
hybridization experiments show that Sox9 and Jun co-localize to the same region of 
the growth plate in mouse tibia (He et al, 2016).   
 
67% of SOX9 peaks had at least one overlapping JUN peak, this shows that the 
majority of SOX9 binding is accompanied by the AP-1 transcription factor in 
chondrocytes. SOX9 can bind to gene promoters where it regulates transcription of 
non-chondrogenic genes and can also bind to enhancers to regulate chondrogenesis 
and cartilage related genes, termed class I and class II SOX9 binding sites respectively 
(Ohba et al, 2015). SOX9 peaks with at least one overlapping JUN peak were 
intersected with chondrocyte chromatin states to investigate where in the chondrocyte 
genome co-binding of these transcription factors occur (Fig. 6.4).   
 
 
 
Figure 6.4 – Overlapping SOX9-JUN peaks in chondrocyte chromatin states. Overlaps were found using BEDTools 
intersect; some peaks span more than one chromatin state, where this was the case both states were included. 
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The chromatin state with the most overlapping SOX9-JUN was the strong active 
promoter/TSS state (2_TssS) indicating that highly expressed genes possess SOX9 
and AP-1 binding at their promoters. The strong enhancer (13_EnhS) and quiescent 
(16_Quies) states both have similar numbers of SOX9-JUN overlapping peaks. SOX9 
is known to bind to enhancers but it is unclear why a similar number of SOX9-JUN 
peaks are found in the quiescent state. The quiescent state is the largest chromatin 
state in the genome, if transcription factor binding was assumed to be random then 
most binding sites would be located in this state. However, transcription factor binding 
is not random. Poised enhancers (14_EnhP) also contain a large number of SOX9-
JUN overlap peaks. Few SOX9-JUN peaks are found in chromatin states covering 
gene bodies demonstrating that regulation of genes through SOX9 and AP-1 is primary 
through binding at the promoter of genes or at distal cis-regulatory regions.  
 
GO terms for genes associated with SOX9-JUN peaks in 2_TssS, 13_EnhS and 
16_Quies were retrieved using GREAT Ontology after converting hg38 coordinates to 
hg19 (GREAT does not support hg38). As hypothesised, SOX9-JUN peaks at 2_TssS 
states regulate genes involved in general cell function whereas binding in the 13_EnhS 
state regulate cartilage development genes. GO terms for 14_EnhP include cartilage 
development related terms as well as terms associated with other developmental 
processes. Terms related to chondrogenesis may reflect a temporal difference 
between SOX9 binding and activation of poised enhancers and GO terms connected 
to other differentiation processes could represent poised enhancers which may never 
be activated in chondrocytes. Interestingly, GO terms for SOX9-JUN peaks present in 
the 16_Quies state were related to development of other cell types although regulation 
of cartilage development was also among these GO terms (Fig. 6.5). GO terms for 
SOX9-JUN in chondrocyte 16_Quies state is suggestive that co-binding of SOX9 and 
AP-1 is also important in other developmental processes. As well as chondrogenesis, 
SOX9 is known to regulate differentiation of other cell types. SOX9 is also involved in 
gliogenesis (Stolt et a, 2003; Vong et al, 2009), maintenance of hair follicle stem cells 
(Kadaja et al, 2014), pancreas development (Seymour, 2014) and more. Apart from 
differentiation processes, SOX9 is also involved in sex determination in mammals 
(Koopman, 2001). With such a large repertoire of roles, SOX9 requires the interaction 
of other proteins and epigenetic mechanisms in order to promote the correct cell 
process. 
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SOX9 has multiple roles and binds to different cis-regulatory regions in the genome 
but binding at gene enhancers in chondrocytes yielded the most GO terms related to 
chondrogenesis compared to other chromatin states.  This illustrates the complex 
relationship between DNA binding proteins and histone modifications. Further 
investigation is required to fully understand gene regulation by SOX9 and its binding 
partners. It will be interesting to include SOX9 ChIP-seq data from different cells types 
in future analyses. Unfortunately, the investigation of SOX9 binding in different cell 
types is beyond the scope of this project.    
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Figure 6.5 – Top 20 significant (FDR < 0.05) GO terms found using GREAT GO Ontology tool for SOX9-JUN 
overlapping peaks within chondrocyte chromatin states (A) 2_TssS, (B) 13_EnhS and (C) 14_EnhP and (D) 
16_Quies  
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6.3.2 Identification of super enhancers 
 
Following the validation that mouse SOX9 and JUN ChIP-seq data produced similar 
results when lifted over to humans, we sought to identify super enhancers in 
chondrocytes using these transcription factors as enhancer markers. The general 
method for identifying super enhancers involves a three step process (Pott and Lieb, 
2015). First, typical enhancers must be identified. Active enhancers are marked by 
H3K27ac and this histone mark is usually used to classify enhancer locations. Other 
enhancer markers such as the Mediator 1 protein complex which is also associated 
with active enhancers (Kuras et al, 2003) can also be used for this first step. The 
second step clusters individual enhancers within 12.5kb of each other. The third step 
involves another enhancer marker which is intersected with clustered enhancers and 
ranked on ChIP-seq peak signal. Clustered enhancers also exhibiting high levels of 
the enhancer marker used for the third step are classed as super enhancers. 
Determining the enhancer marker enrichment threshold for super enhancers is 
somewhat arbitrary; enhancers are ranked and plotted on the basis of the second 
enhancer marker and the signal value cut off is the point of the curve where the slope 
equals 1 (Fig. 6.6).  Super enhancers may be defined using different markers for step 
one and step three or using the same marker for both steps (Hnisz et al, 2013).  
 
To identify chondrocyte super enhancers, strong enhancer states (13_EnhS) in our 
chondrocyte chromatin states were used; this constitutes step one in the method 
outlined above. As an extra control, we also stipulated that strong enhancer states 
must also be an enhancer state in Roadmap BM-MSC derived chondrocytes (cell type 
E049). The level of SOX9 peak enrichment was used to define super enhancers from 
typical enhancers. SOX9 peaks must also have an overlapping JUN peak, although 
the JUN enrichment signal was not directly taken into account. SOX9 peaks meeting 
these criteria were plotted by ranking SOX9 signal enrichment (MACS2 signal value 
score) and an enrichment value threshold above 19 was used to define super 
enhancers (Fig. 6.6). Using this method, 746 super enhancers were identified in 
chondrocytes.   
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Figure 6.6 – Identification of super enhancers in chondrocytes. Chromatin states characterised as strong 
enhancers (13_EnhS) were used to identify all enhancers. SOX9-JUN overlapping peaks were intersected with 
13_EnhS states. Strong enhancer regions were ranked on the basis on SOX9 peak enrichment. The SOX9 
enrichment cut off for super enhancers was defined as above 19, this is the point of the curve where the slope = 
1. There were 746 identified in chondrocytes. 
 
DNA methylation levels in super enhancers did not differ significantly from typical 
enhancers (p > 0.05; Fig. 6.7); only the level of SOX9 enrichment separates super 
enhancers from typical enhancers in our dataset.  GO terms for super enhancers were 
retrieved using the GREAT GO tool (Fig. 6.8). As expected, almost all terms were 
related to cartilage development. These results were similar to GO terms for the strong 
enhancer state (Chapter 5) but are more chondrogenesis specific. Super enhancers 
yielded 8 GO terms containing the words “cartilage” or “chondrocyte” whereas the 
strong enhancer state contained 2 terms with these words.  
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Figure 6.7 – DNA methylation levels (β values) in SOX9 defined super enhancers and SOX9 bound typical enhancers  
 
 
 
 
Figure 6.8 – Biological process GO terms for chondrocyte super enhancers. Super enhancer co-ordinates were 
converted from hg38 to hg19; GO terms were retrieved using GREAT (default settings).  
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6.3.3 Assessment of enhancer activity using a luciferase reporter assay 
 
Following the generation of a list of super enhancers, some were selected for further 
validation based on their proximity to cartilage related genes (Table 6.1). SOX9 peak 
regions within super enhancers were cloned into a PGL3-promoter vector and 
transfected into the SW1353 and HEK293T cell lines with and without SOX9 
overexpression. The PGL3-promoter vector contains a luciferase gene; potential 
enhancers may be cloned upstream of the luciferase gene and SV40 promoter. After 
transfection into cells, luciferase activity may be measured as a proxy for enhancer 
activity.  
 
Table 6.1 – Super enhancer segments selected to be cloned into PGL3-promoter vectors. Regions selected are 
SOX9 peaks within a super enhancer. Super enhancer segments were given a number for simpler referencing; 
no. 2 is absent due to the unsuccessful cloning of the region.  
Insert no. Locus 
(hg19) 
Length Nearest gene Predicted gene 
target 
1 chr2:74810421-74811389 968 DOK1 LOXL3 
3 chr16:69924387-69924932 545 WWP2 WWP2 
4 chr16:17452680-17453167 487 XYLT1 XYLT1 
5 chr12:104879495-104880612 1117 CHST11 CHST11 
6 chr1:183922069-183922664 595 COLGALT2 COLGALT2 
 
 
Initially, enhancer luciferase assays were performed using the SW1353 cell line. This 
chondrosarcoma cell line is commonly used in cartilage research and is often 
considered a chondrocyte cell line (Tew et al, 2007; Gebauer et al, 2005; Santoro et 
al, 2015). Of the five enhancer regions successfully cloned into a PGL3-promoter 
vector, three showed significantly increased luciferase activity compared to an empty 
vector control (Fig. 6.9A). One of the aims of this experiment was to observe whether 
overexpression of SOX9 affected enhancer activity. Although three enhancer 
constructs increased luciferase activity (insert no. 1, 3, 6), overexpression of SOX9 did 
not increase this further. We hypothesized that endogenous SOX9 expression in 
SW1353 may be sufficient to saturate enhancers and therefore overexpression of 
SOX9 may not influence luciferase activity. Consequently, the experiment was 
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repeated in a human embryonic kidney cell line, HEK293T, which should exhibit little 
SOX9 expression (Blache et al, 2004). The three enhancer constructs that increased 
luciferase activity in SW1353 cells also increased in HEK293T cells, plus an extra 
enhancer construct (insert no. 4). For inserts no. 1, 3 and 6 in HEK293T cells, 
overexpression of SOX9 significantly increased luciferase activity further compared to 
an empty vector control (Fig. 6.9B). Interestingly, overexpression of SOX9 led to a 
decrease of luciferase activity in enhancer construct no. 5. A protein immunoblot was 
performed to confirm SOX9 overexpression (Fig. 6.10). There appears to be more 
endogenous SOX9 present in SW1353 cells compared to HEK293T cells without 
overexpression of SOX9. However, endogenous SOX9 was also observed in 
HEK293T cells showing that HEK293T cells do indeed express SOX9.   
  
 
 
 199 
 
 
Figure 6.9 – Enhancer luciferase assays performed in (A) SW1353 and (B) HEK293T cell lines. Small regions of 
super enhancers containing a SOX9 peak were cloned into PGL3-promoter vectors, transfected into SW1353 and 
HEK293T cell lines for 24hrs and the relative light unit (RLU) measured. Light units were normalised against a 
Renilla control. A t-test (two tailed, unpaired, equal variances not assumed) was performed to test for statistical 
significance between enhancer constructs and empty vector control, and SOX9 overexpression vs empty SOX9 
control.  Error bars show the standard deviation. Significant contrasts are marked by lines, significant p values 
are indicated by asterisks: * < 0.05, ** < 0.01, *** < 0.001.  
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Figure 6.10 – Immunoblot of SOX9 overexpression in HEK293T and SW1353 cell lines. A SOX9 expression plasmid 
or empty vector control was transfected into cells for 24hrs. Protein was extracted and an immunoblot 
performed to detect levels of SOX9 protein.  The SOX9 protein has a molecular weight of 56kDa. An immunoblot 
against GAPDH was used as a protein loading control.  
 
In summary, enhancer luciferase reporter assays showed that at least three out of five 
segments of separate super enhancers assayed exhibited independent enhancer 
activity in SW1353 and HEK293T cell lines. Overexpression of SOX9 increased 
luciferase activity further in two reporter assays in HEK293T cells but not in SW1353 
cells, possibly due to endogenous SOX9 being present in SW1353 cells. Unfortunately, 
luciferase reporter assays are unable to define which gene is being directly targeted 
by the cloned enhancer.  Table 6.1 includes the nearest gene to the super enhancer 
and its predicted target gene. In all cases except one, the predicted target gene is also 
the nearest gene. As enhancers do not always target the nearest gene, super 
enhancers next to a gene upregulated in chondrogenesis were chosen as these were 
deemed more likely to be targeted by the super enhancers. The nearest gene to the 
super enhancer containing insert no. 1 is DOK1 (Fig. 6.11). However, DOK1 does not 
have an established role in chondrogenesis. The gene downstream of DOK1 is LOXL3 
which is involved in collagen crosslinking (Lee and Kim, 2006). Consequently, we 
predicted that this super enhancer targets LOXL3 rather than DOK1. Further 
characterisation and functional analysis is required to validate this hypothesis.  
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6.3.4 Super enhancer cell type comparisons and gene target predictions 
 
There have been many studies investigating super enhancers since their discovery in 
2012 and databases have been created to store information about super enhancers. 
One such database is dsSUPER which contains super enhancers found in the mouse 
and human genomes (Khan and Zhang, 2016). Super enhancers in 86 Roadmap 
Epigenomics human cells and tissues were identified using H3K27ac (Hnisz et al, 
2013) and deposited into dbSUPER. The overlap tool within dbSUPER was used to 
assess the overlap between chondrocyte super enhancers and those in other cell types 
available in the database. Chondrocyte super enhancers coordinates were converted 
from hg38 to hg19 because dbSUPER only supports hg19. Super enhancers with at 
least a 10% overlap were considered present in both cell types (default setting).  
 
The cell type that exhibited the most overlap with our chondrocyte super enhancers 
was the U87 cell line with 287 overlaps (Table 6.2). The U87 cell line was originally 
thought to derive from a human glioblastoma but their origin has since been called into 
question (Dolgin, 2016; Allen et al, 2016). Therefore, U87 may be an aberrant and 
potentially contaminated cell line and its super enhancer similarities to chondrocytes a 
coincidence. However, recent studies have shown that U87 cells may have MSC-like 
qualities (Oh et al, 2017; Svensson et al, 2017) which could explain why they possess 
so many super enhancers in common with those identified in chondrogenesis. As 
super enhancers are widely considered to be associated with cell type specific 
processes, it is unknown exactly why the U87 cell line would have so many in common 
with chondrocytes.  
 
The second cell type with the most matches to chondrocyte super enhancers was 
primary osteoblasts. Osteoblasts derive from MSCs and share many similarities to 
chondrocytes (Gomez-Picos and Eames, 2015). During development, bone tissue can 
originate from cartilage via endochondral ossification, a process that occurs after the 
terminal hypertrophic stage of chondrogenesis (Yang et al, 2014; Zhou et al, 2014).  
One of the criteria to define our super enhancers was the presence of a SOX9 and 
JUN overlapping peak; co-binding of these proteins at enhancers is proposed to 
promote chondrocyte hypertrophy (He et al, 2016). Therefore, it is unsurprising that 
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osteoblast super enhancers overlap many chondrocyte super enhancers. Although 
adipocytes also derive from MSCs, chondrocytes are more similar to osteoblasts and 
this is reflected in the number of super enhancers the cells have in common. These 
results corroborate with the findings of Chapter 5 which showed that enhancers from 
similar cell types tended to cluster together. This is further evidence that gene 
enhancers can be used to infer relationships between different cell types.  
 
Table 6.2 –  dbSUPER overlap of chondrocyte super enhancers 
Cell type Overlap with chondrocyte super enhancers 
U87 286 
Osteoblasts 212 
Adipose nuclei 127 
 
 
An important caveat to consider when using public databases and tools is the variety 
of different methods used to define enhancers and super enhancers. Furthermore, 
databases can suffer from lack of recent annotation and caution must be taken to avoid 
concluding that an absence of data is a negative result.  
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Previously we observed that the LOXL3 gene may be associated with a super 
enhancer. The potential super enhancer is upstream of LOXL3 within the M1AP gene 
and adjacent to the DOK1 gene. We predicted that this super enhancer is acting on 
LOXL3 rather than DOK1 due to LOXL3 being involved in collagen crosslinking. 
Enhancers target gene promoters through chromatin looping. Physical looping of 
chromatin occurs within topologically associating domains (TADs), whose boundaries 
are marked by insulator or boundary elements (Whalen et al, 2016). Chromatin 
conformation studies such as Hi-C are used to elucidate the genome wide chromatin 
interactions and characterize TADs. Although Hi-C data is not available for 
chondrocytes, it has been performed in a variety of other cell types. The 3D genome 
browser is a repository of high throughput chromatin conformation studies and can be 
used to view chromatin interaction (Wang et al, 2017). This was used to investigate 
whether the potential LOXL3 super enhancer could interact with the LOXL3 gene 
promoter. The H1-ESC is stem cell line and can be induced to differentiate into 
chondrocytes (Brown et al, 2014). The potential LOXL3 super enhancer is within the 
same TAD as the LOXL3 promoter in H1-MSCs showing that is possible for LOXL3 to 
be regulated by this super enhancer (Fig. 6.12A). We observed that this interaction 
could also occur in an unrelated cell line, GM12878 (a lymphoblastoid cell line; Fig. 
6.12B). TAD boundaries can change between cell types and chondrocyte chromatin 
conformation data is required to confirm whether this interaction occurs in 
chondrocytes. However, other genes are also within the same TAD and further 
experiments are required to validate which gene is regulated by this super enhancer 
in chondrocytes.  
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Figure 6.12 – Hi-C interaction matrix of LOXL3 in (A) H1-MSC (human MSC) and (B) GM12878 (human 
lymphoblastoid cell line). Enhancer-LOXL3 promoter interaction is shaded. Red pyramids indicate the intensity of 
interaction, maroon lines are DNAseI hypersensitivity sites (DHS data not available for H1-MSC) and yellow/blue 
regions are separate TADs. Image generated using Hi-C 3D genome browser (Wang et al, 2017).  
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Enhancer-promoter prediction tools aim to identify likely gene targets of enhancers, 
usually based on existing data such as chromatin conformation and open chromatin 
studies.  One such tool is PETModule (Zhao et al, 2016) which considers factor such 
as distance, conservation, GO terms and correlation of DNAseI hypersensitivity site 
signals in enhancers and promoters from existing datasets to generate a probability of 
enhancer-promoter pairing. This tool was chosen because the authors claim it to be 
superior to existing tools and because of its simple input requirement of enhancer 
coordinates, whereas other tools such as IM-PET (He et al, 2014) require more data 
input and preprocessing of data. PETModule was run using all 746 identified 
chondrocyte super enhancers (in hg19; hg38 not supported) using default parameters.  
 
As a case study, we again considered the potential LOXL3 super enhancer. Although 
the super enhancer is closest to the promoter of the DOK1 gene, we predicted that this 
super enhancer is actually regulating LOXL3 due to its important role in collagen 
crosslinking. PETModule output suggests that this super enhancer does indeed 
regulate LOXL3 instead of DOK1. However, it is equally as likely to regulate other 
genes in the vicinity (Table 6.3). Enhancer-promoter target prediction tools are a 
helpful aid but can struggle with predictions when multiple genes are in close proximity 
in the genome; prediction scores can be very similar. These tools represent the first 
generation of enhancer-promoter prediction software and there is much scope for 
improvement. Manuals for these tools can be incomplete or vague and they are not 
user friendly even for researchers familiar with using command line tools.    
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Table 6.3 – PETModule output for the predicted LOXL3 super enhancer. 
GENE PROB SE_CHR SE_START SE_END 
AUP1 1 chr2 74787327 74813927 
DQX1 1 chr2 74787327 74813927 
LBX2-AS1 1 chr2 74787327 74813927 
LOXL3 1 chr2 74787327 74813927 
PCGF1 1 chr2 74787327 74813927 
SLC4A5 1 chr2 74787327 74813927 
TLX2 0.99 chr2 74787327 74813927 
WDR54 0.98 chr2 74787327 74813927 
HTRA2 0.97 chr2 74787327 74813927 
LBX2 0.97 chr2 74787327 74813927 
MOGS 0.97 chr2 74787327 74813927 
WBP1 0.97 chr2 74787327 74813927 
DOK1 0.96 chr2 74787327 74813927 
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6.3.5 siRNA depletion of LOXL1-4 genes 
 
The LOXL (lysl oxidase) family of genes have an established role in collagen and 
elastin crosslinking. This family comprises LOX and the LOX-like members 1-4; 
although all are involved in crosslinking different collagens, they appear to have 
disparate roles depending on cell type.  The different family members are implicated 
in a range of pathologies involving aberrant ECM formation.  Disruption of the Lox gene 
in mice caused death shortly before or after birth due to defective cardiovascular 
development, likely due to impaired elastic fibre formation (Maki et al, 2002). Single 
nucleotide polymorphisms in LOXL1 are associated with glaucoma and 
pseudoexfoliation syndrome, a disease characterised by abnormal crosslinking in the 
ECM of the eye (Schlötzer-Schrehardt and Naumann, 2006; Thorleifsson et al, 2007). 
LOXL2 is required for chondrogenesis and depletion of LOXL2 inhibits SOX9 
expression, suggesting it also acts as a transcriptional regulator separate from its role 
as a collagen cross linker (Iftikhar et al, 2011). Knockout of Loxl3 in mice leads to cleft 
palate formation and spinal deformity due to abnormal cartilage development (Zhang 
et al, 2015). Mutations in LOXL3 was observed in a family with the cartilage disease 
Stickler syndrome (Alzahrani et al, 2015).  
 
Apart from LOXL2, there have not been any studies on the function of LOXL proteins 
in chondrogenesis despite their role in collagen crosslinking and chondropathies. From 
our chondrogenesis RNA-seq data, we observed gene expression changes of LOXL 
genes from day 0 to day 6. LOXL1 is downregulated during chondrogenesis whereas 
LOXL2, LOXL3 and LOXL4 were upregulated (Table 6.4). Following the observation 
that LOXL3 may potentially be regulated by a super enhancer, we investigated whether 
siRNA depletion of LOXL3 mRNA would influence chondrogenesis. Family members 
LOXL1, LOXL2 and LOXL4 were also investigated. hMSCs (donor 2454e) were 
transfected with siRNAs for 48hrs before inducing chondrogenesis in transwell inserts. 
RNA was extracted prior to differentiation (day 0) and at day 7 of chondrogenesis. 
Gene expression was measured using RT-qPCR. All siRNAs successfully depleted 
mRNA levels of their target genes at day 0 compared to controls (Fig. 6.13A).  
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Table 6.4 – Gene expression changes of LOXL1-4 at day 0 and day 6 of chondrogenesis. Gene expression 
reported in TPM, quantified by Salmon (quasi-mapping mode).  
 
DAY 0 DAY 6 LOG2FC 
LOXL1 67.86678 
 
0.6980193 -6.603294828 
LOXL2 29.899996 
 
61.474932 1.039852943 
LOXL3 28.364686 
 
83.169144 1.55195249 
LOXL4 6.10088 
 
13.4118 1.136413615 
 
 
 
At day 7 of chondrogenesis, LOXL1-4 genes remained depleted (Fig. 6.13B). LOXL1 
expression decreased from day 0 to day 7. Gene expression of LOXL1-4 measured by 
RT-qPCR largely corroborated our RNA-seq results although RNA-seq was performed 
at RNA extracted at day 6 and RT-qPCR at day 7. Gene expression of SOX9 and 
ACAN were also assayed at day 7 (Fig. 6.14), unfortunately SOX9 and ACAN 
expression were not assayed at day 0. Expression of SOX9 decreased when LOXL2 
was depleted, as previously reported (Iftikhar et al, 2011). We also observed a 
decrease of SOX9 when LOXL1 and LOXL3 were depleted although the highest 
decrease was seen with siLOXL2. Although LOXL1 is normally downregulated in 
chondrogenesis, further decreases using siRNA treatment resulted in SOX9 
downregulation, suggesting that LOXL1 regulates chondrogenesis in a concentration 
dependent manner. Interestingly, the same pattern of gene expression decreases with 
depletion of LOXL1-4 was also seen in ACAN. This is possibly due to downregulation 
of SOX9; ACAN is a direct target of SOX9 in chondrogenesis (Zhang et al, 2015).  
 
To determine whether siRNA depletion of LOXL1-4 has an effect on 
glycosaminoglycan production, a GAG assay was performed at day 7 of 
chondrogenesis. This assay measures the levels of proteoglycans such as aggrecan 
and glycoaminoglycans such as hyaluronic acid (Frazier et al, 2008).  hMSCs were 
differentiated into chondrocytes using a pellet model of chondrogenesis (Zhang et al, 
2010).  
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Figure 6.13 – Gene expression of LOXL1-4 in (A) hMSCs after transfection for 48hrs with siRNAs against LOXL1-4. 
(B) Gene expression of LOXL1-4 in day 7 chondrocytes; 48hr siRNA transfected hMSCs were differentiated in 
transwell inserts over 7 days in chondrogenic media. RNA was extracted and gene expression was measured 
using RT-qPCR after cDNA synthesis. Gene expression was normalised to an 18S control. Experiments performed 
at n = 2 (hMSC donor 2454e). Errors bars represent the standard error of the mean (SEM). 
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Figure 6.14 – Gene expression of (A) SOX9 and (B) ACAN at day 7 chondrogenesis after hMSC transfection with 
siRNAs against LOXL1-4 for 48hrs. RNA was extracted and gene expression was measured using RT-qPCR after 
cDNA synthesis. Gene expression was normalised to an 18S control. Experiments performed at n = 2 (hMSC 
donor 2454e). Errors bars represent the SEM. 
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Figure 6.15 – GAG assay performed at day 7 of chondrogenesis after hMSC transfection with siRNAs against 
LOXL1-4 for 48hrs. hMSCs were differentiated into chondrocytes in pellet cultures. Experiments were performed 
at n = 6 (hMSC donor 2454e). Errors bars represent the standard deviation. 
 
Despite ACAN being downregulated in chondrogenesis with siLOXL1, siLOXL2 and 
siLOXL3 treatment in hMSCs, concentrations of glycoaminoglycans did not change 
(Fig. 6.15). Although this could suggest the upregulation of other proteoglycans and 
glycoaminoglycans as a response, this may be due to the differences in the two 
chondrogenesis models used; gene expression changes were measured in RNA 
extracted from the transwell model whereas the GAG assay was performed using a 
pellet culture chondrogenesis model. To avoid discrepancies between models 
affecting outcomes, the same model should be used in future.  
 
To summarize this section, siRNA knockdown of LOXL1, LOXL2 and LOXL3 in hMSCs 
appeared to result in downregulation of SOX9 and ACAN during chondrogenesis. This 
may suggest that LOXL1-3 have a role in transcriptional regulation, previously 
undefined for LOXL1 and LOXL3, or that collagen crosslinking in the ECM feeds back 
to regulate gene transcription. ECM properties are known to influence gene expression 
in chondrocyte differentiation (Allen et al, 2012). GAG concentrations did not change 
with siRNA treatment. The four LOXL genes have well defined roles in collagen 
crosslinking. Unfortunately, we were unable to quantify or measure collagen 
crosslinking within the timeframe of this project. These experiments were preliminary 
but the results merit further investigation to fully elucidate the roles of these four LOXL 
genes in chondrogenesis.    
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6.4 Discussion 
 
De novo motif discovery using SOX9 peaks derived from lifted over ChIP-seq data 
revealed that the top second motif found belonged to the SOX family of proteins. 
However, the top motif displayed matches to other transcription factors such as SP-1 
and EGR-1. These transcription factors - whilst important for chondrogenesis, are not 
exclusive to chondrogenesis or MSC differentiation in general. SP-1 and EGR-1 have 
roles in regulating differentiation of many other different types of stem cells. 
Transcription factor binding can help elucidate features that are specific to 
differentiation in general, MSC or otherwise, and binding that is exclusive to 
chondrogenesis. Motif searching has offered an insight into the intricate interplay of 
transcription factors involved in chondrogenesis. SOX9 has been shown to bind at 
gene promoters as well as gene enhancers (Ohba et al, 2015), with binding at 
enhancers leading to upregulation of chondrogenesis specific genes. The SOX9 
protein functions as a homodimer and does not act alone (Bernard et al, 2003). SOX9 
can also dimerize with other binding partners to regulate gene transcription. The 
majority of SOX9 binding in chondrocytes is accompanied by the JUN family of 
proteins, which makes up the AP-1 transcription factor along with its binding partner 
FOS. There is evidence that SOX9 forms a complex with other transcription factors 
first before binding to DNA as a protein complex (Jo et al, 2014). SOX9 can activate 
or repress genes at different stages of chondrogenesis depending on its binding 
partner. For example, SOX9 binds to GLI proteins to repress COL10A1 prior to 
chondrocyte hypertrophy; COL10A1 expression is a marker for chondrocyte 
hypertrophy. Hypertrophy of chondrocytes is the final stage of chondrocyte 
differentiation and precedes ossification (van der Kraan and van den Berg, 2012). 
COL10A1 is known to be regulated by an enhancer (Chambers et al, 2002). 
Chondrocytes resident in permanent cartilage, such as the articular cartilage found in 
synovial joints, do not enter this terminal stage except in cartilage diseases, particularly 
osteoarthritis (von der Mark et al, 1992). The repression of COL10A1 by SOX9-GLI 
heterodimers prevent cells from entering this stage (Leung et al, 2011). In contrast, 
SOX9 and AP-1 transcription factor binding at enhancers promotes hypertrophy (He 
et al, 2016). These studies highlight the importance of gene regulation through 
enhancers in chondrocyte development.  
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Although SOX9 and JUN binds to many chromatin states across the genome, binding 
in chondrocyte enhancers yielded the most GO terms related to chondrocyte 
differentiation. This is further evidence that gene enhancers are the main cis-regulatory 
feature driving chondrogenesis. We also observed that SOX9-JUN binding in 
chondrocyte quiescent state yielded GO terms related to development of other cells 
and tissues. More research is needed to elucidate how SOX9 and AP-1 binding sites 
change between cell types and processes. 
 
Motif searching using transcription factor ChIP-seq peaks derived from lifted over 
reads (mm10 to hg38) yielded similar results as motif searching in the original mouse 
data (Ohba et al, 2015; He et al, 2016). Transcription factor DNA binding motifs are 
highly conserved between species (Hemberg and Kreiman, 2011). Liftover of genome 
coordinates from different species may not yield such synonymous results if the 
regions exhibit low synteny or if the species are not closely related. Furthermore, some 
loss of data is to be expected. Nonetheless, this shows that it is indeed possible to use 
data from another (albeit closely related) species to uncover biologically useful results. 
This has important implications for genomic research, and bioinformatics as a research 
tool. Although the cost of next-generating sequencing has dramatically decreased in 
recent years, it still remains a monumental task for one research group to gather all 
the datasets required for large scale projects. The sharing of datasets can facilitate 
‘omics research and reduces the burden of generating data for a single group. Mice 
are widely used as a proxy for human research where the use of human cells and 
tissue is prohibitive. Many findings in mice can also be applied to humans, especially 
for highly conserved processes such as development (Breschi et al, 2017). The use of 
a mouse dataset in this analysis can therefore be considered analogous to the use of 
mouse models in laboratory based research.  
 
The term “super enhancer” was coined in 2012 by Richard Young (Whyte et al, 2013). 
The same year, stretch enhancers, defined as long enhancers, were described by 
Francis Collins (Parker et al, 2013). Super enhancers and stretch enhancers may be 
largely synonymous. Since their identification, there has been much interest in super 
enhancers and how they define a cell type and contribute to diseases such as cancer 
(Loven et al, 2014; Niederriter et al, 2015). However, there is some controversy 
surrounding the existence of super enhancers. Critics have claimed that super 
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enhancers do not exist and are simply a series of typical enhancers that happen to be 
in the same genomic region (Pott and Lieb, 2014). Super enhancers may be defined 
by different enhancer markers and therefore, depending on the markers used, reported 
super enhancers may be different even within the same cell type. There are online 
databases containing super enhancers identified in different cell types; however, the 
lack of consensus about what constitutes a super enhancer means these repositories 
can be considerably heterogeneous. Furthermore, the mechanism of how super 
enhancers act is currently unknown, contributing to the uncertainty of super enhancer 
definition. However, there have been many studies investigating super enhancers and 
their role in human development and disease and their existence has been well 
documented. There is no doubt that clusters of enhancers are present in the genome. 
Consequently, the question should not be whether they exist, but rather what do they 
do and how do they do it? There are two main mechanisms proposed for how super 
enhancers regulate gene transcription. It may be that each individual enhancer has an 
additive effect yet still show enhancer activity independent of other enhancers within 
the super enhancer (Hay et al, 2016). The other mechanism proposed is that individual 
enhancers within a super enhancer exhibit little to no independent enhancer activity 
but act synergistically with other neighbouring enhancers to regulate gene expression 
i.e. greater than the sum of its parts (Dukler et al, 2017). It could also be that different 
super enhancers have different mechanisms of action. Regardless of whether super 
enhancers constitute a separate class of enhancers, they have been shown to be 
important regulators of cell specific processes and therefore merit investigation.  
 
In this study, enhancer luciferase reporter assays yielded mixed results. The entire 
super enhancers defined in our dataset were too large to clone into a vector and 
therefore only small sections were selected. Some regions of super enhancers 
exhibited independent enhancer activity suggesting that they do not require other 
enhancers within the same super enhancer to regulate gene transcription. However, 
others did not show any independent enhancer activity. Plasmid constructs are an 
artificial environment for gene enhancers and the plasmid DNA is not surrounded by 
histone proteins as is the case with endogenous chromatin. Vectors are unlikely to 
possess the correct endogenous chromatin domains and therefore the outcomes of 
enhancer luciferase reporter assays may not accurately reflect the process that occurs 
in endogenous chromatin.  Furthermore, the cloned enhancer and luciferase gene may 
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be a lot closer in the vector compared to the enhancer and its target promoter in the 
genome. Overexpression of SOX9 did increase luciferase activity of some enhancer 
constructs in HEK293T cells but not in SW1353 cells. The presence of JUN binding 
peaks was also stipulated in our super enhancer identification criteria. Therefore, it will 
be interesting to observe whether overexpression of JUN (and its binding partner FOS) 
would also increase enhancer activity. Conversely, it will also be of interest to deplete 
SOX9 and JUN-FOS to elucidate whether this decreases enhancer activity.  
 
There are far more enhancers present in the genome than genes (Pennacchio et al, 
2013) and genes may be regulated by more than one enhancer and one enhancer may 
regulate multiple genes (Mohrs et al, 2001). There is evidence that some enhancers 
are partially redundant and act together to fine tune gene expression (Moorthy et al, 
2017). Redundancy in gene enhancers may reflect their role in driving important cell 
specific processes; loss of function of one gene enhancer may also be less detrimental 
if there are several backups. Gene enhancers generally are not evolutionarily 
conserved in mammals and evolve more rapidly than protein coding genes and gene 
promoters (Villar et al, 2015). Exceptions are enhancers involved in regulating 
development genes which are often highly conserved among vertebrates (Plessy et al, 
2005; Visel et al, 2008). 
 
As more and more data is being gathered by researchers, it is crucial to understand 
how data can be consolidated; it is also important to consider what is and what is not 
appropriate to integrate. Groups use different model organisms and systems to study 
a biological process and therefore, although data is being generated, it may not 
necessarily be suitable to apply the data to a different project. The use of high 
throughput chromatin conformation studies to study higher order chromatin structure 
is increasing in popularity due to cheaper next-generation sequencing (Schmitt et al, 
2016). This technology is also used to validate and detect enhancer-promoter 
interactions. Hi-C and 4C studies have been performed on a number of cell types, but 
so far not in chondrocytes. Confirming enhancer-promoter interactions in this project 
has proved impossible without further relevant data. Although we have shown that 
some small sections of super enhancers show independent enhancer activity using 
luciferase reporter assays, it is unknown which genes they directly target.  
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We have consistently shown throughout this project that gene enhancers are cell type 
specific and distinct between cell types. Therefore, it was not considered entirely 
appropriate to integrate chromatin conformation data from other cell types to confirm 
chromatin interactions in chondrocytes. If enhancers are distinct between cell types 
and the main mechanism of enhancers is through physical looping of chromatin, then 
it follows that chromatin conformation will be different between cell types with different 
enhancers. Without chromatin conformation data or other validation, the next best 
approach is to link enhancers to the nearest gene or use other prediction methods. 
Some groups have proposed to link enhancers to the nearest upregulated or active 
gene as a better approach to linking to any nearest gene (Blattler et al, 2014; Zhang 
et al, 2013). Linking to the nearest upregulated gene necessitates the availability of an 
accompanying genome wide transcriptome dataset. Computational tools have been 
designed to aid the prediction of enhancers to target genes, authors of these tools 
have claimed high accuracy and reliability. However, predictive tools are just that and 
experimental validation of gene targets of enhancers is still required to pinpoint their 
gene target and ascertain its importance in the biological process being studied.  
 
siRNA depletion of LOXL1, LOXL2 and LOXL3 during chondrogenesis led to 
downregulation of SOX9 and ACAN gene expression; the decrease in ACAN 
expression may be an indirect effect of SOX9 downregulation. This may point to an 
additional role of LOXL1-3 as transcriptional regulators, potentially independent of their 
established role as collagen and elastin crosslinkers. Previous studies have found that 
the LOXL2 protein has a role in transcriptional regulation (Iturbide et al, 2014). 
However, the ECM in cartilage is not inert and can influence gene expression. Both 
ECM stiffness and mechanical stress affects gene expression and turnover of ECM 
proteins (Allen et al, 2012; Maldonado and Nam, 2013). Therefore, the downregulation 
of SOX9 may be caused by abnormal collagen crosslinking when LOXL1-3 are 
depleted. As SOX9 regulates many chondrogenesis genes, we anticipate that other 
genes are also affected by LOXL1-3 depletion. Further experiments are required to 
fully characterize this potential novel role of LOXL1-3 genes as transcriptional 
regulators or to ascertain whether changes to collagen crosslinking is feeding back to 
regulate gene expression. LOXL3 is predicted to be associated with a super enhancer. 
As siRNA depletion of mRNA levels of these genes led to decreased SOX9 and ACAN 
expression, it will be interesting to investigate whether targeting the enhancers to 
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disrupt gene expression would also lead to a downregulation of SOX9 and other genes 
during chondrogenesis.  
 
To conclude this chapter, we have utilized external cross-species datasets to aid the 
interrogation of our chondrogenesis histone ChIP-seq experiment. Using this 
integrated data, we identified chondrocyte super enhancers. Sections of super 
enhancers were confirmed to exhibit independent enhancer activity using luciferase 
reporter assays. We used siRNAs to deplete the LOXL family of genes and found that 
LOXL1-3 may act to regulate the transcriptional programme necessary for 
chondrogenesis.  Further investigations are required to fully elucidate super enhancer 
mechanisms and the genes they target.   
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6.5 Conclusion 
 
• Analysis of mouse Sox9 and Jun ChIP-seq data lifted over to human 
coordinates achieved expected outcomes. Lifted over SOX9 and JUN co-bind 
at strong promoters, strong enhancers and quiescent chromatin states.  
 
• We identified 746 chondrocyte super enhancers, defined by strong enhancer 
states and JUN and SOX9 co-binding.  
 
• Luciferase activity assays showed that some regions of super enhancers 
displayed independent enhancer activity 
 
• siRNA depletion of LOXL1, LOXL2 and LOXL3 resulted in the downregulation 
of SOX9 and ACAN, indicating that these genes could act as transcriptional 
regulators – a role not previously described for LOXL1 or LOXL3.  
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Chapter 7. General discussion 
 
7.1 Summary and main findings 
 
The epigenome of an in vitro model of chondrogenesis was investigated by generating 
a histone modification ChIP-seq dataset (H3K4me3, H3K4me1, H3K27ac, H3K27me3 
and H3K36me3). RNA-seq of the same chondrogenesis model was also generated. 
Histone mark enrichments correlated with the level of gene expression but a change 
in enrichment of single marks did not correlate with gene expression changes. The 
software ChromHMM was used to characterise 16 distinct chromatin states using the 
histone ChIP-seq dataset; cis-regulatory elements such as promoters and enhancers 
were included. Pathway analysis showed that enhancers were associated with cell 
type specific GO terms. Similarity analysis with Roadmap epigenomes found that 
enhancers are more distinct between cell types compared to other chromatin states. 
DNA 450k methylation arrays were performed for chondrogenesis, osteoblastogenesis 
and adipogenesis. Enhancers marked by H3K4me1 and H3K27ac were found to be 
de-methylated during chondrogenesis and osteoblastogenesis but not adipogenesis. 
Chondrocyte super enhancers were identified with the aid of publically available mouse 
Sox9 and c-Jun ChIP-seq datasets. Selected regions of chondrocyte super enhancers 
were cloned into PGL3-promoter vector and luciferase assays showed that some 
regions exhibited independent enhancer activity whilst others did not. The LOXL family 
of genes have previously defined roles as enzymes involved in collagen cross-linking. 
We observed that LOXL3 may be associated with a super enhancer. We found that 
siRNA depletion of LOXL1, LOXL2 and LOXL3 resulted in the downregulation of SOX9 
and ACAN during chondrogenesis. The LOXL family of genes may potentially have a 
role in transcriptional regulation that is independent of their roles as collagen cross-
linkers.  
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7.2 Limitations and caveats 
 
We differentiated hMSCs into chondrocytes using a scaffold-free transwell model of 
chondrogenesis. Chondrocytes were isolated from the cartilage-like disc that forms in 
the transwell insert using enzyme digestion prior to chromatin extraction. However, 
enzymatic digestion at 37oC can lead to altered gene expression (Hayman et al, 2006) 
and potentially histone modification changes. Enzyme incubation times were optimised 
to minimise potential disruption to cells. However, it is unknown if and to what extent 
the enzyme digestion steps had on the isolated chondrocytes. hMSC donors are 
variable and therefore multiple donors are required to minimise any individual donor 
effects. In this project, ChIP-seq was performed using two hMSC donors. Whilst two 
independent biological replicates are considered enough by ENCODE (Landt et al, 
2012), other studies have found that three or more replicates reduces technical noise 
(Yang et al, 2014). Using additional hMSC donors and thus more replicates was not 
possible due to financial constraints. QC of ChIP-seq data found that one replicate was 
inferior to the other, possibly due to excess PCR amplification during the library 
preparation step.  
 
It is impossible to confirm co-localisation of histone marks in the same cell in ChIP-seq 
data generated from a population of heterogeneous cells. Consequently, single cell or 
sequential ChIP-seq (ChIP using fragments from a previous ChIP) may be better 
options for assaying co-occurrence of histone marks and transcription factors in the 
same cell.  
 
We observed that differential DNA methylation during chondrogenesis occurs in 
enhancer regions more than promoters. However, probes on the 450K array are biased 
towards promoters; less than 5% of probes were located in chondrocyte enhancers 
marked by H3K4me1 and H3K27ac. There are 28 million CpG sites in the human 
genome (Lövkvist et al, 2016). Therefore, genome-wide bisulfite sequencing is a more 
suitable method to assay all CpG sites in the genome. Furthermore, material used for 
chondrogenesis RNA-seq and DNA 450k array was collected from different 
experiments. Although the same chondrogenesis model was used, cells may be 
subject to slightly different conditions. Additionally, cells in a population may be at 
slightly different stages of chondrogenesis upon nucleic acid isolation.  
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To identify super enhancers, mouse rib chondrocyte Sox9 and c-Jun ChIP-seq reads 
were converted into human genome co-ordinates prior to peak calling. The MACS2 
signal value of SOX9 peaks derived from mouse were used to identify super enhancers 
in differentiated chondrocytes. Whilst subsequent pathway analysis of chondrocyte 
super enhancers yielded GO terms associated with chondrogenesis, the use of mouse 
datasets in lieu of human is not ideal. A human SOX9 or JUN ChIP-seq dataset was 
not publically available. UCSC liftover between different genome assemblies relies on 
DNA sequence homology and synteny (Kuhn et al, 2012). The SOX family of 
transcription factors is highly conserved both at the protein level (Kamachi and 
Kondoh, 2013) as well as the gene level (Jager et al, 2011) including the consensus 
binding motif. Our liftover and motif analysis confirmed the presence of the SOX9 (and 
JUN) motif in syntenic human genomic regions. However, lifted over data only 
encompasses SOX9 (and JUN) peaks that are conserved between human and mouse. 
The use of data in this way naturally excludes human specific binding sites and the 
mouse specific data is lost during the liftover process. Whilst we acknowledge this 
disadvantage and the limitations of the method, it can also be argued that the 
conserved binding sites between human and mouse are the most important for 
development as evolutionary conservation is a positive indicator of functional 
importance (Georgi et al, 2013).  
 
Another chondrogenesis histone ChIP-seq dataset is available from Roadmap 
Epigenomics, generated from a 3D alginate scaffold model of chondrogenesis. The 
associated publication became available early on during this project (Herlofsen et al, 
2013) and we contacted the authors for access to the raw data. However, this was not 
provided and did not become publically available until the publication of Roadmap’s 
flagship paper in 2015. We have provided integrated DNA 450k methylation data and 
histone ChIP-seq of the same model of chondrogenesis. Whilst we could have used 
the existing chondrogenesis histone ChIP-seq data once it was released, integrating 
data from the same model from the same laboratory reduces batch effects and 
eliminates the presence of model specific effects. Herlofsen et al also attempted to 
integrate DNA methylation and cDNA microarray data with their histone ChIP-seq data. 
They observed a correlation between potential H3K4me1 and H3K27ac marked 
enhancers with gene expression but did not observe a correlation of DNA methylation 
 
 
 223 
with gene expression. However, Herlofsen et al used reduced representation bisulfite 
sequencing (RRBS) to quantify DNA methylation which only effectively assays CpG 
dense regions like promoters. This is in agreement with our analysis as we also did not 
observe major DNA methylation changes at gene promoters. Crucially, Herlofsen et al 
did not integrate the RRBS data with the histone ChIP-seq data, although it is unclear 
whether DNA methylation at enhancers would be detected using the RRBS method. 
Therefore, our study offers a valuable insight into the connection between histone 
modifications and the DNA methylome during chondrogenesis. Despite being from a 
different in vitro model, similarity analysis showed that our chondrocyte enhancers 
clustered with chondrocyte enhancers from Herlofsen et al. This shows that there is a 
distinct chondrocyte epigenome which can be identified regardless of culture methods 
and conditions. However, neither the Herlofsen et al. study nor this project defined a 
complete reference epigenome for human chondrocytes according to new guidelines 
from the International Human Epigenome Consortium (IHEC) due to the lack of 
H3K9me3 mark in our study and absence of whole genome bisulfite sequencing 
(WGBS) in both studies. IHEC consists of multiple international epigenomics consortia 
such as ENCODE, Roadmap Epigenomics, European BLUEPRINT, Canadian 
Epigenetics Environment and Hong Kong Epigenomics project (Stunnenberg et al, 
2016). IHEC aims to co-ordinate the efforts of the various member consortia to 
streamline epigenomics research by defining global guidelines and sharing data, 
methods and bioinformatics tools. Consequently, WGBS is required in chondrocytes 
to satisfy the IHEC stipulations for a minimal reference epigenome.   
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7.3 Future work 
 
In this project, potential enhancers and super enhancers have been identified. Future 
work includes validation of enhancer-promoter pairings and possible modulation of 
chondrogenesis by targeting cis-regulatory elements. The CRISPR-Cas9 genome 
editing system may be modified to direct transcriptional co-activators or repressors to 
chosen loci in the genome. This may also help to elucidate the mechanism of how 
super enhancers regulate transcription. Chromatin conformation assays can be used 
to confirm predicted connections and discover new interactions. Single interactions 
may be assayed using the 3C method or genome wide using Hi-C.  
 
Further computational work could include network analysis of enhancers to elucidate 
the association between different enhancers and the genes they potentially regulate. 
This could also classify genes that are regulated by similar epigenetic mechanisms. 
Some regions of the genome originally thought to be non-coding are in fact, 
transcribed. There is evidence that enhancers may be transcribed (Li et al, 2016). 
Enhancer RNAs (eRNAs) are RNA molecules transcribed from the nucleotide 
sequence of enhancers and may regulate genes both in cis and trans (Lam et al, 2014). 
Identification of eRNAs in chondrocytes and investigation into whether they are 
transcribed may be incorporated into future studies. We have investigated briefly the 
DNA methylation changes in chromatin states of osteoblasts and adipocytes during 
differentiation of hMSCs. Further larger studies involving more samples and other 
differentiation processes would be of interest to elucidate the mechanisms ubiquitous 
to all differentiation processes, and those unique to chondrogenesis. Traditional DNA 
methylation assays such as the 450k array do not distinguish between 5mC and 5hmC. 
The 5hmC mark is associated with gene activation during chondrogenesis (Taylor et 
al, 2016).  Therefore, it will be interesting to include this data for more complete picture 
of the epigenomic changes during chondrogenesis.  
 
We had hoped to visualise and quantify collagen crosslinking after depletion of LOXL1-
4 genes but this was not feasible within the timeframe of this project. Therefore, 
subsequent studies could use techniques such as atomic force microscopy to visualise 
collagen fibrils and mass spectrometry methods to quantify crosslinking (Eyre et al, 
2008).  
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Performing ChIP-seq in an in vitro model of chondrogenesis opens up the possibility 
of further ChIP-seq studies in normal human articular chondrocytes or diseased 
chondrocytes. Comparisons between normal and diseased chondrocytes may uncover 
the epigenetic mechanisms associated with disease. With this project, we have built 
the foundations for other studies into the epigenetics of chondrocytes.  
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7.4 Contribution to epigenomics research 
 
Genome-wide methods involving high throughput sequencing are becoming more 
widespread and there are many consortia established to generate and share 
sequencing data. Although a histone ChIP-seq dataset for differentiated chondrocytes 
exists as part of the Epigenomics Roadmap project, this project offers a more in depth 
investigation into the chondrocyte epigenome. We hope to publish this work and make 
our data publically available so other research groups can benefit from the findings.  
 
The general areas of biology this project belongs to includes molecular biology, 
genomics and its subfield, epigenomics. How epigenetic mechanisms regulate 
biological processes and contribute to disease has received increasing attention over 
the past 20 years (Ebrahim, 2012). The non-coding majority of the genome was 
previously thought to contain noise of no biological importance. It is now clear that so 
called “junk DNA” is not junk at all and contains features necessary for the regulation 
of gene transcription (Pallazo and Lee, 2015) and also has implications for genome 
evolution (Juan et al, 2013). Epigenetic marks can be found in both coding and non-
coding regions of the genome. This is the first study, to our knowledge, to observe a 
global de-methylation of enhancers during chondrogenesis. Super enhancers are 
reported to target genes involved in cell identity. In this project, we have identified 
super enhancers in differentiated chondrocytes. Chondrocyte super enhancers are not 
currently part of the repertoire of super enhancers present in the dbSUPER database 
(Khan and Zhang, 2016). Once published, we can recommend that these be included 
in future releases.  
 
This PhD project has contributed to the body of literature documenting the epigenetic 
marks and regulatory elements present within the genome. This project utilised a 
bioinformatics approach to analyse, integrate and interpret data. Modern 
bioinformatics is a relatively new and emerging field and is evolving at a fast rate. 
Bioinformatics was originally seen as a biological tool rather than a field in its own right 
(Hagen, 2000). However, bioinformatics is now ubiquitous in biology and has become 
a fundamental discipline (Kanehisa and Bork, 2003; Hogeweg, 2011). An important 
distinction must be made between a bioinformatics researcher or scientist, and a 
bioinformatics developer or engineer. The bioinformatics researcher applies tools to 
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analyse biological data, discover new information, and generate or confirm 
hypotheses. In contrast, bioinformatics developers generally focus on designing and 
building new tools (Smith, 2015).  Whilst there can be overlap between the two, most 
bioinformaticians can be broadly defined as one or the other and the skillsets required 
for each role are different. This project used and adapted existing bioinformatics tools 
to answer biological questions rather than developing a new tool or resource. However, 
this project has illustrated how integral bioinformatics methods are to ‘omics research.  
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Appendix i 
 
 
 
Appendix I Figure 1  – MultiQC report of read quality scores for all histone ChIP-seq samples from hMSC donor 8a (replicate 
1). All read samples achieved a quality score above 30.  
 
 
Appendix I Figure 2 – MultiQC report of read quality scores for all histone ChIP-seq samples from hMSC donor 2454e 
(replicate 2). The mean quality score across samples was between 30 and 40.  
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Appendix I Table 1 – MutiQC report of percentage duplication, GC content and total reads of histone ChIP-seq samples from 
hMSC donor 8a (replicate 1). 
Sample Name Sample ID % Dups % GC M Seqs 
CHON H3K4me1 CHE_sample_10_CAGATCTG_L007_R1_001 73.6% 39% 57.6 
CHON H3K27ac CHE_sample_11_GCCAATGT_L007_R1_001 44.2% 38% 52.8 
CHON H3K27me3 CHE_sample_12_CTTGTACT_L004_R1_001 92.6% 41% 56.2 
CHON H3K36me3 CHE_sample_13_CTTGTACT_merged 91.5% 39% 64.5 
CHON IgG CHE_sample_14_CTTGTACT_L007_R1_001 41.5% 40% 54.2 
MSC input CHE_sample_1_TGACCACT_merged 60.6% 36% 54.8 
MSC H3K4me3 CHE_sample_2_TGACCACT_L004_R1_001 40.0% 41% 54.4 
MSC H3K4me1 CHE_sample_3_CAGATCTG_L006_R1_001 81.9% 39% 65.9 
MSC H3K27ac CHE_sample_4_GCCAATGT_L006_R1_001 25.9% 42% 43.8 
MSC H3K27me3 CHE_sample_5_GCCAATGT_L004_R1_001 89.2% 36% 56.5 
MSC H3K36me3 CHE_sample_6_GCCAATGT_merged 91.7% 39% 56.1 
MSC IgG CHE_sample_7_CTTGTACT_L006_R1_001 26.3% 40% 46.3 
CHON input CHE_sample_8_CAGATCTG_merged 74.3% 38% 61.9 
CHON H3K4me3 CHE_sample_9_CAGATCTG_L004_R1_001 81.6% 40% 55.9 
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Appendix I Table 2 - MultiQC report of percentage duplication, GC content and total reads of histone ChIP-seq samples from 
hMSC donor 2454e (replicate 2) 
Sample Name Sample ID % Dups % GC M Seqs 
CHON H3K4me3 (reseq) 08_S1_L001_R1_001 4.5% 44% 18.6 
MSC input KC01-David-Young_S1_L001_R1_001 2.9% 40% 9.7 
MSC input KC01-David-Young_S1_L002_R1_001 2.9% 40% 9.6 
MSC input KC01-David-Young_S1_L003_R1_001 3.0% 40% 10.1 
MSC input KC01-David-Young_S1_L004_R1_001 3.0% 40% 10.1 
MSC H3K4me3 KC02-David-Young_S2_L001_R1_001 4.5% 48% 20.7 
MSC H3K4me3 KC02-David-Young_S2_L002_R1_001 4.5% 48% 20.6 
MSC H3K4me3 KC02-David-Young_S2_L003_R1_001 4.7% 48% 21.5 
MSC H3K4me3 KC02-David-Young_S2_L004_R1_001 4.7% 48% 21.4 
MSC H3K4me1 KC03-David-Young_S3_L001_R1_001 1.7% 42% 7.9 
MSC H3K4me1 KC03-David-Young_S3_L002_R1_001 1.6% 42% 7.8 
MSC H3K4me1 KC03-David-Young_S3_L003_R1_001 1.7% 43% 8.1 
MSC H3K4me1 KC03-David-Young_S3_L004_R1_001 1.7% 43% 8.1 
MSC H3K27ac KC04-David-Young_S4_L001_R1_001 2.1% 44% 9.3 
MSC H3K27ac KC04-David-Young_S4_L002_R1_001 2.1% 44% 9.3 
MSC H3K27ac KC04-David-Young_S4_L003_R1_001 2.3% 44% 9.7 
MSC H3K27ac KC04-David-Young_S4_L004_R1_001 2.2% 44% 9.6 
MSC H3K27me3 KC05-David-Young_S5_L001_R1_001 3.8% 43% 13.1 
MSC H3K27me3 KC05-David-Young_S5_L002_R1_001 3.8% 43% 13.0 
MSC H3K27me3 KC05-David-Young_S5_L003_R1_001 3.9% 43% 13.6 
MSC H3K27me3 KC05-David-Young_S5_L004_R1_001 3.9% 43% 13.6 
MSC H3K36me3 KC06-David-Young_S6_L001_R1_001 4.9% 43% 16.0 
MSC H3K36me3 KC06-David-Young_S6_L002_R1_001 5.0% 43% 15.9 
MSC H3K36me3 KC06-David-Young_S6_L003_R1_001 5.0% 43% 16.6 
MSC H3K36me3 KC06-David-Young_S6_L004_R1_001 4.9% 43% 16.5 
CHON input KC07-David-Young_S7_L001_R1_001 2.9% 40% 10.4 
CHON input KC07-David-Young_S7_L002_R1_001 2.8% 40% 10.2 
CHON input KC07-David-Young_S7_L003_R1_001 2.9% 40% 10.7 
CHON input KC07-David-Young_S7_L004_R1_001 2.9% 40% 10.6 
CHON H3K4me3 KC08-David-Young_S8_L001_R1_001 1.8% 44% 3.4 
CHON H3K4me3 KC08-David-Young_S8_L002_R1_001 1.8% 44% 3.3 
CHON H3K4me3 KC08-David-Young_S8_L003_R1_001 1.9% 44% 3.5 
CHON H3K4me3 KC08-David-Young_S8_L004_R1_001 1.8% 44% 3.5 
CHON H3K4me1 KC09-David-Young_S9_L001_R1_001 2.5% 42% 13.3 
CHON H3K4me1 KC09-David-Young_S9_L002_R1_001 2.4% 42% 13.2 
CHON H3K4me1 KC09-David-Young_S9_L003_R1_001 2.6% 42% 13.9 
CHON H3K4me1 KC09-David-Young_S9_L004_R1_001 2.5% 42% 13.8 
CHON H3K27ac KC10-David-Young_S10_L001_R1_001 2.6% 42% 13.5 
CHON H3K27ac KC10-David-Young_S10_L002_R1_001 2.6% 42% 13.3 
CHON H3K27ac KC10-David-Young_S10_L003_R1_001 2.7% 42% 14.0 
CHON H3K27ac KC10-David-Young_S10_L004_R1_001 2.7% 42% 13.9 
CHON H3K27me3 KC11-David-Young_S11_L001_R1_001 3.5% 42% 9.7 
CHON H3K27me3 KC11-David-Young_S11_L002_R1_001 3.5% 42% 9.6 
CHON H3K27me3 KC11-David-Young_S11_L003_R1_001 3.7% 42% 10.0 
CHON H3K27me3 KC11-David-Young_S11_L004_R1_001 3.6% 42% 9.9 
CHON H3K36me3 KC12-David-Young_S12_L001_R1_001 6.1% 41% 13.0 
CHON H3K36me3 KC12-David-Young_S12_L002_R1_001 6.2% 41% 12.9 
CHON H3K36me3 KC12-David-Young_S12_L003_R1_001 6.3% 41% 13.5 
CHON H3K36me3 KC12-David-Young_S12_L004_R1_001 6.2% 41% 13.5 
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Appendix I Table 3 – Read numbers for ChIP-seq samples from both replicates.  
Replicate Sample name 
total 
reads 
reads 
mapped 
% 
mapped RPM scale 
Duplicate 
mapped 
reads 
Uniquely 
mapped 
reads 
1  MSC_input 54781975 53567485 97.78 0.018668041 32337393 21230092 
1 MSC_H3K4me3 54445014 53322473 97.94 0.018753819 21879648 31442825 
1 MSC_H3K4me1 65871548 59759649 90.72 0.016733699 50705654 9053995 
1 MSC_H3K27ac 43783953 43190153 98.64 0.023153426 11186827 32003326 
1 MSC_H3K27me3 56478748 40585867 71.86 0.024639119 37171899 3413968 
1  MSC_H3K36me3 56134283 30653142 54.61 0.032623083 29045392 1607750 
1  CHON_input 61900480 59199642 95.64 0.016891994 43738430 15461212 
1 CHON_H3K4me3 55885851 53115817 95.04 0.018826784 44172842 8942975 
1 CHON_H3K4me1 57644630 54247873 94.11 0.018433902 41224176 13023697 
1 CHON_H3K27ac 52782375 51879594 98.29 0.019275401 23602573 28277021 
1 CHON_H3K27me3 56168560 21819215 38.85 0.045831163 20627085 1192130 
1  CHON_H3K36me3 64468380 39477404 61.24 0.025330946 36724666 2752738 
2 MSC_input 39546203 38857682 98.26 0.025734937 1634899 37222783 
2 MSC_H3K4me3 84082773 82398018 98 0.012136214 11644251 70753767 
2 MSC_H3K4me1 31948658 31379659 98.22 0.031867778 1115069 30264590 
2 MSC_H3K27ac 37842038 37118603 98.09 0.026940669 2006616 35111987 
2 MSC_H3K27me3 53281894 52109519 97.8 0.019190352 2973659 49135860 
2 MSC_H3K36me3 65120119 63548834 97.59 0.01573593 4111910 59436924 
2 CHON_input 41956694 41325393 98.5 0.024198197 1893984 39431409 
2  CHON_H3K4me3 32248437 31633522 98.09 0.031612035 1382639 30250883 
2 CHON_H3K4me1 54224635 53290514 98.28 0.018765066 3080637 50209877 
2 CHON_H3K27ac 54669205 53504496 97.87 0.018690018 3064249 50440247 
2 CHON_H3K27me3 39173561 38335139 97.86 0.026085728 1966391 36368748 
2 CHON_H3K36me3 52824567 51546571 97.58 0.019399933 3620732 47925839 
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Appendix I Figure 3 – H3K4me3 read density plot. H3K4me3 reads are mainly located close to the TSS of genes. 
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Appendix I Figure 4 – Read densities for enhancer marks H3K4me1 and H3K27ac. High densities of H3K4me1 sample reads 
are located on either side of the TSS. H3K27ac reads were seen at the TSS as well as around the TSS.  
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Appendix I Figure 5 – Read densities of H3K27me3 and H2K36me3 samples. Samples from donor 071508A had fewer reads 
than 2454e in the region shown (+/- 6000bp from TSS).   
 
 
 235 
 
 
 
 
 
Appendix I Figure 6 – NSC and RSC plots for H3K4me3 sample. The blue dotted line shows the phantom peak, corresponding 
to read length. The red dotted lines show the best estimations of fragment length, with values given in brackets below the 
plot. NSC, RSC and quality values are also given below the plots. Qtags are based on RSC values and ranges from -2 to 2, 
with higher values indicating better quality  
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Appendix I Figure 7 – NSC and RSC plots for H3K4me1 samples 
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Appendix I Figure 8 – NSC and RSC plots for H3K27ac samples 
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Appendix I Figure 9 – NSC and RSC plots for H3K27me3 samples 
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Appendix I Figure 10 – NSC and RSC plots for H3K36me3 plots 
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Appendix ii 
 
 
 
Appendix ii Figure 1 – Quality scores after trimming for chondrogenesis RNA-seq samples. FastQC 
was performed individually for each sample before summarising using MultiQC 
 
 
 
 
Appendix ii Table 1 – MultiQC general statistic report of chondrogenesis RNA-seq paired end reads 
after trimming 
SAMPLE NAME % DUPS % GC M SEQS 
TRIMMED_DAY0_1 54.4% 50% 52.8 
TRIMMED_DAY0_2 55.8% 52% 52.8 
TRIMMED_DAY14_1 68.6% 52% 47.5 
TRIMMED_DAY14_2 69.3% 54% 47.5 
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Appendix ii Figure 2 – Gene expression (TPM) density plots at for chondrogenesis samples day 0 (A) 
and day 14 (B)  
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Appendix iii 
 
 
Appendix iii Table 1 – Chromatin state emission parameters. Output by ChromHMM 
state (User 
order) 
H3K4me3 H3K4me1 H3K27ac H3K27me3 H3K36me3 
1 0.816024963 0.072049299 0.038605152 0.020246479 0.016770888 
2 0.992609078 0.056259084 0.939698616 0.003763232 0.00425547 
3 0.902509445 0.88670947 0.158882985 0.009916558 0.015085619 
4 0.941394687 0.673942642 0.559298287 0.003135921 0.900152465 
5 0.022041174 0.597236878 0.132133207 0.001149502 0.645764563 
6 0.792054808 0.261267951 0.032311347 0.860093383 0.067220417 
7 0.004623883 0.005450119 0.008333466 0.03397753 0.26372209 
8 0.003027268 0.006516287 0.023162381 0.004902518 0.939459581 
9 0.958937942 0.971008904 0.951671278 8.99E-04 0.025467969 
10 0.007150536 0.065843825 0.541856976 8.41E-04 0.893499464 
11 0.071764218 0.865330674 0.858478997 5.10E-04 0.807737025 
12 0.00555704 0.063212405 0.474481827 0.005120965 0.020984179 
13 0.046431507 0.901302483 0.837542311 6.24E-04 0.012490048 
14 0.016378588 0.669189546 0.065174242 0.005394518 0.006239919 
15 0.006275049 0.004557815 0.002835327 0.516957667 0.015594047 
16 0.001318563 0.002559291 0.00222194 0.013031156 0.004085968 
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Appendix iii Table 2 – Chromatin state overlap enrichment categories in hMSCs 
 
 
 
Appendix iii Table 3 – Chromatin state overlap enrichment categories in chondrocytes 
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Appendix iii Figure 1 - GREAT gene ontology analysis for hMSC 1_TssA chromatin state. (A) number of 
associated genes, (B) distance to TSS and (C) biological process GO terms 
 
Appendix iii Figure 2 - GREAT gene ontology analysis for CHON 1_TssA chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 3 - GREAT gene ontology analysis for hMSC 2_TssS chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 4 - GREAT gene ontology analysis for CHON 2_TssS chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 5 - GREAT gene ontology analysis for hMSC 3_TssFlnk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 6 - GREAT gene ontology analysis for hMSC 3_TssFlnk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms  
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Appendix iii Figure 7 - GREAT gene ontology analysis for hMSC 4_TssFlnkU chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
 
Appendix iii Figure 8 - GREAT gene ontology analysis for CHON 4_TssFlnkU chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 9 - GREAT gene ontology analysis for hMSC 5_TssFlnkD chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 10 - GREAT gene ontology analysis for CHON 5_TssFlnkD chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 11 - GREAT gene ontology analysis for hMSC 6_TssBiv chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 12 - GREAT gene ontology analysis for CHON 6_TssBiv chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 13 - GREAT gene ontology analysis for hMSC 7_TxWk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 14 - GREAT gene ontology analysis for CHON 7_TxWk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 15 - GREAT gene ontology analysis for hMSC 8_TxS chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 16 - GREAT gene ontology analysis for CHON 8_TxS chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 17 - GREAT gene ontology analysis for hMSC 9_TxFlnk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 18 - GREAT gene ontology analysis for CHON 9_TxFlnk chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms  
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Appendix iii Figure 19 - GREAT gene ontology analysis for hMSC 10_EnhG1 chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 20 - GREAT gene ontology analysis for CHON 10_EnhG1 chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
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Appendix iii Figure 21 - GREAT gene ontology analysis for hMSC 11_EnhG2 chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 22 - GREAT gene ontology analysis for hMSC 11_EnhG2 chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms  
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Appendix iii Figure 23 - GREAT gene ontology analysis for hMSC 12_EnhA chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 24 - GREAT gene ontology analysis for CHON 12_EnhA chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms   
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Appendix iii Figure 25 - GREAT gene ontology analysis for hMSC 14_EnhP chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 26 - GREAT gene ontology analysis for hMSC 14_EnhP chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms  
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Appendix iii Figure 27 - GREAT gene ontology analysis for hMSC 15_Repr chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 28 - GREAT gene ontology analysis for CHON 15_Repr chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms  
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Appendix iii Figure 29 - GREAT gene ontology analysis for hMSC 16_Quies chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms 
 
Appendix iii Figure 30 - GREAT gene ontology analysis for CHON 16_Quies chromatin state. (A) number of 
associated genes, (B) distance to TSS, (C) biological process GO terms   
 
 
 259 
 
Appendix iii Figure 31 – Principal component analysis of equivalent (A) active promoter states (1_TssA vs 
2_TssS) and (B) weak enhancer/poised enhancer (11_EnhWk vs 14_EnhP) states between Roadmap 18 state 
model and chondrogenesis 16 state model. hMSC and differentiated chondrocytes are circled on the plot. PCA 
plot was generated using ggplot2 in RStudio.  
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Appendix iii Figure 34 - Principal component analysis of equivalent strong transcription states (A) and weak 
transcription states (B) between Roadmap 18 state model and chondrogenesis 16 state model. hMSC and 
differentiated chondrocytes are circled on the plot. PCA plot was generated using ggplot2 in RStudio. 
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Appendix iii Figure 37 – Principal component analysis of equivalent quiescent states (A) and repressed states (B) 
between Roadmap 18 state model and chondrogenesis 16 state model. hMSC and differentiated chondrocytes 
are circled on the plot. PCA plot was generated using ggplot2 in RStudio. 
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Appendix iii Figure 40 – DNA methylation distribution of samples prior to normalisation 
 
 
Appendix iii Figure 41 – DNA methylation distribution of samples after functional normalisation in minfi 
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Appendix iii Table 4 - Empirical distribution of DNA methylation changes (delta beta) between hMSC and 
differentiated chondrocytes in chondrocyte chromatin states 
CHON state Min 1st quarter Median  Mean 3rd quarter Max 
1_TssA -0.6188 -0.009713 -0.002017 -0.00581 0.001862 0.2052 
2_TssS -0.6332 -0.005231 -0.00146 -0.00392 0.0009095 0.1869 
3_TssFlnk -0.7435 -0.0147 -0.003249 -0.008072 0.002796 0.3083 
4_TssFlnkU -0.4716 -0.02324 -0.00204 -0.01404 0.01102 0.08802 
5_TssFlnkD -0.5295 -0.01052 0.0007305 -0.00604 0.01325 0.3794 
6_TssBiv -0.2584 -0.01371 -0.003269 -0.006599 0.001716 0.1608 
7_TxWk -0.4573 -0.01347 -0.0005072 -0.003695 0.009153 0.1624 
8_TxS -0.5169 -0.006201 0.001349 0.001007 0.01134 0.1689 
9_TxFlnk -0.841 -0.02058 -0.004874 -0.01731 0.001844 0.2256 
10_EnhG1 0.2286 -0.007144 0.001484 0.0008697 0.01286 0.1384 
11_EnhG2 -0.672 -0.01518 0.000193 -0.01198 0.01114 0.129 
12_EnhA -0.7849 -0.01518 -0.001214 -0.009232 0.008849 0.2007 
13_EnhS -0.9286 -0.0473 -0.009413 -0.04137 0.005245 0.3959 
14_EnhP -0.8519 -0.0284 -0.004783 -0.02006 0.008739 0.4673 
15_Repr -0.3769 -0.02206 -0.006423 -0.009258 0.005397 0.1459 
16_Quies -0.7053 -0.02331 -0.005419 -0.01031 0.005948 0.2825 
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Appendix iii Table 5 - Empirical distribution of DNA methylation changes (delta beta) between hMSC and 
differentiated osteoblasts in Roadmap E129 chromatin states 
E129 state Min 1st quarter Median  Mean 3rd quarter Max 
1_TssA -0.43340 -0.00217 -0.00023 -0.00053 0.00180 0.18130 
2_TssFlnk -0.23010 -0.00353 -0.00043 -0.00090 0.00260 0.17870 
3_TssFlnkU -0.65220 -0.00696 -0.00045 -0.00349 0.00470 0.18090 
4_TssFlnkD -0.44120 -0.00700 -0.00015 -0.00064 0.00689 0.17880 
5_Tx -0.37300 -0.01193 -0.00191 -0.00367 0.00521 0.67330 
6_TxWk -0.47540 -0.01277 -0.00193 -0.00324 0.00696 0.21010 
7_EnhG1 -0.54080 -0.01579 -0.00300 -0.00591 0.00705 0.12750 
8_EnhG2 -0.42520 -0.01901 -0.00406 -0.00915 0.00595 0.13160 
9_EnhA1 -0.70750 -0.02582 -0.00551 -0.01781 0.00517 0.12870 
10_EnhA2 -0.44080 -0.01663 -0.00289 -0.00741 0.00675 0.15830 
11_EnhWk -0.73650 -0.01936 -0.00309 -0.00840 0.00959 0.17260 
12_ZNF_Rpts -0.10350 -0.01132 -0.00041 0.00043 0.01230 0.10070 
13_Het -0.11280 -0.00739 0.00434 0.00548 0.01921 0.14560 
14_TssBiv -0.15800 -0.00320 -0.00006 0.00102 0.00451 0.14630 
15_EnhBiv -0.24280 -0.00557 0.00023 0.00126 0.00788 0.22200 
16_ReprPC -0.24840 -0.00807 0.00012 0.00084 0.00992 0.17620 
17_ReprPCWk -0.30630 -0.01084 0.00079 0.00116 0.01402 0.27990 
18_Quies -0.46420 -0.01191 0.00027 0.00024 0.01337 0.29740 
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Appendix iii Table 6 - Empirical distribution of DNA methylation changes (delta beta) between hMSC and 
differentiated adipocytes in Roadmap E063 chromatin states 
E063 state Min 1st quarter Median  Mean 3rd quarter Max 
1_TssA -0.1597 -0.00109 0.0003925 0.001164 0.00253 0.1719 
2_TssFlnk -0.1155 -0.001295 0.0004909 0.002082 0.003486 0.146 
3_TssFlnkU -0.1739 -0.001702 0.0009707 0.002168 0.00527 0.136 
4_TssFlnkD -0.141 -0.002043 0.001076 0.002604 0.006783 0.1807 
5_Tx -0.1621 -0.007228 0.0001078 0.0002887 0.00677 0.3799 
6_TxWk -0.3052 -0.006806 0.001209 0.002437 0.01082 0.2985 
7_EnhG1 -0.162 -0.007198 0.000525 0.001325 0.009332 0.1248 
8_EnhG2 -0.08794 -0.006185 0.001206 0.001991 0.0105 0.1474 
9_EnhA1 -0.148 -0.005908 0.002052 0.003185 0.01245 0.1539 
10_EnhA2 -0.1294 -0.008043 0.001141 0.002266 0.01223 0.137 
11_EnhWk -0.2227 -0.005551 0.002087 0.003602 0.01262 0.1536 
12_ZNF_Rpts -0.1179 -0.004248 0.004799 0.005729 0.01597 0.1203 
13_Het -0.1189 -0.003935 0.006 0.007768 0.01882 0.12 
14_TssBiv -0.1252 -0.001627 0.001065 0.003016 0.006569 0.1152 
15_EnhBiv -0.1066 -0.002173 0.001792 0.003839 0.009527 0.1621 
16_ReprPC -0.219 -0.003583 0.003034 0.004866 0.01348 0.1744 
17_ReprPCWk -0.1533 -0.004556 0.004344 0.005932 0.01638 0.2593 
18_Quies -0.1792 -0.005752 0.003936 0.005736 0.01691 0.1603 
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Appendix IV 
 
 
 
Appendix IV Table 1 – All matches to the top 3 motifs found by MEME in the top 500 significant SOX9 peaks 
Database No. Logo No. 
matches 
Matches 
MEME 1 
 
 
 
 
 
 
 
16 MA0528.1 
(ZNF263), 
MA0162.2 (EGR1), 
MA0516.1 (SP2), 
UP00021_1 
(Zfp281_primary), 
MA0469.1 (E2F3), 
ZNF740_full, 
MA0079.3 (SP1), 
ZNF740_DBD, 
MA0014.2 (PAX5), 
Zfp740_DBD, 
UP00022_1 
(Zfp740_primary), 
MA0470.1 (E2F4), 
UP00043_2 
(Bcl6b_secondary), 
MA0073.1 
(RREB1), 
UP00002_1 
(Sp4_primary), 
SP3_DBD 
 
MEME 2  
 
 
 
 
7 MA0143.3 
(Sox2), 
MA0442.1 
(SOX10), 
MA0514.1 
(Sox3), 
MA0515.1 
(Sox6), 
MA0078.1 
(Sox17), 
MA0077.1 
(SOX9), 
SOX9_DBD 
 
MEME 3  
 
 
 
 
 
9 MA0476.1 (FOS), 
MA0099.2 
(JUN:FOS),  
MA0491.1 
(JUND),  
JDP2_full_1,  
Jdp2_DBD_1,  
JDP2_DBD_1,  
MA0490.1 
(JUNB),  
MA0478.1 
(FOSL2),  
MA0477.1 
(FOSL1) 
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Appendix IV Table 2 – All matches to the top 3 motifs found by MEME in the top 500 significant JUN peaks 
Database No. Logo No. 
matches 
Matches 
MEME 1  
 
 
 
 
 
 
16 MA0478.1 (FOSL2),  
MA0490.1 (JUNB),  
MA0477.1 (FOSL1),  
MA0501.1 
(NFE2::MAF),  
MA0150.2 (Nfe2l2),  
MA0591.1 
(Bach1::Mafk),  
MA0491.1 (JUND),  
MA0489.1 (JUN),  
MA0099.2 
(JUN::FOS),  
MA0476.1 (FOS),  
JDP2_full_1,  
Jdp2_DBD_1,  
UP00103_2 
(Jundm2_secondary),  
JDP2_DBD_1,  
NFE2_DBD,  
MA0462.1 
(BATF::JUN) 
 
MEME 2  
 
 
 
 
 
 
18 MA0146.2 (Zfx),  
MA0516.1 (SP2),  
UP00021_1 
(Zfp281_primary),  
MA0162.2 (EGR1),  
MA0469.1 (E2F3),  
MA0528.1 (ZNF263),  
MA0079.3 (SP1),  
UP00002_1 
(Sp4_primary),  
UP00022_1 
(Zfp740_primary),  
MA0163.1 (PLAG1),  
MA0024.2 (E2F1),  
UP00102_1 
(Zic1_primary),  
ZNF740_full,  
KLF16_DBD,  
MA0471.1 (E2F6),  
ZNF740_DBD,  
MA0470.1 (E2F4),  
MA0073.1 (RREB1) 
MEME 3 
 
2 MA0472.1 (EGR2),  
MA0073.1 (RREB1)
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